Clinical Development  
MCS110 
Protocol CMCS110Z2102 / [STUDY_ID_REMOVED]
A Phase Ib/II, open label, multicenter study of MCS110 in 
combination with PDR001 in patient s with advanced 
malignancies 
Document type  Amended Protocol Version  
EUDRACT number  2016 -000210 -29 
Version number  05 (Clean ) 
Development phase  Ib/II 
Document status  Final  
Release date  23-Jul-2019
Property of Novartis  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of Novartis  
Template version 17- Nov-2014  
Novartis  Confidential  Page 2 
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Table of contents 
Table of contents ................................................................................................................. 2 
List of figures  ...................................................................................................................... 6 
List of tables  ........................................................................................................................ 6 
List of abbreviations ............................................................................................................ 8 
Glossary of terms  ............................................................................................................... 10 
Protocol summary: ............................................................................................................. 12 
Amendment 05 (23-Jul-2019) ........................................................................................... 15 
Amendment 04 (20-July-2018) ......................................................................................... 17 
Amendment 03 (14 -Feb-2018) .......................................................................................... 21 
Amendment 02 (07- Feb-2017) .......................................................................................... 24 
Amendment 01 (11-Jul-2016) ........................................................................................... 27 
1 Background ........................................................................................................................ 28 
1.1 Overview of disease pathogenesis, epidemiology and current treatment .............. 28 
1.1.1  Overview of PD -1 ................................................................................. 28 
1.1.2  Overview of CSF -1 ............................................................................... 29 
1.2 Introduction to study treatment .............................................................................. 30 
1.2.1  Overview of PDR001 ............................................................................ 30 
1.2.2  Overview of MCS110 ........................................................................... 31 
1.3 Overview of combination treatment  ...................................................................... 35 
1.3.1  Non-clinical  ........................................................................................... 35 
1.3.2  Clinical .................................................................................................. 35 
1.3.3  Potential for drug-drug interactions ...................................................... 35 
1.3.4  Expected overlapping toxicities ............................................................ 35 
2 Rationale  ............................................................................................................................ 36 
2.1 Study rationale and purpose ................................................................................... 36 
2.2 Rationale for the study design ............................................................................... 37 
2.3 Rationale for dose and regimen selection .............................................................. 38 
2.4 Rationale for choice of combination drugs ............................................................ 38 
3 Objectives and endpoints ................................................................................................... 38 
4 Study design ...................................................................................................................... 41 
4.1 Description of study design ................................................................................... 41 
4.2 Timing of interim analyses and design adaptations ............................................... 43 
4.3 Definition of end of the study ................................................................................ 43 
4.4 Early study termination  .......................................................................................... 44 
5 Population .......................................................................................................................... 44 
Novartis  Confidential  Page 3 
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
5.1 Patient population .................................................................................................. 44 
5.2 Inclusion criteria  .................................................................................................... 44 
5.3 Exclusion criteria  ................................................................................................... 45 
6 Treatment  ........................................................................................................................... 48 
6.1 Study treatment ...................................................................................................... 48 
6.1.1  Dosing regimen ..................................................................................... 48 
6.1.2  Ancillary treatments  .............................................................................. 49 
6.1.3  Treatment duration  ................................................................................ 49 
6.2 Dose escalation guidelines ..................................................................................... 49 
6.2.1  Starting dose rationale ........................................................................... 49 
6.2.2  Provisional dose levels .......................................................................... 50 
6.2.3  Guidelines for dose escalation and determination of MTD or RP2 D ... 50 
6.2.4  Definitions of dose limiting toxicities (DLTs)  ...................................... 53 
6.3 Dose modifications  ................................................................................................ 54 
6.3.1  Dose modification and dose delay ........................................................ 54 
6.3.2  Follow-up for toxicities ......................................................................... 60 
6.3.3  Anticipated risks and safety concerns of the study drug ....................... 60 
6.4 Concomitant medications  ...................................................................................... 60 
6.4.1  Permitted concomitant therapy requirin g caution and/or action ........... 61 
6.4.2  Prohibited concomitant therapy ............................................................ 61 
6.5 Patient numbering, treatment assignment or randomization ................................. 62 
6.5.1  Patient numbering ................................................................................. 62 
6.5.2  Treatment assignment or randomization  ............................................... 62 
6.6 Study drug preparation and dispensation ............................................................... 62 
6.6.1  Study drug packaging and labeling ....................................................... 62 
6.6.2  Drug supply and storage ........................................................................ 62 
6.6.3  Study drug compliance and accountability ........................................... 63 
6.6.4  Disposal and destruction ....................................................................... 63 
7 Visit schedule and assessments  ......................................................................................... 64 
7.1 Study flow and visit schedule ................................................................................ 64 
7.1.1  Screening  ............................................................................................... 69 
7.1.2  Treatment period  ................................................................................... 69 
7.1.3  Discontinuation of Study Treatment  ..................................................... 70 
7.1.4  Withdrawal of Consent ......................................................................... 71 
7.1.5  Follow-up period ................................................................................... 72 
7.1.6  Lost to follow-up ................................................................................... 73 
Novartis  Confidential  Page 4 
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
7.2 Assessment types ................................................................................................... 73 
7.2.1  Efficacy assessments  ............................................................................. 73 
7.2.2  Safety and tolerability assessments  ....................................................... 75 
7.2.3  Pharmacokinetics and immunogenicity assessments ............................ 79 
  81 
8 Safety monitoring and reporting ........................................................................................ 83 
8.1 Adverse events  ....................................................................................................... 83 
8.1.1  Definitions and reporting ...................................................................... 83 
8.1.2  Laboratory test abnormalities ................................................................ 85 
8.2 Serious adverse events  ........................................................................................... 85 
8.2.1  Definitions  ............................................................................................. 85 
8.2.2  Reporting ............................................................................................... 86 
8.3 Pregnancies  ............................................................................................................ 87 
8.4 Warnings and precautions ...................................................................................... 87 
8.5 Data Monitoring Committee  .................................................................................. 87 
9 Data collection and management  ....................................................................................... 88 
9.1 Data confidentiality  ............................................................................................... 88 
9.2 Site monitoring  ...................................................................................................... 89 
9.3 Data collection  ....................................................................................................... 89 
9.4 Database management and quality control  ............................................................ 90 
10 Statistical methods and data analysis  ................................................................................ 90 
10.1  Analysis sets .......................................................................................................... 91 
10.1.1  Full Analysis Set ................................................................................... 91 
10.1.2  Safety Set  .............................................................................................. 91 
10.1.3  Per-Protocol Set .................................................................................... 91 
10.1.4  Dose -determining analysis set............................................................... 92 
10.1.5  Pharmacokinetic analysis set  ................................................................. 92 
10.2  Patient demographics/other baseline characteristics  ............................................. 92 
10.3  Treatments (study treatment, concomitant therapies, compliance) ....................... 92 
10.4  Primary objective  ................................................................................................... 93 
10.4.1  Variable  ................................................................................................. 93 
10.4.2  Statistical hypothesis, model, and method of analysis .......................... 94 
10.4.3  Handling of missing values/censoring/discontinuations ....................... 99 
10.4.4  Supportive analyses ............................................................................... 99 
10.5  Secondary objective ............................................................................................... 99 
10.5.1  Key secondary objective ....................................................................... 99 

Novartis  Confidential  Page 5 
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
10.5.2  Other secondary efficacy objectives  ................................................... 100 
10.5.3  Safety objectives  ................................................................................. 100 
10.5.4  Pharmacokinetics  ................................................................................ 100 
  101 
10.7  Interim analysis  .................................................................................................... 103 
10.8  Sample size calculation  ........................................................................................ 103 
10.9  Power for analysis of key secondary variables .................................................... 105 
11 Ethical considerations and administrative procedures .................................................... 105 
11.1  Regulatory and ethical compliance ...................................................................... 105 
11.2  Responsibilities of the investigator and IRB/IEC/REB  ....................................... 105 
11.3  Informed consent procedures ............................................................................... 105 
11.4  Discontinuation of the study ................................................................................ 106 
11.5  Publication of study protocol and results............................................................. 106 
11.6  Study documentation, record keeping and retention of documents ..................... 107 
11.7  Confidentiality of study documents and patient records ..................................... 107 
11.8  Audits and inspections ......................................................................................... 108 
11.9  Financial disclosures  ............................................................................................ 108 
12 Protocol adherence  .......................................................................................................... 108 
12.1  Amendments to the protocol ................................................................................ 108 
13 References (available upon request)  ................................................................................ 109 
14 Appendices ...................................................................................................................... 113 
14.1  Appendix 1: Guidelines for Response, Duration of Overall Response, TTF, 
TTP, Progression-Free Survival and Overall Survival (based on RECIST 1.1) . 113 
14.1.1  Introduction ......................................................................................... 114 
14.1.2  Efficacy assessments  ........................................................................... 114 
14.1.3  Efficacy definitions ............................................................................. 123 
14.1.4  Data handling and programming rules ................................................ 132 
14.1.5  References (available upon request)  ................................................... 135 
14.2  Appendix 2: Guidelines for immune- related Response Criteria (irRC) using 
one-dimensional measurements (simulating RECIST 1.1) ................................. 136 
14.2.1  Introduction ......................................................................................... 136 
14.2.2  New lesions and non- target lesions  ..................................................... 136 
14.2.3  Follow-up evaluation of target and non- target lesions  ........................ 136 
14.2.4  Definitions of response categories and evaluation of overall lesion response ............................................................................................... 137
 
14.2.5  Only non- measurable disease at baseline  ............................................ 138 
14.2.6  References (available upon request)  ................................................... 138 

Novartis  Confidential  Page 6 
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
14.3  Appendix 3: Statistical Details for the Phase Ib Part: Bayesian logistic 
regression model (BLRM): prior and design properties for hypothetical data scenarios  .............................................................................................................. 139
 
14.3.1  Statistical Models  ................................................................................ 139 
14.3.2  Prior specifications  .............................................................................. 139 
14.3.3  Hypothetical on-study scenarios ......................................................... 145 
14.3.4  Operating characteristics for MCS110 + PDR001 combination arm.. 146 
14.3.5  References (available upon request)  ................................................... 149 
 
List of figures 
Figure 1-1  Blockade of PD-1/PD-1 interaction by PDR001 .................................. 29 
Figure 1-2  Macrophage polarization and function  .................................................. 29 
Figure 2-1  Rationale  for combined treatment with PDR001 and MCS110 ............ 36 
Figure 4-1  Study design .......................................................................................... 42 
 
List of tables 
Table 1 -1 Clinical trials with MCS110 .................................................................. 33 
Table 3 -1 Objectives and related endpoints .......................................................... 39 
Table 6 -1 Dose and treatment schedule ................................................................. 48 
Table 6 -2 Provisional dose levels .......................................................................... 50 
Table 6 -3 Criteria for defining dose- limiting toxicities ......................................... 53 
Table 6 -4 Dose modification for drug related toxicities ........................................ 55 
Table 7 -1 Visit evaluation schedule ...................................................................... 65 
Table 7 -2 Disease assessment collection plan  ....................................................... 74 
Table 7 -3 ECOG performance status  ..................................................................... 76 
Table 7 -4 Local/Central Clinical laboratory parameters collection plan  .............. 76 
Table 7 -5 Local ECG collection plan  .................................................................... 78 
Table 7 -6 Phase Ib Part: Pharmacokinetic blood collection log for MCS110, PDR001 and IG samples ....................................................................... 79
 
Table 7 -7 Phase II Part: Pharmacokinetic blood collection log for MCS110, PDR001 and IG samples  ....................................................................... 80
 
  81 
Table 10 -1 Pharmacokinetic Parameters to be analyzed  ....................................... 101 
Table 10 -2 Operating characteristics of the design (Group 1, 3) .......................... 104 
Table 10 -3 Operating characteristics of the design (Group 4) .............................. 104 
Table 10 -4 Operating characteristics of the design (Group 2 at R P2D)  ................ 105 

Novartis  Confidential  Page 7 
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Table 10 -5 Operating characteristics of the design (Group 2b) ............................ 105 
Table 14 -1 Response criteria for target lesions  ..................................................... 119 
Table 14 -2 Response criteria for non- target lesi ons .............................................. 121 
Table 14 -3 Overall lesion response at each assessment  ........................................ 122 
Table 14-4  Overall lesion response at each assessment: patients with non -
target disease only  ............................................................................... 129 
Table 14 -5 Options for event dates used in PFS, TTP, duration of response ........ 130 
Table 14 -6 Overall response at each assessment  ................................................... 137 
Table 14 -7 Prior distributions for the parameters of the MAP model used to 
derive the prior for the single-agent MCS110 model parameters ....... 141 
Table 14 -8 Historical data from [CMCS110A2101] ............................................. 141 
Table 14 -9 Historical data from [CMCS110X2201] ............................................. 141 
Table 14 -10 Prior distributions for the parameters of the MAP model used to derive the prior for the single-agent PDR001 model parameters ........ 143
 
Table 14 -11 Historical data from [CPDR001X2101] .............................................. 143 
Table 14 -12 A priori interaction at the provisional and reference dose levels  ........ 144 
Table 14 -13 Prior distribution for the model parameters ........................................ 144 
Table 14 -14 Summary of prior distribution of DLT rates ....................................... 145 
Table 14-15  Dose decisions recommended by BLRM under EWOC ..................... 145 
Table 14 -16 True underlying cumulative probabilities of DLT for different scenarios  .............................................................................................. 147
 
Table 14-17  Results  ................................................................................................. 148 
Novartis  Confidential  Page 8 
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
List of abbreviations 
AE Adverse Event  
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT  
ASCO  American Society for Clinical Oncology   
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT  
BLRM  Bayesian Logistic Regression Model  
CBR  Clinical Benefit Rate  
CDP  Clinical Development Plan  
cfDNA  Circulating free DNA  
CK Creatine Kinase  
CL Clearance  
Cmax  maximum drug concentration  
CR Complete Response  
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper  
CRO  Contract Research Organization   
CSF-1 Colony Stimulating Factor 1 (see M -CSF)  
CSF-1R Colony Stimulating Factor 1 Receptor  
CSR  Clinical study report  
CTLA -4 Cytotoxic T -Lymphocyte -Associated protein 4  
CTX-1 C-terminal Telopeptide of type I collagen  
CYPP450  Cytochrome P450  
DCR  Disease Control Rate  
DDI Drug -Drug Interaction  
DLT Dose Limiting Toxicity  
DOR  Duration of Response  
DS&E  Drug Safety and Epidemiology  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  
EOT End Of Treatment  
eSAE  Electronic Serious Adverse Event  
ESMO  European Society for Medical Oncology  
EWOC  Escalation With Overdose Control  
FIH First In Human  
GGT  Gamma -glutamyl transferase  
GLP Good Laboratory Practice  
HNSTD  Highest No Severely Toxic Dose  
HV Healthy Volunteer  
i.v. intravenous(ly)  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IG Immunogenicity  
IL-2 Interleukin 2  
IRB Institutional Review Board  
irRC Immune -related Response Criteria  
Kd Constant of dissociation  
LDH Lactate Dehydrogenase  
mAb Monoclonal Antibody  
Novartis  Confidential  Page 9 
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
MAP Master Analysis Plan documents project standards in the statistical methods which will 
be used within the individual clinical trial RAP documentation  
M-CSF Macrophage Colony stimulating factor  
MDSCs  Myeloid -Derived Suppressor Cells  
MRT  Mean Residence Time  
MTD  Maximum Toler ated Dose  
NCCN  National Comprehensive Cancer Network  
o.d. omnia die /once a day  
ORR  Overall Response Rate  
OS Overall Survival  
p.o. per os /by mouth/orally  
PD Pharmacodynamic / Progressive Disease  
PD-1 Programmed Death -1 
PD-L1 Programmed Death -Ligand 1  
PD-L2 Programmed Death -Ligand 2  
PFS Progression Free Survival  
PgP P-glycoprotein 1 also known as multidrug resistance protein 1  
PHI Protected Health Information  
PR Partial Response  
PVNS  Pigmented VilloNodular Synovitis  
Q2W, Q3W, Q4W  Respectively, every two, three, four week  
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides evidence 
of preplanned analyses  
REB Research Ethics Board  
RP2D  Recommended Phase two Dose  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SEB Staphylococcal Enterotoxin B  
SOP  Standard Operating Procedure  
TAM  Tumor Associated Macrophage  
TCP thrombocytopenia  
Tregs  Regulatory T cells  
Novartis  Confidential  Page 10  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Glossary of terms 
Assessment  A procedure used to generate data required by the study  
Biologic Sa mples A biological speci men including, for ex ample, blood (plas ma, serum), saliva, 
tissue,  urine, stool,  etc. t aken fr om a study s ubject or  study patient  
Control drug  A study treatment used as a comparator to reduce assessment bias, 
preserve blinding of investigational drug, assess internal study validity, 
and/or evaluate comparative effects of the investigational drug  
Cohort  A group of newly enrolled patients treated at a specific dose and regimen 
(i.e. treatment gr oup) at the same time  
Cycles  Number and timing or recommended repetitions of therapy are usually 
expressed as number of days (e.g.: q28 days)  
Dose level  The dose of drug given to the patient (total daily or weekly etc.)  
Enrollment  Point/time of patient entry into the study; the point at which informed consent must be obtained (i.e. prior to starting any of the procedures 
described in the protocol)  
Inves tigational drug  The study treatment whose properties are being tested in the study; this definition is consistent with US CFR 21 Section 312.3 and is synonymous 
with “investigational new drug.”  
Investigational treatment  Drug whose properties are being tested in the study as well as their associated placebo and active treatment controls (when applicable). This also includes approved drugs used outside of their indication/approved 
dosage, or that are tested in a fixed combination. Investigational tr eatment 
generally does not include other study treatments administered as 
concomitant background therapy required or allowed by the protocol when 
used in within approved indication/dosage  
Medication number  A unique identifier on the label of each study tr eatment package which is 
linked to one of the treatment groups of a study  
Other study treatment  Any drug administered to the patient as part of the required study 
procedures that was not included in the investigational treatment  
Subject Number (Subject N o.) A unique identifying number assigned to each patient/subject/healthy 
volunteer who enrolls in the study  
Period A subdivision of the study timeline; divides stages into smaller functional 
segments such as screening, baseline, titration, washout, etc.  
Personal Data  Subject information collected by the Investigator that is transferred to Novartis for the purpose of the clinical trial. This data includes subject 
identifier information, study inf ormation and biological sample  
Randomization number  A unique treatment identification code assigned to each randomized patient, 
corresponding to a specific treatment arm assignment  
Stage related to study timeline  A major subdivision of the study timeline; begins and ends with major study 
milestones such as e nrollment, randomization, completion of treatment, etc.  
Stage in cancer  The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer 
has spread from the original site to other parts of the body  
Stop study participation  Point/time at which the patient came in for a final evaluation visit or when 
study treatment was discontinued whichever is later  
Study treatment  Includes any drug or combination of drugs in any study arm a dministered to 
the patient (subject) as part of the required study procedures, including 
placebo and active drug run- ins. 
 
In specific examples, it is important to judge investigational treatment component relationship relative to a study treatment combination; study 
treatment in this case refers to the investigational and non-investigational 
treatments in combination.  
Novartis  Confidential  Page 11  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Study treatment discontinuation Point/time when patient permanently stops taking study treatment for any 
reason  
Supportive treatment  Refers to any treatment required by the exposure to a study treatment, e.g. 
premedication of vitamin supplementation and corticosteroid for pemetrexed 
disodium.  
Treatment group  A treatment group defines the dose and regimen or the combination, and may con sist of 1 or more cohorts. Cohorts are not expanded, new cohorts 
are enrolled.  
Variable Identifier used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specified timepoints  
Withdrawal of Co nsent Withdrawal of cons ent occurs only whe n a patient d oes not want to 
partic ipate in the study any  longer, a nd does not allow  any further collection 
of personal data  
Novartis  Confidential  Page 12  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Protocol summary:  
Protocol number  CMCS110Z2102  
Title A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in 
patients with advanced malignancies  
Brief title  Phase Ib/II study of MCS110 in combination with PDR001 in patients with advanced 
malignancies  
Sponsor and 
Clinical Phase  Novartis  
Ib/II 
Investigation type  Drug  
Study type  Interventional  
Purpose and 
rationale  The purpose of this study of MCS110 with PDR001 is to characterize the safety, 
tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors  
Combined treatment with MCS110 and PDR001 is expected to result in TAM depletion, 
enhanced T -cell activation and synergistic antitumor activity in the clinical setting.  
Primary 
Objectives  • Phase Ib :To characterize the safety and tolerability of MCS110 in combination with 
PDR001 in patients with advanced solid malignancies and to identify a recommended dose combination for Phase II  
• Phase II : To estimate the anti -tumor activity of the combination of M CS110 with 
PDR001  
Secondary Objectives  • To further characterize the safety and tolerability of MCS110 given in combination 
with PDR001  
• To characterize the pharmacokinetic profile of the combination of MCS110 with 
PDR001  
• To further evaluate the preliminary anti-tumor activity of the combination of MCS110 
with PDR001 by additional efficacy measures  
• To assess emergence of anti -MCS 110 or anti-PDR001 antibodies  
•  
• To describe survival with MCS110 and PDR001 given in combination  
Study design  • This study has been designed as a Phase Ib/II , multi -center, open-label study 
starting with a Phase Ib dose escalation part  followed by a Phase II part . 
• MCS110 and PDR001 will be administered every 3 weeks until patient experiences 
unacceptable toxicity, progressive disease per immune related Response Criteria 
(irRC) and/or treatment is discontinued at the discretion of the investigator or the 
patient.  
Population  The Phase Ib  part of the study will be conducted in adult patients with advanced 
melanoma, endometrial, pancreatic and triple negative breast cancer.  
The Phase II  part of the study will be conducted in adult patients  enrolled in distinct 
groups:  
• PD1/PD-L1 treatment naïve TNBC  
• PD1/PD-L1 treatment naïve pancreatic cancer  
• PD1/PD-L1 treatment naïve endometrial carcinoma  
• PD1/PD -L1 treatment resistant melanoma.  

Novartis  Confidential  Page 13  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Inclusion criteria  • Age ≥ 18 years [For Japan only: written consent is necessary both from the patient 
and his/her legal representative if he/she is under the age of 20 years.]  
• Phase Ib part : Patients with advanced melanoma, endometrial carcinoma, 
pancreatic or triple negative breast cancer, with measurable or non- measurable 
disease as determined by RECIST version 1.1, who have progressed despite 
standard therapy or are intolerant of standard therapy, or for whom no standard 
therapy exists.  
• Phase II part : Patients with advanced solid tumors with at least one measurable 
lesion as determined by RECIST version 1.1,  who have received standard therapy 
or are intolerant of standard therapy, who have progressed following their last prior therapy, and fit into one of the following groups:  
• Group 1: TNBC who did not receive prior anti -PD-1/PD -L1 treatment  
• Group 2: Pancreatic adenocarcinoma who did not receive prior anti -PD-
1/PD-L1 treatment  
• Group 3: Endometrial carcinoma who did not receive prior anti -PD-1/PD-L1 
treatment  
• Group 4: Melanoma who progressed on prior PD -1- and PD -L1-directed 
therapies.  
• ECOG Performance Status ≤ 2. 
• Patient must have a site of disease amenable to biopsy, and be a candidate for 
tumor biopsy according to the treating institution’s guidelines. Patient must be 
willing to undergo a new tumor biopsy at screening, and during therapy on this 
study . Exceptions for patients with sites of disease not amenable to biopsy may be 
considered after discussion with the sponsor.  
Exclusion criteria  • Presence of symptomatic CNS metastases, or CNS metastases that require local 
CNS -directed therapy  
• History of severe hypersens itivity reactions to other mAbs  
• Patient having out of range laboratory values defined as:  
• Creatinine clearance (calculated using Cockcroft -Gault formula, or 
measured) < 40 mL/min  
• Total bilirubin > 1.5 x ULN, except for patients with Gilbert’s syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN  
• Alanine aminotransferase (ALT) > 3 x ULN  
• Aspartate aminotransferase (AST) > 3 x ULN  
• Absolute neutrophil count < 1.0 x 10
9/L 
• Platelet count < 100 x 109/L 
• Hemoglobin (Hgb) < 9 g/dL  
• Impaired cardiac function or clinically significant cardiac disease  
• Active autoimmune disease or a documented history of autoimmune disease within 
three years before screening  
• Acti ve infection, including active tuberculosis, requiring systemic antibiotic therapy  
• Known history of HIV infection  
• Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, or requiring 
antiviral treatment  
• Malignant disease, other than that being treated in this study  
• Any medical condition that would prevent the patient’s participation in the clinical 
study due to safety concerns, compliance with clinical study procedures or interpretation of study results,  including but not limited to:  
• Prior immune -related adverse events requiring treatment discontinuation  
• Ongoing symptomatic interstitial lung disease (ILD), noninfectious 
pneumonitis or history of drug induced interstitial lung disease  
Novartis  Confidential  Page 14  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
• Systemic anti -cancer therapy within 2 weeks or 5 x T ½, whichever is longer of the 
first dose of study treatment. Cytotoxic agents that have major delayed toxicity, e.g. 
mitomycin C and nitrosoureas, within 4 weeks and CTLA -4, PD -1 or PD -L1 
antagonists, within 6 weeks of the f irst dose of study treatment  
• Patients requiring chronic treatment with systemic steroid therapy or any 
immun osuppressive therapy  
• Use of any live vaccines against infectious diseases within 4 weeks of initiation of 
study treatment  
• Major surgery within 2 wee ks of the first study drug  
• Radiotherapy within 2 weeks of  the first dose of study drug  
• Participation in an interventional, investigational study within 2 weeks of the first dose 
of study treatment  
• Presenc e of ≥ CTCAE Grade 2 toxicity  
• Use of hematopoietic c olony -stimulating growth factors (e.g. G -CSF, GM -CSF) ≤ 2 
weeks prior start or study drug.  
• Pre gnant or lactating women  
• Women of child-bearing potential, unless they are using highly effective methods of 
contraception  
Investigational and reference 
therapy  MCS110 and PDR001  
Efficacy 
assessments  Tumor assessment per RECIST v1.1 and per irRC  
Safety 
assessments  Incidence and severity of AEs and SAEs, including changes in laboratory values, vital 
signs  and ECG s 
Other 
assessments  • Serum PK parameters and immunogenicity  
•  
 
Data analysis  The study data will be analyzed and reported based on all patients’ data of the Phase Ib 
and Phase II parts up to the time when all patients have completed at least six cycles of 
treatment or discontinued the study.  
Key words  Phase Ib/II, MCS110, PDR001, immune checkpoint inhibitor, PD -1, PD -L1, CSF -1, 
tumor associated macrophage.  

Novartis  Confidential  Page 15  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Amendment 05 (23- Jul-2019) 
Amendment rationale  
This protocol amendment revises the definition of end of study to include the option for patients 
still on study treatment and who, in the opinion of the investigator, are still deriving clinical benefit at the time of end of study, to transfer to another study to continue providing study 
treatment to these patients or to an alternative treatment option.  
In addition, based on a health authority request, the use of condom s for male study participants 
and pregnancy outcome collection for female partners of male study participants has been 
reintroduced only for patients treated in Korea. Exclusion criterion  #21 has been updated 
accordingly. 
Lastly, PK and IG assessments are no longer mandated at the E nd of T reatment visit as 
sufficient data have already been collected . 
Study Status  
The CMCS110Z2102 study started enrollment on 29-Jun-2016. The last patient was enrolled 
on 10- Jan-2019. The pre-defined decision  criteria for further expansion of the pancreatic cancer, 
TNBC , endometrial cancer and melanoma groups were not met  (see Section 4.2 and 10.4.4.2) . 
By consequence, no further patients will be enrolled in this study. A total of 141 patients have 
been treated: 60 patients in the dose escalation part and 81 patients in Phase II part of study ( 20 
in pancreatic group, 20 in TNBC group, 21 in endometrial group and 20 in melanoma group). 
As of 08- Jul-2019, 6  patients were still on treatment (in phase II only)  and 41 patients in survival 
follow-up.  
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions. 
Section 4.3: Definition of end of study: 
• Addition of language to account for patients who would transfer into another study or an 
alternative treatment option to continue provision of study treatment. 
Section 5.3: Exclusion criteria: 
• Re-insertion of exclusion criteria 21 fo r Korea only where the use of condom for male study 
participants remains  mandatory . 
Section 7.1.3: Discontinuation of study treatment: • Addition of language to specify that patients who transfer to another study or an alternative 
treatment option to continue provision of study treatment will complete end of treatment procedures. 
Section 7.1.5: Follow up period: 
• Addition of language to specify that patients who transfer into another study or an 
alternative treatment option to continue provision of study treat ment will not complete the 
Novartis  Confidential  Page 16  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
safety, disease progression and survival follow up. For all other patients, the safety 
evaluation period will be completed but the disease -progression and survival follow up will 
not be performed or pursued. 
Section 7.2.3: Pharmacokinetics and immunogenicity assessments, Table 7 -1: Visit evaluation 
schedule and Table 7 -7: Phase II Part: Pharm acokinetic blood collection log for MCS110, 
PDR001 and IG samples: 
• Removal of PK and IG samples collection at End of Treatment. 
Section 8.3: Pregnancies: • Re-insertion of the pregnancy outcome collection for the female partners of any males 
which remains valid for Korea only. 
IRBs/IECs  
• A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics C ommittee (IECs) and Health Authorities.  
• The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.  
• The changes herein  affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informe d Consent that takes into account the changes described in this 
protocol amendment. 
 
Novartis  Confidential  Page 17  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Amendment 04 (20-July-2018)  
Amendment Rationale  
The main purpose for this amendment is to: 
• Allow exploration of an additional, lower dose of MCS110 in patients with pancreatic 
cancer. Data generated in the dose escalation part of the study show preliminary signals of efficacy (1 PR, 2 SD >1 year) at the lowest dose level of MCS110 (1 mg/kg, Q3W) in combination with PDR001 in pancreatic cancer patients. In order to further explore this, two additional groups, each consisting of up to 20 patients with pancreatic ductal adenocarcinoma (PDAC) may be enrolled at either 1 mg/kg Q3W or the RP2D (7.5mg/kg, Q3W) of MCS110 in combination with PDR001 (300 mg, Q3W) respectively. Recruitment into these two groups will be contingent upon evidence of clinical benefit in the first 20 PDAC patients treated at the RP2D.  
Additional changes to the protocol: 
•  
 
 
 
 
• Add laboratory measurements during study visits. Asymptomatic CK elevations were 
noted in healthy volunteers and in pigmented villonodular synovitis (PVNS) patients treated with MCS110. Maximal CK elevations in PVNS patients were observed 28-43 days after a single dose of MCS100. In order to assess the dynamics of CK elevations later during the course of treatment with MCS110, additional blood chemistry samples have been added on Cycle 4 Day 8. 
• Remove the requirement for use of condom for male study participants. Monoclonal antibodies are not genotoxic due to their high molecular weight, and are not expected to interact with DNA. In addition, they have a low distribution to the semen, a relatively small volume of semen delivered to the partner, and very low absorption. Fetal harm from semen delivery is therefore biologically implausible and the amount of monoclonal antibodies able to gain access to the partner’s systemic circulation via trans -epidermal 
transfer would be expected to be extremely low. Therefore, the use of condom for male study participants is no longer required. 
• Include new guidance on dose modifications for suspected immune- related adverse events. 
To align with recently published guidelines on the clinical management of suspected immune -related toxicities, and to provide guidance for the management of immune related 
acute dermatologic adverse events seen in study with PDR001, the dose modification section of the protocol and corresponding table were updated. After the recent occurrence of a case of Stevens Johnson Syndrome in a study with PDR001, the dose modification guidelines for protocols using PDR001 were updated to mandate permanent discontinuation of study treatment for patients who experience SJS or Lyell syndrome/toxic epidermal necrolysis (TEN). This change has already been implemented 

Novartis  Confidential  Page 18  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
as part of an urgent safety measure released on 15 June 2018. This protocol a mendment is 
now formalizing these changes in the table describing the criteria for dose 
reduction/interruption and re-initiation of treatment for adverse drug reactions. 
• The withdrawal of consent language was revised to differentiate sample use after a pat ient 
withdraws consent based on the different regulations/laws around the world. 
Study status  
The CMCS110Z2102 study is ongoing in the phase 2 part with MCS110 at 7.5 mg/kg in combination with PDR001. As of 10 April 2018, 60 patients have received the combination of 
MCS110 and PDR001 at doses of 1 mg/kg and 100 mg (6 patients), 3 mg/kg and 100 mg (12 patients), 3 mg/kg and 300 mg (12 patients), 5 mg/kg and 300 mg (13 patients), 7.5 mg/kg and 300 mg (6 patients), and 10 mg/kg and 300 mg (11 patients), respec tively.  
Changes to the protocol  
Changes to specific sections of the protocol are shown in the tracked changes version of the protocol using strike through red font for deletions and red underlined for insertions. 
Section 2.2: Rationale for study design 
• The text was updated to reflect the change of design for PDAC patients participating 
Phase II.  
Section 3: Objectives and endpoints • Table 3 -1 Clinical benefit rate in the pancreatic cancer disease group, added as per 
Amendment 3 is now clearly indicated in the table.  
 

Novartis  Confidential  Page 19  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Section 4.1: Description of study design 
• The description of the design of Phase II was updated.  
• Figure 4-1 was updated to reflect the change in study design. 
Section 4.2: Timing of interim analysis and design adaptations 
• The text was updated to reflect the change in the design of Phase II 
Section 5.3: Exclusion criteria 
• Exclusion criteria #21 was deleted as use of condom for male participants is no more 
required. 
Section 6.3.1: Dose modification and dose delay 
• The section was updated with new recommendations for the management of suspected 
immune -related adverse events.  
Table 6 -4 Dose modification for drug related toxicities 
• The table was updated with new recommendations for the manag ement of immune- related 
adverse events.  
Table 7 -1: Visit evaluation schedule  
• Blood chemistry and hematology added at Cycle 4 Day 8. 
•  
•  
Section 7.1.4 Withdrawal of consent 
• The withdrawal of consent language was revised. 
 
•   
•  
 
•  
Section 8.1: Adverse events • Reference to the dose modification recommendations provided in Section 6.3.1 was 
added . 
Section 8.3: Pregnancies 
• Collection of pregnancy outcome for female partners of male participants was removed. 
Section 8.5: Data Monitoring Committee  
• The text was updated to reflect the change in the design of Phase II 
Section 10: Statistical methods and data analysis 
• It was clarified that the outputs for Group 2 in expansion will be reported by dose level, 
when applicable.  

Novartis  Confidential  Page 20  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Section 10.4.2.2: Statistical methods and data analysis for Phase II 
• Language about the Bayesian model for a lower dose group for Phase II Group 2 was 
added. 
 
•   
Section 10.7: Interim analysis 
• The text was updated to reflect the change in the design of Phase II 
Section 10.8: Sample size calculation  
• The sample size justification section was updated to reflect the changes in Phase II Group 
2 design. 
IRB/IEC  
A copy of this amended protocol will be sent to the Institutional Review Board (IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes in this amendment identified above as being related to the USM have already been implemented by a USM letter issued on 15 June 2018. These changes are required for patient safety (i.e. necessary to eliminate immediate hazards to the tr ial subjects ICH GCP 3.3.8). 
Therefore they were required to have been implemented prior to IRB/IEC approval of this amendment.  
All other changes described in this amended protocol require IRB/IEC approval prior to 
implementation.  
The changes herein affe ct the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment. 

Novartis  Confidential  Page 21  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Amendment 03 (14- Feb-2018)  
The main purpose for this amendment is to: 
1. Increase the number of pancreatic cancer patients to be enrolled in the Phase II part of the 
study from 20 to 40 
2. Change the primary endpoint for antitumor activity in pancreatic cancer from overall response rate (ORR) to clinical benefit rate (CBR)  
 
 
4. Mention that statins should be used with caution. 
These changes are proposed for the following reasons: 
• Preliminary data (data cut -off 24 -Nov-2017) from this study show encouraging clinical 
activity in advanced pancreatic patients treated at a range of doses in dose escalation, with 
long-lasting clinical benefit (confirmed objective response or SD>4 months) in 2 of 30 evaluable patients per RECIST v1.1. Evaluable patients ar e defined as patients with at 
least 1 post-baseline efficacy assessment or has discontinued study treatment. Per irRC, there is one patient who showed pseudo-progression per RECIST, but achieved SD > 4 months. Therefore, under irRC, there is a 10% long- lasting clinical benefit in 3 out of 30  
advanced pancreatic patients. To allow further exploration of anti- tumor activity of the 
combination in this patient population, approximately 40 patients will be enrolled in the Phase II pancreatic cancer group.  
 
 
• Recent clinical data demonstrate that combined blockade of CSF -1R and PD-1 results in a 
long lasting (6 to 9 + months) objective response rate and clinical benefit rate (CBR) of 13% and 16%, respectively, in patients with advanced pancreatic cancer (Wainberg et al., 2017). Given that objective responses are rare in advanced pancreatic cancer and that long lasting stable disease is considered beneficial to patients, the primary endpoint for antitumor activity in this study will be changed from objective response to clinical benefit rate (confirmed objective response or SD>4 months). 
•  
 
  
• Statins are known to be frequently associated with CK elevations and transient CK elevations were noted in healthy volunteers and patients studies with MCS110. 
Study status  
The CMCS110Z2102 study is ongoing in the dose escalation part of the study. As of 29 January 2018, 56 patients have received the combination of MCS110 and PDR001 at doses of 1 mg/kg and 100 mg (6 patients), 3 mg/kg and 100 mg (12 patients), 3 mg/kg and 300 mg (12 patients), 5 mg/kg and 300 mg (13 patients), 7.5 mg/kg and 300 mg (6 patients), and 10 mg/kg and 300 
mg (7 patients), respectively. 

Novartis  Confidential  Page 22  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Changes to the protocol  
Changes to specific sections of the protocol are shown in the tracked changes version of the 
protocol using strike through red font for deletions and red underlined for insertions. 
Section 2.2: Rationale for study design 
• The text was updated to specify that clinical benefit rate will be evaluated in 
approximately 40 patients in the pancreatic cancer group 
Section 3: Objectives and endpoints 
• Table 3.1 was updated to mention clinical benefit rate in the pancreatic cancer disease group,  
 
Section 4.1: Description of study design 
• The text is updated to mention that 40 pancreatic cancer patients will be enrolled  
• Figure 4.1 is updated to reflect the change in study design. 
Section 4.2: Timing of interim analysis and design adaptations 
• The text is updated to reflect the change introduced between pancreatic cancer and other disease group. 
Section 6.4.1: Permitted concomitant therapy requiring caution and/or action 
• Statins are mentioned as to be used with caution 
Table 7.1: Visit evaluation schedule  
•  
 
•  
Section 10.4.1: Variables 
• Clinical benefit rate is defined as the primary efficacy variable for the pancreatic cancer group, while overall response rate remains the primary efficacy variable for the other cancer groups. 
Section 10.4.2.2: Phase II 
• The text has been updated to differentiate between pancreatic cancer group (Group 2) and other groups (groups 1, 3 and 4). 
• Parameters of priors of BLRM are defined for clinical benefit rate in pancreatic cancer patients.  
Section 10.5.2: Other secondary efficacy objectives 
• Duration of stable disease of 4 months is defined for clinical benefit 

Novartis  Confidential  Page 23  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
10.8: Sa mple size calculation  
• Pancreatic cancer is deleted from table 10 -2 and a new table 10 -4 is introduced for 
pancreatic cancer  
13: References  
• The list of references was updated  
14.3: recommended management algorithms for suspected toxicities 
• Management of neu rological adverse events is now mentioned 
IRB/IEC  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation.  
The changes herein affect the Informed Consent Form for the patients. Sites are required to 
update and submit for approval a revised Informed Consent Form that takes into account the changes described in this protocol amendment.  
Novartis  Confidential  Page 24  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Amendment 02 (07- Feb-2017)  
The main reasons for this amendment are to make changes requested by the Health Authorities 
(HA), to prepare the protocol for inclusion of Japanese patients and to update safety monitoring. Furthermore, clarifications and correction of typos have been made to the protocol. 
As requested by HA, patients with active tuberculosis, interstitial lung disease or non-infectious 
pneumonitis or history of drug induced interstitial lung disease will be excluded from  enrolment 
in the study. Additionally, a washout period of 7 days for immunosuppressive therapy and 
corticosteroids will be required before starting study treatment. Furthermore, country- specific 
wordings have been added to the protocol to allow Japanese patients to participate in the phase II part of the study. In accordance with HA requirements, Japanese patients will remain inpatients during the first treatment cycle and will have repeat chest X - rays performed at 
baseline and after one week of treatment . 
Given that Grade 1 -2 adverse events, possibly related to cytokine release (fever, weight gain 
and pleural effusion) have been observed during study treatment, an extended immune modulation marker panel will be assessed at any safety events suspected to be related to cytokine release to further characterize these events. In addition, urinalysis to evaluate possible protein leakage will be performed for all patients at the beginning of each treatment cycle. Furthermore, since the safety follow -up period after PDR001 treatment was extended from 90 
to 150 days in the last amendment, additional safety follow -ups will be performed at 30 and 90 
days. To add flexibility all safety follow -ups may be performed by phone. Consequently, the 
protocol- specified lab tests  or visits will not be requested during the safety follow-up period. 
This protocol amendment clarifies  
 the definition of post -menopausal stat us, 
corrects the imaging assessment schedule    
Lastly, the criteria for 
Hy’s law has been corrected in Table 6 -3 Criteria for defining dose- limiting toxicities.  
Study status  
The CMCS110Z2102 study is currently enrolling. As of 12th January 2017, seventeen patients have received the combination of MCS110 and PDR001 at doses of 1  mg/kg and 100 mg (6 patients) and 3 mg/kg and 100 mg (11 patients), respectively. No drug limiting toxicities were observed at this date. 
Chan ges to the protocol  
Changes to specific sections of the protocol are shown in the tracked changes version of the 
protocol using strike through red font for deletions and red underlined for insertions. 
• Table 1 -1 was updated with information of the ongoing phase 1 study in Japan. 
•  
• Section 5.2:  Inclusion criteria 2 was updated with text specific for Japan. 

Novartis  Confidential  Page 25  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
• Section 5.3: Exclusion criteria 6 was updated to specify that patients with active 
tuberculosis are excluded from the study. Exclusion criteria 10 was updated to specify that patients with interstitial lung disease, non -infectious pneumonitis, history of drug induced 
interstitial lung disease or history of immune related adverse events are excluded from the study.  The requirement of a washout period of 7 days for immunosuppressive treatment and corticosteroids was added to exclusion criteria 12.  Repeat text was deleted from exclusion criteria 18. Definition of post-menopausal status was updated in exclusion criteria 20.  
•  Table 6 -3: The typo in the definition dose limiting toxicity linked with bilirubin increase 
was corrected.  
• Section 6.3.3 : Management of anticipated risks were further clarified  
• Section 7.1 : Japanese patients will need to stay hospitalized during the first cycle of treatment  
• Table 7 -1 was updated to delete the optional tests planned during the safety follow up visits.  
• Table 7 -1 and section 7.2.2.5.3 were updated to include r egular urinal ysis testing.  
• Section 7.2.1: The imaging assessment schedule was corrected to be performed until week 51 after start of treatment to align with the assessment schedule in patients still on treatment.  
•  
 
•  
  
• Section 7.1.5, the definition of safety follow-up, disease progression follow-up, and survival follow-up periods were clarified. Phone contacts with the patients are now requested also on day 30 and 90 after treatment discontinuation. 
• Section 7.2.2.1 : oxygen saturation will be measured with vital signs in Japanese patients  
• Table 7 -4 was updated to reflect that an extended cytokine panel will be tested in case of 
adverse event suspected to be related to cytokine release.  
 
 
 
• Section 7.2.2.7 : chest x- ray will be  performed in Japanese patients at screening an d Day 
8 of Cycle 1  
• Section 8.2.2 was updated with language specific for Japan. 
• Groupings for safety analysis was updated under Section 10.4.2.1.2. 
• Section 11.5 was updated to better describe Novartis publication policy 

Novartis  Confidential  Page 26  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
IRB/IEC/HA Approval  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation. The changes herein affect the Informed Consent. Sites are required to update and submit for approval a revised Informed Consent that takes into account the changes described in this protocol amendment. 
Novartis  Confidential  Page 27  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Amendment 01 (11- Jul-2016)  
Amendment rationale  
The main reason for this amendment is to add more specific guidance for dose modifications 
and to revise definitions for dose limiting toxicities (DLTs), following Health Authority (HA) feed-back. In addition the routine chemistry lab test Lactate dehydrogenase (LDH) has been 
added since a recent publication suggest that TNBC and metastatic melanoma patients with aggressive tumor growth, with elevated LDH, may have less benefit of PD -1 inhibition 
compared to those with more slowly growing tumors (Diem et al., 2016, Nanda et al., 2016). 
 
 
With the available PK data obtained from the single agent first -in-human study 
CPDR001X2101, an exploratory population PK (PopPK) analysis showed that the T1/2 of PDR001 in man is 20 [17,  23] days (mean [90% CI]). Using five times the upper limit of the 
half-life of 23 days and an added safety margin, the protocol is amended to increase the duration 
of contraception and safety follow -up periods post PDR001 treatment from 90 days to 150 days. 
These changes are related to an Urgent Safety Measure communicated on 08 -June- 2016 to all 
investigators. 
Minor corrections of typos/clarifications of text were also made. The details are provided in the 
below section “Changes to the protocol”. 
Study status  
The CMCS110Z2102 study is currently under review by Health authorities . Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions. 
• Section 6.1.1 Dosing regimen. Adding instructions to resume treatment at a lower level 
after skipping an administration (if meeting criteria for DLT)  
• Section 6.2.4 Defi nitions of dose limiting toxicities. The following Grade 4 AEs should be 
defined as DLTs: Electrolyte abnormalities and CK elevation  
• Section 6.3.1 Dose modification and dose delay. Update of dose modification recommendations for drug related toxicities and instructions to reduce dose after DLT. 
• Section 4 Study design, and Section 7.1.5 Follow-up period. Update of the safety period duration 
• Section 7.2.2.5 Laboratory evaluation: LDH was added in the list of clinical laboratory parameters to be analyzed.  
• Information about update of the follow-period duration were inserted in Section 5.3, 
Section 6.3.2., Section 7.2.2.5.8, Section 8.1.1, Section 8.2.2, Section 10.4.2 and Table 7-1. 

Novartis  Confidential  Page 28  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
1 Background 
1.1 Overview of disease pathogenesis, epidemiology and current 
treatment 
Immunotherapies that target immune checkpoints are currently emerging as key agents in 
cancer therapy. Antibodies inhibiting cytotoxic T -lymphocyte- associated protein 4 ( CTLA -4) 
and programmed death- 1 (PD -1) demonstrate strong efficacy, durable antitumor e ffects and an 
acceptable safety profile. Response to checkpoint inhibition differs strongly across tumor types, with highest rates of response observed in advanced melanoma. Both non- responsiveness to 
checkpoint inhibition as well as initial response follo wed by progression have been observed, 
indicating the presence of intrinsic resistance  and therapy-induced acquired resistance  
(Kelderman 2014). Tumor associated macrophages (TAMs) and myeloid- derived suppressor 
cells (MDSCs) are among the most abundant immune cells in the tumor microenvironment and are known to mediate therapeutic resistance in cancer ( Jiang 2015, Ruffell 2015). Thus, immune 
escape mediated by TAMs and MDSCs is a potential cause of limited clinical benefit of immune check -point blockade ( Zhou 2014). Recently, a clinical study showed an association between 
circulating MDSCs and intrinsic resistance to PD -1 inhibition in melanoma patients 
(Zhou 2014, Weber 2015 ). Additionally, preclinical studies show that single agent blockade of 
CSF-1/CSF- 1R or PD -1 results in limited efficacy by restraining tumor growth, but combined 
blockade of CSF -1R and PD -1 pote ntly elicits tumor regressions ( Zhu 2014 ). Currently, several 
clinical studies are ongoing evaluating the efficacy of dual targeting of PD -1 and TAMs, 
supported by synergistic antitumor activity demonstr ated in a preclinical pancreatic cancer 
model ( Zhou 2014).  
1.1.1  Overview of PD -1 
PD-1 is a critical co -inhibitory receptor that is upregulated on T cells upon activation 
(Freeman  2008 ). It is also expressed by B cells, NK cells, dendritic cells, and activated 
monocytes. The ligands for PD -1, programmed death- ligand 1 (PD -L1) and programmed death-
ligand 2 (PD -L2), are expressed by macrophages and monocytes, and can be induced on 
numerous cell types (T cells, endothelial cells, and tumor cells) during inflammation (Keir 2008). Engagement of PD -1 by its ligands transduces a signal that inhibits T -cell 
proliferation, cytokine production, and cytolytic function ( Riley 2009). During tumorigenesis, 
cancer cells from a wide range of tumor types exploit immune checkpoint pathways, such as PD-1, to avoid detection by the adaptive immune system ( Murphy 2011). Blockade of the PD -
1 pathway has been shown to lead to both accumulation and increased activity of antitumor effector T cells and reduced numbers of regulatory  T cells (Tregs) at the tumor site ( Wang 2009, 
Mangsbo 2010, Mkrtichyan 2011, Rosenblatt 2011).  
Novartis  Confidential  Page 29  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Figure 1-1 Blockade of PD -1/PD -1 interaction by PDR001  
 
APC: antigen presenting cell; MHC: major histocompatibility; TCR: T cell receptor  
1.1.2  Overview of CSF -1 
CSF-1, also known as macrophage colony- stimulating factor (M -CSF) is a protein that is 
produced by several cell types and tissues, including various cancer cell types ( Aharinejad 2007, 
Priceman 2010, Tarhini 2012). CSF-1 binds to the tyrosine kinase receptor, CSF -1 receptor 
(CSF -1R), on myeloid cells, which results in increased proliferation and differentiation of 
myeloid cells into type M2 macrophages (TAMs) and MDSCs, and recruitment into tumors 
(Dai 2001, Li 2006).  TAMs and MDSCs use several mechanisms to induce T -cell inhibition; 
directly through PD -L1 and indirectly through secretion of IL -10, leading to an 
immunosuppressive tumor environment ( Gabrilovich 2009, Kuang 2009, Ruffell 2015).  
Figure 1-2 Macrophage polarization and function  
 
Modified figure from Sica 2006. TAMs induce T -cell inhibition resulting in immune suppression.  

Novartis  Confidential  Page 30  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Preclinical and clinical studies demonstrate that blockade of CSF -1 or CSF -1R activates the 
immune system by limiting tumor infiltration by TAMs and MDSCs, or altering macrophage 
polarization, resulting in significantly enhanced antigen presentation and an increase in CD8+ T-cells ( DeNardo 2011, Pyonteck 2013, Ruffel 2014, Ries 2014, Zhou 2014). However, 
inhibition of CSF- 1 signaling upregulates checkpoint molecules, including PDL1 and CTLA4, 
thereby limiting the potential beneficial therapeutic effects ( Zhu 2014 ). 
1.2 Introduction to study treatment 
1.2.1  Overview of PDR001  
PDR001 is a high- affinity, ligand- blocking, humanized anti -PD-1 IgG4 antibody that blocks 
the binding of PD -L1 and PD -L2 to PD -1. PDR001 recognizes PD -1 in cynomolgus monkeys 
and shows functional activit y in vitro  and ex vivo . For further details, please refer to the 
[PDR001 Investigator’s Brochure]. 
1.2.1.1  Non-clinical experience of PDR001  
PDR001 binds specifically and with high affinity to human PD -1. In Biacore assays, the 
constant of dissociation (K D) of PDR 001 on human PD -1 is 0.827 nM. In ex vivo  lymphocyte 
stimulation assays using human blood, PDR001 enhances interleukin- 2 (IL -2) production by 
approximately 2 fold in response to super antigen stimulation with Staphylococcal enterotoxin 
B (SEB). PDR001 does  not cross -react with rodent PD -1, and thus, cannot be evaluated in 
murine tumor models. It does cross -react with cynomolgus monkey PD -1, and is functionally 
active, making cynomolgus monkey a relevant species for toxicology studies. The affinity of PDR001 for cynomolgus PD-1 is 0.929 nM, nearly the same for human PD-1, as noted above. 
A GLP tissue cross reactivity study using frozen human and cynomolgus monkey tissues was 
also done in support of the safety of PDR001. There was no unexpected binding observed. The non-clinical toxicology of PDR001 was evaluated in a five week GLP toxicology study in 
cynomolgus monkeys with safety pharmacology endpoints and an eight week recovery. All main phase data as well as recovery pathology data are reported here. All other recovery phase data are pending. Repeat administration of PDR001 to monkeys was well tolerated at all doses tested in the GLP toxicology study. No test article -related in -life, mortality, organ weight 
changes, or macroscopic findings were noted. There were no PDR001- related effects seen in 
any of the safety pharmacology endpoints assessed (cardiovascular, neurobehavioral, and respiratory). Macrophage infiltrates into the splenic white pulp were observed in animals given 100 mg/kg/week and mononuclear ce ll infiltrates, often associated with fibrosis, were also 
observed around the injection site blood vessel (saphenous vein) in a few animals given 
≥25 mg/kg/week. These PDR001- related microscopic changes were fully reversible after  an 
eight week recovery period. 
The following changes were noted in main phase and recovery treated animals as well as control 
recovery animals. Mostly low grade changes were noted in several tissues in the form of mononuclear infiltrates in the vascular and perivascular space. In general, in most organs, vascular/perivascular changes were limited to one or a few blood vessels in each organ and sometimes involved a segment of a blood vessel with occasional vessel wall degeneration. No evidence of parenchyma l damage was associated with the vascular/perivascular changes in any 
Novartis  Confidential  Page 31  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
of the organs examined and the changes were not associated with any frank tissue injury. While 
these effects were not exclusive to treated animals, because of their nature and close asso ciation 
with the expected pharmacology of PD -1 blockade, a potential PDR001 related effect cannot 
be excluded. There were no test article related effects seen in the cardiovascular assessments. All other microscopic findings were considered spontaneous or otherwise unrelated to PDR001 administration.  
Dose -dependent exposure to PDR001 in each dose group was confirmed. A pharmacodynamic 
ex vivo  superantigen stimulated whole blood assay measuring IL -2 release was performed. 
Blood from untreated control animals  showed augmentation of IL -2 release when PDR001 was 
added ex vivo , whereas blood from treated animals at all doses did not show augmented IL -2 
release, indicating target engagement and inability to further dis -inhibit the SEB induced 
response with the fur ther addition of PDR001. The Highest Non -Severely Toxic Dose 
(HNSTD) in this study was 100 mg/kg. PDR001 has a favorable safety profile in monkeys that supports a projected human starting dose of 1 mg/kg in the first in human study [CPDR001X2101] . For further details, please refer to the [PDR001 Investigator’s Brochure]. 
1.2.1.2  Clinical experience of PDR001  
PDR001 is being tested in a FIH, multi -center, open -label study [CPDR001X2101]  starting with 
a Phase I dose escalation part, followed by a Phase II part. 
The [CPDR001X2101]  study started enrollment on 27 April 2015 and is ongoing. As of 17 
December 2015, a total of 58 patients had been treated in the study at the dose levels of 1, 3 and 
10 mg/kg Q2W and 3 and 5 mg/kg Q4W. No patient experienced a dose limiting toxicity (DLT) and the toxicity profile appears to be similar to that of marketed inhibitors of PD -1. The PK 
data obtained from the dose escalation, and modeling of the exposure data, support the use of flat dosing for PDR001 of 400 mg given every 4 weeks. The expected PDR001 C
trough 
concentrations are in line with observed steady state mean C trough concentrations for 
pembrolizumab, which is approved with substantial efficacy in several cancer types. The data also support the use of 300 mg Q3W as an alternative dose regimen if it is more convenient for scheduling purposes, for example in combination treatment regimens. 
1.2.2  Overview of MCS110 
MCS110 is a high- affinity, humanized monoclonal antibody directed against human 
macrophage colony stimulating factor (M -CSF; also known as colony- stimulating factor -1 
[CSF -1]). CSF -1 binds to the receptor tyrosine kinase CSF -1R (CSF -1 Receptor) to drive the 
differentiation, migration and survival of tissue macrophages. MCS110 neutralizes multiple 
forms of human CSF -1 inhibitin g its effect on monocytes and macrophages. See [MCS110 
Investigator’s Brochure] for further information.  
1.2.2.1  Non-clinical experience of MCS110  
The ability of MCS110 to neutralize the activity of CSF -1 was established in several in vitro  
and in vivo  studies. 
The preclinical pharmacokinetics (PK) and pharmacodynamics (PD) of MCS110 were 
evaluated in cynomolgus monkeys following a single intravenous (i.v) bolus injection of 0.2, 2 
Novartis  Confidential  Page 32  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
or 20 mg/kg, or multiple weekly iv bolus injections of 10 mg/kg for 3 weeks and 2, 20 or 100 
mg/kg for up to 13 weeks. Free MCS110 (unbound to target CSF -1) exhibited dose -dependent 
PK, with decreasing clearance (CL) and increasing mean residence time (MRT) or effective t1/2 when dose increased. The PK profiles of free MCS110 were notably nonlinear at 
concentrations below approximately 20 μg/mL, presumably due to target -mediate disposition. 
In the 13 -week study, 2 out of 22 animals tested had anti -drug antibodies detected in serum, 
which correlated with lower MCS110 exposure at the corresp onding time points. For PD, time 
and dose dependent increase in total CSF -1 was observed in the 13- week study following 
MCS110 administration, presumably due to slower clearance of the CSF -1 after it formed 
immune complexes with MCS110, indicating target e ngagement. Decreases in other 
downstream biomarkers such as circulating monocytes and serum NTx were also observed following MCS110 administration. 
The cynomolgus monkey was selected as the relevant species for toxicology studies because 
MCS110 showed similar functional activity against cynomolgus monkey and human CSF -1 in 
in vitro bioassays. In cynomolgus monkey studies there were no severe toxicological effects in any animal given MCS110 intravenously as a single dose or as multiple doses once weekly up to 13 weeks and up to doses of 100 mg/kg, showing good tolerability of MCS110 with systemic administration. Mild increases in liver enzymes were seen  in all studies without 
histopathological correlates, which resolved with clearance of the drug. This included consistent mild/moderate, dose -dependent increases in lactate dehydrogenase (LDH), mild increases in 
AST, and minimal increases in gamma -glutamyl transpeptidase  (GGT) and ALT. 
All parameters returned to baseline levels with the clearance of MCS110 from the serum. The 
most likely cause of these increases is reduced clearance rate of the serum enzymes due to the diminished numbers of Kupffer cells in the liver. This was demonstrated in cynomolgus 
monkey study with a single intravenous dose of MCS110, which showed a decreased clearance of histidine -tagged creatine kinase injected in parallel to MCS110. After 13 weekly doses, 
minimal or mild interstitia l edema was seen in multiple organs histopathologically in all dose 
groups, including the low -dose group. Although periorbital swelling was observed to occur 
sporadically in all groups (including controls), the increased incidence and severity of periorbit al swelling observed at 100 mg/kg suggested a relationship of this effect with MCS110 
administration. No interstitial or periorbital edema was present at the end of the recovery period showing the reversal of this effect. All other effects seen, such as bone morphology changes and monocyte depletion, were due to the expected pharmacological effects of MCS110. The data support the intravenous use of MCS110 in clinical trials at the doses selected ( Section 2 .3). 
Please refer to the most recent edition of the [MCS110 Investigator’s Brochure] for further information. 
1.2.2.2  Clinical experience  
Four clinical trials with MCS110 have been initiated. Brief information on clinical experience 
of relevant MCS110 studies is provided below. For additional information, please refer to [MCS110 Investigator Brochure]. 
Novartis  Confidential  Page 33  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Table 1-1 Clinical trials with MCS110  
Trial  Study type  Study objectives  Patients  MCS110 dose range 
and schedule  
[MCS110A2101]  
Closed First in 
human, dose 
escalation  MTD, safety, PK/PD, 
preliminary efficacy  Prosta te cancer with 
bone metastases, n=3  0.01mg/kg every 14 days  
[MCS110X2101]  
Completed  Healthy 
volunteers, dose 
escalation  MTD, safety, PK/PD  Healthy, n= 52  0.01-20 mg/kg, 1-2 iv infusions every 21- 56 
days  
[MCS110X2201]  
Ongoing  Efficacy 
study  Safety, tolerability, 
PK/PD, efficacy  Pigmented Villonodular 
Synovitis (PVNS), 
n=16  10 mg/kg, 1-4 iv 
infusions every 28 days 
[MCS110Z2201]  
Ongoing  Efficacy study  Safety, tolerability, PK/PD, efficacy  Triple Negative Breast Cancer (TNBC), n=24  
10 mg/kg iv infusions 
every 21 days 
(additional dose C1D8)  
[MCS110Z1101]  
(ongoing)  Healthy volunteers, dose 
escalation in 
Japanese 
population  Safety, tolerability, 
PK/PD Japanese healthy male, n= 21  1,3,5,10mg/kg iv infusion single dose.  
1.2.2.2.1  CMCS110X2101, a clinical trial in healthy volunteers  
[CMCS110X2101]  was a Phase I study designed to evaluate safety, tolerability and MTD of 
MCS110 in 52 healthy volunteers (HV). MCS110 was delivered to 27 HV at increasing single 
doses from 0.01- 20 mg/kg. Additionally, 6 HV received 2 doses (5 mg/kg) given 21 days apart, 
and another 6 received 2 doses (10 mg/kg) given 56 days apart. 
Clinical safety and tolerability  
Asymptomatic and reversible creatine kinase (CK) elevations (Grade 1 to Grade 4) were seen 
in 15 of 52 HV. The CK elevation did not appear to reflect muscle damage since neither troponin T (marker for cardiac muscle damage) nor aldolase (marker for skeletal muscle tissue damage) was elevated. The CK elevations are thought to be caused by the pharmacological effect of MCS110. 
Mild periorbital edema (Grade 1), was observed in 4 of 52 HV and was transient, lasting 
between 2 and 158 days. None of the subjects who presented with periorbital edema had developed anti-drug antibodies. 
The dose limiting toxicity was identified at 20 mg/kg, based on CK elevations exceeding more 
than 5 times the upper limit of normal. The recommended dose for future studies was set at 10mg/kg. 
Clinical pharmacokinetics  
Following intravenous administration of MCS110 in healthy volunteers, serum free MCS110 
exhibited concentration/dose -dependent pharmacokinetics (PK), with decreasing clearance 
(CL) and increasing mean residence time (MRT) or effective t
1/2 when doses increased from 
Novartis  Confidential  Page 34  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
0.01 to 20 mg/kg across 8 dose levels. The shape of the serum free MCS110 PK profiles 
indicated target mediated disposition, where the MCS110 concentration declined more rapidly at concentrations lower than approximately 10 μg/mL. This was presumably due to binding of MCS110 to the target, suggesting that serum free MCS110 concentrations above approximately 10 μg/mL are required to saturate circulating CSF -1. At the 10 mg/kg single dose level, 
MCS110 concentrations were maintained above 10 μg/mL for up to 42 days post -dose. As 
expected, total CSF -1 exhibited a dose -dependent increase in plasma following MCS110 
treatment, presumably due to slower clearance of CSF -1 after it formed immune complexes 
with MCS110, indicating successful target engagement. The total CSF -1 concentration reached 
a plateau at the single- dose level  at or above 10 mg/kg, and it was maintained at the plateau for 
at least 42 days at the 10 mg/kg dose. 
Clinical pharmacodynamics  
Expected pharmacological responses were observed in downstream biomarkers including dose -
dependent decreases in circulating CD1 4+ or CD14+CD16+ monocytes and C -terminal 
telopeptide of type I collagen (CTX -1), a bone resorption marker. In addition, dose -dependent 
increases in CK were observed. Simulation of steady- state dose- response relationships for 
biomarkers showed that with the once- every -4 week (Q4W) iv administration of MCS110 the 
response of PD biomarkers (CD14+ and CD14+CD16+ monocytes, and CTX- 1) was expected 
to be close to maximal at doses at or above 5 mg/kg and minimal at doses at or below 1 mg/kg.  
1.2.2.2.2  CMCS110X2201, a Phase II study in pigmented villonodular synovitis  
[CMCS110X2201]  is an ongoing Phase II study designed to evaluate safety, tolerability and 
efficacy of MCS110 in pigmented villonodular synovitis (PVNS). PVNS is a benign tumor 
consisting of macrophages and multinucleated giant cells, most commonly located to joints. As of 19- Feb-2015, 16 patients with PVNS have been treated with MCS110. In Part A of the study, 
7 patients received a single dose of 10 mg/kg MCS110. In the multiple dose part B of the study, at the cut-off date of 19- Feb-2015, 9 patients were randomized and had received at least one 
infusion. 
Clinical safety and tolerability  
As of February 19 2015, the most common adverse events reported include elevated CK (Grade 
2-4), periorbital edema (Grade 1) and AST elevations (Grade 1).  
Clinical pharmacokinetics  
PK analysis is ongoing. Preliminary data of the first 3 patients with single i.v. infusion of 10 mg/kg in the ongoing study suggested a similar PK profile as that observed in HV. 
Clinical pharmacodynamics  
Preliminary data from the ongoing study in PVNS patients showed an expected decrease in 
monocytes and CTX -1, while an increase was seen in CK. Maximum values are generally 
observed at Day 28 or Day 43 and then return to baseline. 
Novartis  Confidential  Page 35  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Clinical efficacy  
Efficacy data from four PVNS patients receiving a single dose of 10 mg/kg MCS110 
demonstrated a clear efficacious effect with a mean reduction in tumor volume of 40%. 
1.3 Overview of combination treatment 
1.3.1  Non-clinical  
No preclinical data exist for the  combination of MCS110 and PDR001. 
1.3.2  Clinical  
No clinical data exist for the combination of MCS110 and PDR001. However, several clinical studies are ongoing evaluating the efficacy of dual targeting of PD -1/PD- L1 and TAMs in 
advanced malignancies ( ClinicalTr ials.gov: [[STUDY_ID_REMOVED]], [ [STUDY_ID_REMOVED]], 
[[STUDY_ID_REMOVED]]).  
1.3.3  Potential for drug- drug interactions  
Specific studies to investigate drug- drug interactions (DDI) have not been conducted. MCS110 
and PDR001 are monoclonal antibodies, not metabolized by Cytochrome P450 (CYP450) enzymes or transported by P -glycoprotein (PgP) or related ABC membrane transporters. 
Therefore DDIs at the level of these enzymes and transporters are not expected. MCS110 specifically neutralizes CSF -1 and is not expected to modulate cytokines. Cytokines produced 
by PDR001- activated lymphocytes may impact levels of PgP or CYP450 enzyme activity. The 
clinical relevance of this is unknown but considered unlikely. 
1.3.4  Expected overlapping toxicities  
PD-1 inhibitors are known to cause immune mediated adverse events e.g. pneumonitis, colitis 
etc, whereas no apparent immune related adverse events have been reported with MCS110 and 
other CSF -1/R targeting drugs (USPI/SPC nivolumab/pembrolizumab; Cassier ASCO 2014, 
Rugo ESMO 2014). However, since both MCS110 and PDR001 are immune activating drugs there is a potential risk for higher frequency or aggravation of immune mediated adverse events.  
As of 03- Sep-2015, no liver enzyme elevations have been reported from treatment with PDR001 
[CPDR001X2101] , nonetheless, liver enzyme elevations and immune related hepatitis have 
been reported with other PD -1-inhibitors and a class effect should be suspected, (USPI/SP C 
nivolumab/pembrolizumab). Clinical studies with MCS110 report frequent asymptomatic and transient CK (Grade 3) and AST elevations (Grade 1 -2), whereas ALT elevations (< Grade 1) 
were only seen in occasional patients. The increase of enzymes did not refle ct muscle damage 
since markers for cardiac or skeletal muscle damage were evaluated and found to be normal. Isolated CK/AST elevation (without ALT elevation) is not considered to be consistent with liver damage ( Krishnamurthy 2009). The elevation of CK and liver transaminases is considered a 
pharmacological effect of MCS110 due to reduction in the number of liver macrophages (Kupffer cells) responsible for elimination of these enzymes from circulation. Nonetheless, overlapping liver enzyme elevations may be expected with the combination treatment of MCS110 and PDR001, therefore liver enzymes will be carefully monitored in this study. 
Novartis  Confidential  Page 36  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Skin toxicity have been reported from studies with CSF -1/R inhibitors as well as PD -1 
inhibitors; thus, skin toxicity may be an overlapping toxicity with the study drug combination 
(USPI/SPC nivolumab/pembrolizumab; Cassier ASCO 2014, Rugo ESMO 2014).  
2 Rationale  
2.1 Study rationale and purpose 
Treatment with PD -1 checkpoint inhibitors results in clinically important anti- tumor activity in 
several tumor types ( Topalian 2014, Gettinger 2015, Rizvi 2015). However, intrinsic as well as 
acquired resistance to PD -1 inhibition has been observed ( Section 1.1). Therapeutic resistance 
to various cancer treatments, including PD -1 inhibition, is mediated through 
immunosuppressive cells (TAMs and MDSCs) in the tumor microenvironment ( Ruffell 2015, 
Weber 2015). Preclinical and clinical studies have demonstrated that tumor infiltrating M2 macrophages (TAMs) can be depleted or polarized into M1 macrophages by CSF -1 signaling 
blockade ( Figure 1 -1, DeNardo 2011, Pyont eck 2013, Ruffel 2014, Ries 2014). 
Furthermore,combined targeting of PD -1 and CSF -1 signaling resulted in synergistic antitumor 
activity in a preclinical pancreatic cancer model ( Zhou 2014).  
Figure 2-1 Rationale for combined treatment with PDR001 and MCS110 
 
TAMs induce T -cell inhibition leading to an immunosuppressive tumor environment ( Gabrilovich 2009 , 
Kuang 2009, Ruffell 2015 ). Tumor cells exploit immune checkpoint pathways to inhibit T -cell 
proliferation and avoid detection by the immune system ( Murphy 2011). Combined treatment with 
MCS110 and PDR001 is  expected to result in TAM depletion, enhanced T -cell activation and 
synergistic antitumor activity in the clinical setting.  
Combined treatment with MCS110 and PDR001 will be evaluated in disease indications where single agent PD -1/PD- L1 inhibition did not  result in clinically meaningful responses and 
therapeutic resistance may be mediated by TAMs:  

Novartis  Confidential  Page 37  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
1. Anti-PD-1/PD- L1 treatment naïve  TNBC, pancreatic and endometrial cancer  
Clinical studies show modest, but limited response to PD -1/PD- L1 inhibition in TNBC and 
pancreatic cancer indicating intrinsic resistance ( Nanda 2014, Emens 2015, Segal 2014). 
Additionally, TNBC, pancreatic and endometrial cancers are characterized by an immune 
suppressive tumor microenvironment consisting of a high content of TAMs, known mediators of intrinsic drug resistance ( Yuan 2014, Mielgo 2013, Kübler 2014).  
2. Anti-PD-1/PD- L1 treatment resistant  melanoma  
Clinical studies show high response rates to PD -1/PD- L1 inhibition in melanoma; however, 
non-responsiveness ( intrinsic resistance ) as well as initial response followed by progression 
(acquired resistance)  have been observed ( Topalian 2014). Clinical data demonstrate that 
MDSCs mediate intrinsic resistance to PD -1 inhibition in melanoma ( Weber 2015).  
The purpose of this study is to evaluate the safety, tolerability and efficacy of combined treatment with MCS110 and PDR001. In addition, the mechanisms of intrinsic and acquired resistance to PD -1/PD- L1 inhibition as well as the ability of MCS110 to overcome resistance 
will be explored. 
2.2 Rationale for the study design 
This is an open -label, Phase Ib/II study of the combination of MCS110 and PDR001. The study 
consists of two parts: a dose escalation in the Phase Ib part and a Phase II part where four groups will be treated at the recommended Phase II dose (RP2D ). 
Phase Ib  
In the Phase Ib part, cohorts of patients will receive escalating doses of MCS110 and PDR001 until a MTD/RP2D is identified. The dose escalation decision will be guided by a Bayesian logistic regression model (BLRM) with overdose control (EWOC)  principle based on DLT data 
in the context of available safety, PK and PD information. For details of the dose escalation, please refer to Section 6.2. 
This open- label dose escalation study design using a BLRM is a well -established method to 
estimate the MTD, or identify a lower RP2D in cancer patients. The adaptive BLRM with 
EWOC principle controls the risk of DLT in future patients on study. The decisions on the dose of MCS110 in combination with PDR001 are made by the Investigators and Novartis study 
personnel and will be based upon the dose identified to satisfy the EWOC criterion under the appropriate BLRM, patient tolerability and safety, PK and PD data available at the time of the decision Section 6.2.3. 
Phase II  
The Phase II part of the study will begin after the RP2D is determined for the combination of 
MCS110 and PDR001. The primary objective of the Phase II part is to estimate the preliminary anti-tumor activity of MCS110 in combination with PDR001 in diseases known to respond to 
PD-1/PD- L1 inhibition or where limited response may be attributed to immune escape mediated 
by the tumor microenvironment (TAMs, MDSC). These disease indications include  melanoma, 
TNBC, endometrial and pancreatic cancer.  
Novartis  Confidential  Page 38  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
The efficacy of the combination will be explored both in patients that are naïve to anti -PD-
1/PD- L1 treatment (TNBC, pancreatic, endometrial cancer) and patients that have progressed 
on previous anti -PD-1/PD -L1 treatment (melanoma). Twenty patients are expected to be 
enrolled in each of the TNBC, endometrial and melanoma groups, but enrollment will be 
expanded up to approximately 40 patients in those groups in which objective responses ( CR or 
PR) are obser ved (≥ 3 of 20 patients in the anti -PD-1/PD- L1 naïve groups or ≥ 2 of 20 patients 
in the anti -PD-1/PD- L1 resistant groups).  In addition, 20 patients will be enrolled in the 
pancreatic group at RP2D. Enrollment may be expanded up to approximately a total of 40 patients at RP2D in this group if at least 3 pts with CR, PR or SD > 4 months are observed (addition of Group 2a, see Figure 4 -1). Further, an exploratory group of 20 patients at a lower 
dose (1 mg/kg MCS110 in combination with PDR001 300 mg) may be opened if the above mentioned gating criteria are met (Group 2b, see Figure 4-1) . 
A Bayesian design will be used to estimate the overall response rate (ORR) in each of the 
TNBC, endometrial and melanoma groups and the clinical benefit rate (CBR) in the pancreatic group. For Group 2 (pancreatic cancer), a separate model with same prior as sumptions will be 
used to estimate CBR for the different dose levels. The Phase II groups are designed to detect efficacy signals indicating a patient population where further studies  of the combination of 
MCS110 with PDR001 are warranted. 
2.3 Rationale for dose and regimen selection  
PD-1 inhibition has demonstrated objective responses in several different malignancies, 
whereas blockade of CSF1/R signaling has led to TAM depletion and immune activation, but no objective responses have been reported so far ( Ries 2014, Gomez- Roca 2015). The PDR001 
dose will start at 100 mg, a dose expected to demonstrate antitumor activity,  and MCS110 will 
start at 3 mg/kg. These doses were selected based on preclinical and clinical studies as described in Section 6.2.1. Both antibodies will be administered via i.v. infusion every 3 weeks in 
accordance with ongoing studies  of MCS110 combined with chemotherapy  
[CMCS110Z2201] and single agent PDR001 [CPDR001X2101] . 
2.4 Rationale for choice of combination drugs 
Currently, nivolumab and pembrolizumab are the only PD -1 inhibitors approved by FDA and 
EMA for the treatment of advanced melanoma and non- small cell lung cancer; however, none 
are approved for the treatment of TNBC, pancreatic cancer or endometrial cancer. PDR001 is Novartis’ PD -1 inhibitor currently being evaluated in various advanced malignancies 
[CPDR001X2101] . Therapeutic resistance to PD -1 inhibitors seems to be mediated through 
TAMs ( Weber 2015). Several compounds directed towards CSF -1/CSF- 1R have been reported 
to deplete TAMs in preclinical and clinical studies ( Ries 2014, DeNardo 2011); however, none 
of these compounds are approved yet. MCS110 is Novartis’ anti -CSF-1 antibody currently 
being evaluated in several studies in PVNS and TNBC. Refer to  
Section 1.1 and Section 2.1. 
3 Objectives and endpoints  
Objectives and related endpoints are described in Table 3 -1 below. 
Novartis  Confidential  Page 39  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Table 3-1 Objectives and related endpoints  
Objective  Endpoint  Analysis  
Primary   Refer to Section 10.4  
Phase Ib part : 
To characterize the safety and tolerability of MCS110 given in 
combination with PDR001 and to identify a recommended dose 
combination for Phase II.   
Frequency, severity and seriousness of AEs, laboratory abnormalities and other safety parameters.  
Dose interruptions, reductions, and dose intensity.  
Incidence rate of DLTs during the first two cycles of study treatment.   
Phase II part : 
To estimate the anti -tumor activity of the combination of 
MCS110 with PDR001   -Overall response rate (ORR) per Response Evaluation Criteria in 
Solid Tumors (RECIST v1.1) (groups 1, 3 and 4).  
-Clinical benefit rate (CBR) per Response Evaluation Criteria in Solid 
Tumors (RECIST v1.1), which is defined as confirmed objective 
response or SD>4 months. (Group 2)   
Secondary   Refer to Section 10.5  
Phase Ib part : 
To estimate the preliminary anti -tumor activity of the 
combination of MCS110 with PDR001   ORR, progression free survival (PFS), CBR,duration of response (DOR) and disease control rate (DCR) per RECIST v1.1 and per 
immune related Response Criteria (irRC)   
Phase II part : 
To further characterize the safety and tolerability of MCS110 
given  in combination with PDR001   Frequency, severity and seriousness of AEs, laboratory abnormalities 
and other safety parameters.   
Phase II part : 
To evaluate the preliminary anti -tumor activity of the 
combination of MCS110 with PDR001 by additional efficacy 
measures   
ORR per irRC, PFS, DOR, DCR, CBR per RECIST v1.1 and per irRC 
(Group 1, 3 and 4)  
CBR per irRC, PFS, DOR, DCR, ORR per RECIST v1.1 and per irRC 
(Group 2)   
Phase Ib and Phase II parts: 
To characterize the pharmacokinetics of MCS110 and PDR001 
in combination   
Serum concentration of MCS110 and PDR001 and PK parameters   
To assess immunogenicity of MCS110 and PDR001  Presence and/or concentration of anti -PDR001 or anti -MCS110 
antibodies   
To describe survival with MCS110 and PDR001 in combination  Overall survival (OS)   
Novartis  Confidential  Page 40  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 

Novartis  Confidential  Page 41  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
4 Study design  
4.1 Description of study design 
This study is a Phase Ib/II, multi -center, open -label study starting with a Phase Ib dose 
escal ation part followed by a Phase II part. MCS110 and PDR001 will be administered i.v. 
every three weeks (Q3W) until the patient experiences unacceptable toxicity, progressive 
disease as per irRC and/or treatment is discontinued at the discretion of the inves tigator or the 
patient. Patients should not discontinue treatment based on progressive disease per RECIST v1.1. The study design is summarized in Figure 4-1. 
Phase Ib part  
During the Phase Ib part of the study, cohorts of patients will be treated with increasing doses 
of MCS110 and PDR001 every three weeks until a RP2D is determined for this treatment combination. 
It is expected that an RP2D will be established before the MTD is reached. The RP2D for the 
combination will not exceed the RP2Ds for the single agent administration of MCS110 and 
PDR001. To assure that the combination RP2D does not exceed the MTD, combination MCS110 and PDR001 dose escalation will also be guided by an adaptive Bayesian logistic regression model (BLRM) following the escalation with overdose control (EWOC) principle. 
At least 15 patients are required during dose escalation to define the MTD; however, fewer than 15 patients may be treated if the RP2D is determined without reaching the MTD (for further details see Section 6.2.3).  
Phase II part  
Once the MTD and/or RP2D have been declared, additional patients will be enrolled in the 
Phase II part in order to assess the preliminary anti- tumor activity of MCS110 in combination 
with PDR001. 
In the Phase II part, patients will be assigned to different groups depending on the tumor type 
as shown in Figure 4-1. Please refer t o Section 5.1 for further details.  
All groups will enroll approximately 20 patients each initially. Enrollment to any of these groups may be stopped at fewer patients if achieving these enrollment targets is not logistically feasible.  
For Groups 1 and 3, the sample size may be extended to approximately 40 patients, if at least 3 patients out of the first 20 treated in that group have an objective response (CR or PR) per RECIST v1.1 or irRC. Twenty patients will be enrolled into Group 2 at RP2D. Enrollment may be expanded up to approximately 40 patients if clinical benefit per RECIST v1.1 or irRC  (CR, 
PR or SD > 4 months) is observed in at least 3 pts (addition of Group 2a, see Figure 4 -1). In 
addition, an exploratory group of 20 patients at a lower dose (1 mg/kg MCS110 in combination with PDR001 300 mg) may be opened if the above mentioned gating criteria is met (Group 2b, see Figure 4-1). Group 4 may similarly be expanded if at least 2 patients out of the first 20 
treated in that group have an objective response ( Figure 4-1 ). A Bayesian design will be used 
Novartis  Confidential  Page 42  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
in order to estimate ORR within each expansion group. Details of the sample size calculations 
leading to the patient numbers are provided in Section 10.8. 
Figure 4-1 Study design  
 
The primary clinical study report (CSR) will be based on all patients’ data from the Phase Ib and Phase II parts, up to the time when all patients have completed at least six cycles of treatment or discontinued treatment. Patients who are on study beyond cycle 6 may remain on treatment until they discontinue the study. Any additional data (after the data cut -off date for 
the primary CSR) will be further summarized in a final CSR at completion of the study, as defined in Section 4.3. 
Screening period  
The screening period begins once the patient has signed the study informed consent. Patients 
will be evaluated against study inclusion and exclusion criteria ( Table 7 -1 and Section 5.2, 
Section 5.3 and Section 7.1.1).  
   
 

Novartis  Confidential  Page 43  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
Treatment period  
The treatment period will begin on Cycle 1 Day 1. For the purpose of scheduling and 
evaluations, a treatment cycle will consist of 21 days. 
Further details are provided in Table 7 -1 and Section 7.1.2. 
Follow -up (FU) period 
Patients will be followed up for safety evaluations 150 days after the last administration of 
PDR001. For patients who had to stop PDR001 treatment but continued taking MCS110 at the time of treatment stop, the follow -up evaluation will take place 90 days after the last 
administration of MCS110 or 150 days after the last administration of PDR001, whichever duration is longer ( Table 7 -1 and Section 7.1.5).  
Disease progression FU  
Patients who discontinue study treatment for any reason other than disease progression as per irRC will be followed up for progression of disease ( Section 7.1.5). The disease progression 
follow- up will be performed until all patients enrolled in the Phase II part of the study have had 
progression of disease or discontinued the study for any reason. 
Survival FU  
Patients enrolled in Phase Ib and Phase II part will be followed for survival ( Section 7.1.5) until 
the end of the study is reached, unless patients withdraw consent or are lost to follow-up. 
4.2 Timing of interim analyses and design adaptations 
No formal interim analyses are planned in the study. However, in the Phase Ib part, the dose -
escalation design foresees that decisions based on the current data are taken before the end of 
the study. In the Phase II part the number of patients with tumor response will be monitored in each disease group to decide if the enrollment should be extended (see Section 2.2, Section  4.1 
and Section 10.7). The decision of whether to expand a certain group will be made at the time 
when at least 3 patients , for Group 1or  3, or at least 2 patients for Group 4 have an objective 
response (CR or PR) per RECIST v1.1 or irRC, or the last patient has been on treatment for at least 6 months, whichever occurs earlier. For Group 2, t he decision to expand will be made if 
clinical benefit per RECIST v1.1 or irRC  (CR, PR or SD > 4 months)  is observed in at least 3 
patients or the last patient has been on treatment for at least 6 months . The decision to extend 
enrolment will be made separately for each of the groups.  
4.3 Definition of end of the study 
The end of the study will be when: 
• 80% of th e patients have completed the survival follow -up period (minimum 18 months 
after the first dose of treatment)  or discontinued the study for any reason, and all patients 
have completed treatment and the safety follow -up period (150 days after last PDR001 
dose or 90 days for patients who stopped PDR001 and continued with MCS110 alone for more than 60 days),  
Novartis  Confidential  Page 44  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
or 
• the study is terminated early  
or • another clinical  study becomes available that can continue to provide study treatment in 
this patient population, all patients  ongoing are transferred to that clinical study and all 
discontinued patients have completed the safety follow -up period. The follow -up for 
diseas e progression and survival will not be performed or pursued (see Section 7.1.5). 
At the end of the study, every effort will be made to continue provision of study treatment 
outside this study through an alternative treatment option to patients who, in the opinion of the investigator, are still deriving clinical benefit.  
4.4 Early study termination 
The study can be terminated at any time for any reason by Novartis. Should this be necessary, the patient should be seen as soon as possible for End of Treatment (EOT) visit and the assessments for EOT should be performed as described in Section 7.1.3  for a discontinued or 
withdrawn patient. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the patient’s interests. The investigator will be responsible for informing Institutional Review Boards (IRBs) and/or independent ethi cs committees (IECs) of the early termination of the trial.  
5 Population 
5.1 Patient population 
The investigator or designee must ensure that only patients who meet all the following inclusion and none of the exclusion criteria are offered treatment in the study. 
5.2 Inclusion criteria 
Patients eligible for inclusion in this study have to meet all  of the following criteria:  
1. Written informed consent must be obtained prior to any procedures 
2. Age ≥ 18 years [For Japan only: written consent is necessary both from the patient and his/her legal representative if he/she is under the age of 20 years.] 
3. Phase Ib part: Patients with advanced melanoma, endometrial carcinoma, pancreatic or TNBC, with measurable or non-measurable disease as determined by RECIST v 1.1 (refer to Appendix 1), who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists. 
4. Phase II part: Patients with advanced solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have received standard therapy (no more than 3 prior lines of treatment) or are intolerant of standard therapy, have progressed following their last prior therapy, and fit into one of the following groups: 
• Group 1: TNBC who did not receive prior anti- PD-1/PD- L1 treatment  
Novartis  Confidential  Page 45  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
• Group 2: Pancreatic adenocarcinoma who did not receive prior anti- PD-1/PD- L1 
treatment  
• Group 3: Endometrial carcinoma who did not receive prior anti- PD-1/PD-L1 
treatment  
• Group 4: Melanoma who progressed on prior anti PD-1/ PD- L1-directed treatment.  
5. ECOG performance status ≤ 2 
6. Patient must have a site of disease amenable to biopsy, and be a candidate for tumor 
biopsy according to the treating institution’s guidelines. Patient must be willing to undergo a new tumor biopsy at screening, and during therapy on this study. Patients with an available archival tumor tissue collected less than 6 months before study startup do not need to perform a tumor biopsy at screening. 
5.3 Exclusion criteria 
Patients eligible for this study must not meet any of the following criteria: 
1. Presence of symptomatic CNS metastases, or CNS metastases that require local CNS -
directed therapy (such as radiotherapy or surgery). Patients with treated brain metastases 
should be neurologically stable (for 4 weeks post treatment and prior to study enrol lment) 
and off of steroids for at least 2 weeks before administration of any study drug. 
2. History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs). 
3. Patient having out of range laboratory values defined as: 
• Creatinine clearance (cal culated using Cockcroft-Gault formula, or measured) < 40 
mL/min  
• Total bilirubin > 1.5 x ULN, except for patients with Gilbert’s syndrome who are 
excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN 
• Alanine aminotransferase (ALT) > 3 x UL N 
• Aspartate aminotransferase (AST) > 3 x ULN  
• Absolute neutrophil count < 1.0 x 109/L 
• Platelet count < 100 x 109/L 
• Hemoglobin (Hgb) < 9 g/dL 
4. Impaired cardiac function or clinically significant cardiac disease, including any of the following: 
• Clinically sign ificant and/or uncontrolled heart disease such as congestive heart 
failure requiring treatment (NYHA Grade ≥ 2), uncontrolled hypertension or clinically significant arrhythmia  
• QTcF > 470 msec on screening ECG or congenital long QT syndrome 
• Acute myocardial  infarction or unstable angina pectoris < 3 months prior to study 
entry  
5. Active autoimmune disease or a documented history of autoimmune disease within three years before screening, including the following: 
• A documented history of inflammatory bowel disease (ulcerative colitis or Crohn’s disease, within three years).  
Novartis  Confidential  Page 46  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
• Recent (< 12 months) active diverticulitis.  
• Patients with vitiligo, resolved childhood asthma/atopy and type I diabetes mellitus, 
residual hypothyroidism due to an autoimmune condition and only requiring hormone replacement, are not excluded.  
6. Active infection, including active tuberculosis requiring systemic antibiotic therapy  
7. Known human immunodeficiency virus (HIV) infection (no testing required). 
8. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, or HBV/HCV carriers/infections requiring antiviral treatment (testing required).  
9. Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ  of any type. 
10. Any medical condition that would, in the investigator’s judgment, prevent the patient’s participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results, including but not limited to:  
• Prior immune -related adverse events requiring treatment discontinuation 
• Ongoing symptomatic interstitial lung disease (ILD), noninfectious pneumonitis or history of drug induced interstitial lung disease 
11. Systemic anti- cancer therapy wi thin 2 weeks or 5 x T ½, whichever is longer of the first 
dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, 4 weeks is indicated as washout period. For patients receiving CTLA -4, PD- 1 or PD -L1 antagonists, 6 weeks is indicated as the washout 
period. 
12. Patients requiring chronic treatment with systemic steroid therapy or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency. Any previous steroid or immunosuppressive therapy must be stopped at least 7 days before start of study treatment. Topical, inhaled, nasal and ophthalmic steroids are not prohibited. 
13. Use of any live vaccines against infectious diseases (e.g. varicella, pneumococcus) within 4 weeks of initiation of study treatment. 
14. Major surgery within 2 weeks of the first dose of study treatment (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery). 
15. Radiotherapy within 2 weeks of the first dose of study drug, except for palliative radiotherapy to a limited field. To allow evaluation for response to treatment, patients enrolled in the Phase II part must have remaining measurable disease that has not be en 
irradiated.  
16. Participation in an interventional, investigational study within 2 weeks of the first dose of study treatment.  
17. Presence of ≥ CTCAE Grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ≥ CTCAE Grade 3) due to prior cancer therapy. 
Novartis  Confidential  Page 47  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
18. Use of hematopoietic colony-stimulating growth factors (e.g. G- CSF, GM -CSF, M -CSF) 
≤ 2 weeks prior start or study drug. An erythroid stimulating agent is allowed as long as it 
was initiated at least 2 weeks prior to the firs t dose of study treatment. 
19. Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. 
20. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 150 days after the last dose of PDR001 or 90 days after the last dose of MCS110 for patients who stopped PDR001 and continued MCS110 alone for more than 60 days. Highly effective contraception methods include: 
• Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception 
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) total hysterectomy or tubal ligation at least 1.5 months before taking study treatme nt. In case of oophorectomy alone, only when the reproductive status of 
the woman has been confirmed by follow-up hormone level assessment 
• Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male par tner should be the sole partner for that patient. 
• Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception. 
In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. 
Women are considered post -menopausal and not of child bearing potential if they have had over 
12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile age 
appropriate (e.g. generally 40- 59 years), history of vasomotor symptoms (e.g. hot flushes) in 
the absence of other medical justification or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least 1.5 months ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child bearing potential. 
21. For Korea only: S exually active males unless they use a condom during intercourse while 
taking treatment and for 150 days after the last dose of PDR001 or 90 days after the last 
dose of MCS110 for patients who stopped PDR001 and continued MCS110 alone. They should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent deliv ery of the drug via seminal fluid. 
Novartis  Confidential  Page 48  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
6 Treatment  
6.1 Study treatment 
For this study, the investigational drugs are MCS110, an anti -CSF-1 recombinant humanized 
monoclonal antibody, and PDR001, an anti -PD-1 receptor recombinant humanized monoclonal 
antibody. The study treatment is the combination of MCS110 and PDR001, or single agent 
MCS110 or PDR001 if one of the investigational drug need to be discontinued. 
6.1.1  Dosing regimen  
Table 6-1 Dose and treatment schedule  
Study treatments  Pharmaceutical form and 
route of administration  Dose  Frequency and/or 
Regimen  
MCS110  Liquid concentrate in vial  
i.v. infusion  3 mg/kg (starting dose)  Every 3 weeks  
PDR001  Powder for solution for 
infusion  100 mg (starting dose)  Every 3 weeks  
MCS110 and PDR001 will be administered once every 3 weeks via i.v. infusions over 1 hour 
and30 minutes, respectively. The drugs will be administered separately with at least a 30 min break between the two antibodies. Infusions of each antibody can be extended to up to 2 hours if clinically indicated.  
Both study drugs may be infused using the same i.v. access site. The same administration sequence must be followed for all patients , i.e. PDR001 should be  infused first. If an infusion 
reaction occurs after administration of PDR001, the subsequent MCS110 infusion must be 
delayed until it is safe for the patient to receive MCS110 based on the clinical discretion of the investigator. The delay between PDR001 and MCS110 infusions can be up to 4 hours if 
clinically indicated.  
A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit (see Section 6.3.2). If a scheduled dose  of ongoing study drugs  
is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at a lower dose level (if meeting criteria for DLT) at the next scheduled dose. The assessment schedule will be shifted accordingly. Dose delays refer to all ongoing 
study drugs: for combination treatment both MCS110 and PDR001 and for single agent treatment MCS110 or PDR001. Dose modifications should follow Section 6.3.1 and Section  6.3.2. 
The dose for MCS110 study drug will be calculated from the individual subjects’ body weight as measured at the screening visit and subsequent visits prior to the administration.  
After Phase Ib part, if emerging PK, PD, and safety data indicate that a flat dosing strategy of MCS110 is appropriate, then a flat dosing strategy may be implemented in the Phase II part of the study. The PK data obtained during Phase Ib part of this study will be combined with PK data from the other MCS110 clinical studies to assess the flat dosing vs. body- weight based 
dosing, and a flat dose may be identified for the Phase II part of this study. 
Novartis  Confidential  Page 49  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
6.1.2  Ancillary treatments  
Patients should not r eceive pre- medication to prevent infusion reactions before the first infusion 
of the study treatment, in order to determine if pre -medication is necessary. If a patient 
experiences an infusion reaction, he/she may receive pre -medication on subsequent dosing 
days. The pre -medication should be chosen per institutional standard of care at the discretion 
of the treating physician; however, steroids should be avoided if possible. 
Acute allergic reactions should be treated as needed per institutional standard of care. In the 
event of anaphylactic/anaphylactoid reactions, this includes any therapy necessary to restore normal cardiopulmonary status. If a patient experiences a Grade 3 anaphylactic/anaphylactoid reaction, the patient may only continue on the study following discussion with Novartis. 
Patients should be treated in a facility equipped for cardiopulmonary resuscitation. Appropriate 
resuscitation equipment should be available at the bedside and a physician readily available. 
Guidelines on management of infusion reactions are provided in Table 6 -4. 
The CTCAE category of “Infusion related reaction” should be used to describe infusion 
reactions, unless the investigator considers  another category, such as “Allergic reaction,” 
“Anaphylaxis,” or “Cytokine release syndrome” more appropriate in a specific situation. 
6.1.3  Treatment duration  
A patient may continue to receive study treatment until the patient experiences unacceptable 
toxicity , confirmed disease progression per irRC and/or treatment is discontinued at the 
discretion of the investigator or the patient. Patients will not be withdrawn from the study due to progressive disease per RECIST. In addition to safety and efficacy criteria, investigator’s opinion of the patients best interest and clinical benefit from treatment may be discussed on a case by case basis with Novartis. Refer to Section 6.3.1, Section 7.1.4 and Section 7.1.6. 
6.2 Dose escalation guidelines 
6.2.1  Starting dose rationale  
This is the first study evaluating the combination of MCS110 and PDR001. Potential overlapping toxicities  include liver enzyme elevations caused by immune induction (PDR001) 
or reduced elimination of liver enzymes (MCS110), higher frequency or aggravation of immune mediated adverse events and skin toxicity. 
The starting dose and regimen of MCS110 will be 3 mg/kg iv every 3 weeks, corresponding to 
approximately 40 % of the single agent dose administered in PVNS patients (10 mg/kg every 4 weeks in study [MCS110X2201] ) and 30 % of the dose administered in combination with 
carboplatin/gemcitabine in TNBC (10 mg/kg every 3 weeks in study [MCS110Z2201] ). An 
MCS110 dose of 10mg/kg was well tolerated in HV and PVNS patients ( [CMCS110X2101]  
and [CMCS110X2201] ) and showed significant tumor reduction in PVNS patients. After a 
single dose of 3 mg/kg of MCS110 in HV, it was  observed that CSF -1 has been saturated by 
MCS110 for approximately 21 days [CMCS110X2101] . PD analyses performed in HV studies 
indicate that circulating biomarker response should be close to maximal with dose at or above 5mg/kg and minimal with doses below 3 mg/kg. Considering the risk of potential overlapping 
Novartis  Confidential  Page 50  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
toxicities, the dose of 3 mg/kg MCS110 was selected as the starting dose for the dose escalation 
part of the study. 
The starting dose and regimen of PDR001 will be 100 mg iv every 3 weeks. As of 30-Nov-
2015, PDR001 has been tested up to the dose of 10 mg/kg every 2 weeks in the ongoing [CPDR001X2101]  study. No MTD has been determined and the planned RP2D is 300 mg (3.75 
mg/kg) given every 3 weeks or 400 mg (5 mg/kg) given every 4 weeks. Both of the pr oposed 
RP2Ds would be expected to achieve the steady mean C
trough concentrations that are 
approximately 77 fold higher than the in vitro/ex vivo potency EC50 for PDR001 assessed as 0.42 µg/mL. In addition, the expected PDR001 C
trough concentrations are in line with observed 
steady state mean C trough concentrations for pembrolizumab whose ex vivo potency EC50 is 
approximately 0.4 µg/mL utilizing the same assay. Pembrolizumab has been approved with substantial efficacy in several cancer types. The PDR001 expo sure at a starting dose of 100 mg 
Q3W is within the range of those observed in the CPDR001X2101 study with no DLTs (section 
1.2.1.2). PDR001 is expected to demonstrate antitumor activity at doses of 100 mg or above 
every 3 weeks. The starting dose is in accordance with clinical experience of nivolumab and 
pembrolizumab ( Topalian 2012, Topalian 2014, Hamid 2013b, Robert 2014).  
6.2.2  Provisional dose levels  
Table 6 -2 describes the starting dose and the dose levels that may be evalu ated during this trial.  
Table 6-2 Provisional dose levels  
Dose level *  Proposed dose MCS110  Proposed dose PDR001  
-2** 0.3 mg/kg Q3W  100 mg Q3W  
-1** 1 mg/kg Q3W  100 mg Q3W  
1 (starting dose)  3 mg/kg Q3W  100 mg Q3W  
2 3 mg/kg Q3W  300 mg Q3W  
3 5 mg/kg Q3W  300 mg Q3W  
4 10 mg/kg Q3W  300 mg Q3W  
* It is possible for additional and/or intermediate dose levels to be added during the course of the 
study. Cohorts may be added at any dose level below the MTD in order to better understand safety, 
PK or PD  
** Dose level - 1 or - 2 represent provisional dose levels and/or treatment doses for patients requiring 
a dose reduction from the starting dose level. No dose reduction below dose level -2 is permitted for 
this study  
6.2.3  Guidelines for dose escalation and determination of MTD or RP2D  
The maximum tolerated dose (MTD) is defined as the highest combination drug that is unlikely 
(< 25% posterior probability) to cause DLT in 33% or more of the treated patients in the first two cycles (42 days)  of treatment.  
The applied adaptive Bayesian met hodology provides an estimate of the combinations of 
MCS110 and PDR001 not exceeding the MTD. Typically the MTD is a tested combination with maximum probability of targeted toxicity (DLT rate between 16% and < 33%). The use of the EWOC principle limits the  risk that a potential next dose will exceed the MTD  
(Section 10.4.2). Adverse events and laboratory abnormalities considered to be DLTs are 
defined in Table 6 -3. 
Novartis  Confidential  Page 51  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
For the purposes of dose escalation decisions, each cohort will consist of 3 to 6 newly enrolled 
patients who will be treated at the specified dose level. The first cohort will be treated with the starting doses of 3 mg/kg MCS110 Q3W and 100 mg PDR001 Q3W. 
Patients must complete a minimum of two cycles of treatment with the minimum safety 
evaluation and drug exposure or have had a DLT within the first two cycles of treatment to be considered evaluable for dose escalation decisions ( Section 10.1.4). Dose escalation decisions 
will occur when the cohort of patients has met these criteria. If only 2 of the 3 patients in a cohort are evaluable and  neither subject has experienced a treatment -related toxicity > CTCAE 
Grade 1, dose escalation decisions may be considered. 
Dose escalation decisions will be made by Investigators and Novartis study personnel. 
Decisions will be based on a synthesis of all relevant data available from all dose levels evaluated in the ongoing study including safety information, DLTs, all CTCAE Grade ≥ 2 toxicity data during Cycle 1 and 2, PK, and PD data from evaluable patients. The recommended dose for the next cohort of subjects will be guided by the BLRM with EWOC pr inciple 
evaluating the probability of DLT ( Section 10.4.2 ) 
The adaptive Bayesian methodology provides an estimate of all dose levels of the combination MCS110/PDR001  that do not exceed the MTD and incorporates all DLT information at all dose 
levels for this estimation. In general, the next dose will have the highest chance that the DLT rate will fall in the target interval [16 -33%) and will always satisfy the EWOC principle (less 
than 25% probability that  the DLT rate is ≥ 33%). In all cases, the dose for the next cohort will 
not exceed a 100% increase from the previous dose (except for the first dose escalation step where MCS110 remains at 3 mg/kg, while PDR001 is allowed to have a 200% increase from 100 mg). Smaller increases in dose may be recommended by the Investigators and Sponsor 
upon consideration of all of the available clinical data. 
If 2 patients in a previously untested dose level experience a DLT, enrollment to that cohort 
will stop, the BLRM w ill be updated and the next cohort will be opened at the next lower dose 
level or an intermediate dose level (see Table 6 -2 for provisional dose levels  and Appendix 3) 
that satisfies the EWOC criteria. However, if 2 patients in a new cohort at a previously tested 
dose level experience a DLT (e.g., a total of 8 patients are treated on this dose level with 2 DLTs observed), further enrollment to that cohort will stop, the BLRM will be updated with this new information and re -evaluation of the available safety, PK, and PD data will occur. By 
incorporating information gained at the preceding dose cohorts, additional patients may be enrolled into the current dose level or a lower  dose level as agreed by Investigators and Novartis 
personnel and if the BLRM predicts that the risk for this dose to exceed the MTD(s) remains below 25% (EWOC). Re -escalation may then occur if data in subsequent cohorts supports this 
EWOC criteria are sat isfied and Investigators and Novartis personnel agree  
Dose escalation will continue until identification of the RP2D which is expected to occur before the MTD is reached. This will occur when the following conditions are met: 
1. at least 6 patients have been treated at this dose  
2. this dose satisfies one of the following conditions: 
a. the posterior probability of targeted toxicity at this dose exceeds 50% and is the 
highest among potential doses, or 
Novartis  Confidential  Page 52  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
b. minimum of 15 patients have already been treated on the trial to identify the MTD. 
Recommendation of RP2D may be made with fewer patients, without identification of MTD.  
3. it is the dose recommended for patients, either per the model or by review of all clinical data by Novartis and Investigators in a dose- escalation teleconference, see Section 6.2.3.1. 
To better understand the safety, tolerability and PK of both MCS110 and PDR001, additional cohorts of patients may be enrolled at preceding dose levels, or to intermediate  dose levels 
before or while proceeding with further dose escalation. 
If a decision is made to escalate to a higher dose level but one or more additional patient(s) 
treated at the preceding dose level experiences a DLT during the first two cycles of treatm ent, 
then the BLRM will be updated with this new information before any additional patients are enrolled at that higher dose level. Subjects ongoing will continue treatment at their assigned dose levels.  
6.2.3.1  Implementation of Dose Escalation Decisions 
To implement dose escalation decisions, the available toxicity information (including all safety data, AEs Grade ≥ 2 and laboratory abnormalities that are not DLTs), the assessment of those doses satisfying the EWOC criterion from the BLRM, and the available PK and PD information will all be evaluated by the Investigators and Novartis study personnel (including the study physician and statistician) during a dose decision meeting by teleconference. All occurrences of DLT will be discussed and agreed at the dose decision teleconference among participating investigators and Novartis study personnel. 
Cohort enrollment and drug administration at the next higher dose level may not proceed until 
the investigator receives written confirmation from Novartis indicating that the results of the previous dose level were evaluated and that it is permissible to proceed to a higher dose level with written confirmation of the next higher dose level to be tested. 
6.2.3.2  Intra -Patient dose escalation  
Intra -patient dose escalation is not permi tted at any time within the first 6 months of treatment. 
After the 6 months of treatment is completed, individual patients may be considered for 
treatment at doses of MCS110 and PDR001 in combination higher than the doses to which they were initially assig ned. Only one of the study drugs will be escalated at any one time. Study 
drugs will be escalated as detailed in Section 6.2.2. In order for a patient to be treated at a higher 
treatment dose, he or she must have tolerated the lower dose of MCS110 and PDR001 combination for at least two cycles of therapy (e.g., he or she must not have experienced a toxicity of CTCAE Grade ≥ 2 at the lower dose pair for which relationship to study drug cannot be ruled out). Moreover, the new,  higher dose pair with which the patient is to be treated must 
be a dose pair that has completed evaluation in a dose- escalation meeting and that has satisfied 
the EWOC criterion under the Bayesian model. 
There is no limit to the number of times a patient may have his or her treatment dose increased. 
Any further increases after the initial intra -patient dose escalation are subject to the same rules 
as for the initial intra -patient escalation. Consultation with Novartis must occur prior to any 
Novartis  Confidential  Page 53  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
intra-patient dose escalation occurring. These changes must be recorded on the Dosage 
Administration Record CRF. 
6.2.4  Definitions of dose limiting toxicities (DLTs)  
A dose -limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of 
CTCAE Grade ≥ 3 assessed as unrelated to disease, disease progression, inter -current illness, 
or concomitant medications that occurs within the first two cycles of treatment with the 
combination treatment and meets any of the criteria included in Table 6 -3. 
Emerging data from the new field of immune -immune combination studies suggest that some 
immune -related adverse events have a prolonged latency ( Wolchok 2013). As such, the DLT 
window for the combination cohort in this trial is extended to the length of two cycles or 42 days. 
National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) 
version 4.03 will be used for all grading. For the purpose of dose -escalation decisions, DLTs 
will be considered and included in the BLRM. 
The investigator must notify the Sponsor immediately of any unexpected CTCAE Grade ≥ 3 
adverse events or laboratory abnormalities. Prior to enrolling patients into a higher dose level, 
CTCAE Grade ≥ 2 adverse events will be reviewed for all patients at the current dose level. 
DLTs include any adverse event of CTCAE Grade 3 or higher occurring in the first two cycles 
of treatment during the Phase Ib dose escalation part of the study, for which relationship to study treatment cannot be ruled, with the exceptions defined in Table 6 -3. 
Table 6-3 Criteria for defining dose- limiting toxicities  
For the purpose of dose escalation and cohort expansion, DLT will be defined as follows:  
Any Grade 4 AEs will be considered DLTs with  the exception of:  
 Neutropenia lasting ≤ 5 days that is not associated with fever or other clinical symptoms.  
 Lymphopenia or leukopenia at any grade  
Any Grade 3 AEs will be considered DLTs with the exception of:  
 Electrolyte abnormalities that are not associated with clinical sequelae and are corrected to ≤ 
Gr1 with appropriate management or supplementation within 72 hours of onset.  
 Infusion reaction that resolves to ≤ Grade 1 within 6 hours.  
 Nausea and vomiting persisting  for < 2 days with optimal anti -emetic therapy.  
 Thrombocytopenia without significant bleeding.  
 Diarrhea persisting for < 2 days with optimal anti -diarrhea therapy.  
 Hypertension persisting < 7 days with optimal therapy.  
 Infection or fever in the absence of neutropenia persisting < 7 days.  
 Rash or photosensitivity persisting < 7 days after treatment.  
 Fatigue lasting < 7 days.  
 Immune -related adverse events persisting at Grade3 < 7 days after treatment with 
corticosteroids.  
 *CK elevation without associated muscle damage per investigator discretion  
 *Isolated AST elevations (without bilirubin or ALT elevations ≥ Grade 1)  
The following Grade 2 AEs will be considered as DLTs:  
 Total bilirubin > 2 x ULN with ≥ CTCAE Grade 2 AST/ALT.  
Novartis  Confidential  Page 54  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
 Pneumonitis persisting > 7 days despite treatment with corticosteroids.  
 Eye pain or reduction of visual acuity that does not respond to topical therapy and does not 
improve to Grade 1 severity within 2 weeks of the initiation of topical therapy OR requires 
systemic treatment.  
 Other clinically significant toxicities, including a single event or multiple occurrences of the same 
event may be considered as DLT’s.  
* MCS110 treatment results in CK and AST elevations without any association to muscle damage ( Radi 2011 ). 
The CK/AST elevations are caused by reduced clearance rate from the circulation due to the diminished 
numbers of macrophages (Kupffer cells) in the liver ( Section 1.2.2.1 ). 
6.3 Dose modifications 
6.3.1  Dose modification and dose delay  
For patients who do not tolerate the protocol -specified dosing schedule, dose adjustments are 
permitted in order to allow the patient to continue the study treatment, except during the first 
two cycles when dose modifications are only allowed if the patient experiences a DLT. The following guidelines need to be applied: 
• If a patient experiences an AE meeting the criteria for DLT as outlined in Section 6.2.4, 
treatment should be withheld. Dose modifications for toxicities related to the study medication are summarized in Table 6 -4. Following resolution of the toxicity to Grade 1 
or to the patient’s baseline value, the patient may resume study treatment at a lower dose level than is being tested at that time (on the same dosing schedule), if there is no evidence of disease progression as per irRC. A decision to resume treatment following the occurrence of a DLT i s at the discretion of the Investigator. Following an AE meeting 
criteria for DLT, if a patient resumes study treatment, it should be at the next lower dose level.  Dose reductions to doses below MCS110 0.3mg/kg / PDR001 100 mg Q3W are not permitted. If mo re than 2 consecutive doses have to be skipped due to study treatment-
related toxicities, then the patient must be discontinued from the study unless the patient experiences clinical benefit in the opinion of the investigator. In this case, treatment can be continued at a dose agreed by Novartis and the investigator. 
• For clinical management of suspected immune -related events, reference to consensus 
management guidelines is recommended such as those provided in the National Comprehensive Cancer Network (NCCN) Guidelines for the Management of Immunotherapy- Related Toxicities (available at : 
https//wwwnccn.org/professionals/physician_gls/default.aspx#immunotherapy), the American Society for Clinical Oncology clinical practice guideline for Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy ( Brahmer 2018 ) or the European Society for Medical Oncology (ESMO) Clinical 
Practice Guidelines for Management of Toxicities from Immunotherapy ( Haanen 2017 ).  
Note that in general, study treatment should be interrupted for grade 3 and 4 toxicities and for a subset of lower grade toxicities. 
• Consider early referral to specialists with expertise in the diagnosis and management of immune -related AEs to thoroughly investigate events of uncertain etiology. 
• Events not included in the study protocol or the reference guidance documents should be managed per institutional preference.  
Novartis  Confidential  Page 55  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
• If one of the study drugs is discontinued the patient may continue with the remaining 
study drug, if the investigator considers it to be in the patient’s best interest. The dose of the remaining study drug must be agreed by Novartis and the investigator. 
Patients who discontinue the study treatment for a study related AE or a study- related abnormal 
laboratory value must be followed as described in Section 6.3.2. 
Table 6-4 Dose modification for drug related toxicities  
Toxicity  Dose Adjustment Rules*  
Hematology  
Neutropenia (ANC)  
Grade 3 or Grade 4.  Hold study treatment.  
Upon resolution to ≤ Grade 2 or baseline within ≤ 7 days, resume study 
treatment without dose modification, after discussion with the Novartis 
Medical Monitor  
Febrile neutropenia  
Grade 3 or Grade 4  Hold study treatment.  
Upon resolution of fever and improvement of neutropenia to ≤ Grade 2 or 
baseline, resume study treatment without dose modification, after discussion 
with the Novartis Medical Monitor.  
Thrombocytopenia  
Grade 3  Hold study treatment.  
Upon resolution to ≤ Grade 2 or baseline, resume study treatment without 
dose modification.  
For Grade 3 associated with major bleeding, discontinue study treatment.  
Grade 4  Discontinue study treatment.  
Anemia  
Grade 3 or Grade 4  Hold study treatment.  
Upon resolution to ≤ Grade 2 or baseline within ≤ 7 days, resume study 
treatment without dose modification.  
Lymphopenia  
Any grade  Treatment -related lymphopenia does not require study treatment hold or 
discontinuation.  
Gastrointestinal  
Diarrhea/colitis*  
Grade 1  May continue study treatment without dose modification.  Manage per 
institutional standard guidelines which should include anti -diarrheal 
treatment, consideration of corticosteroid therapy, and hydration.  
Grade 2  Hold study treatment.  
GI consultation.  
Upon resolution to ≤ Grade 1 and tapering of steroid requirement to ≤ 10 mg 
prednisone per day, resume study treatment without dose modification after 
discussion with the Novartis Medical Monitor.  
Grade 3  Hold study treatment.  
GI consultation.  
Upon resolution to ≤ Grade 1 and tapering of  steroid requirement to ≤ 10 mg 
prednisone per day, consider resuming study treatment after discussion with 
the Novartis Medical Monitor.  
Grade4  Discontinue study treatment.  
Novartis  Confidential  Page 56  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
Toxicity  Dose Adjustment Rules*  
Hepatic ( AST and/or ALT elevation ) 
Grade 2 AST and/or ALT  Hold study treatment.  
Manage per institutional practice.  
Upon resolution to ≤ Grade 1 or baseline, consider resuming study treatment 
without dose modification.  
Grade 2 transaminitis with 
bilirubin >1.5 x ULN (unless 
Gilbert’s syndrome)  Discontinue study treatment.  
Grade 3 AST and/or ALT  Hold study treatment.  
Manage per institutional practices.  
Upon resolution to ≤ Grade 1 or baseline within 7 days, consider resuming study treatment without dose modification after discussion with the Novartis Medical Monitor.  
Otherwise, discontinue study treatment  
Grade 4 AST and/or ALT  Discontinue study treatment.  
Isolated total bilirubin elevation** 
Grade 2  Hold study treatment.  
Upon resolution to ≤ Grade 1 or baseline, may continue study treatment 
without dose modification.  
Grade 3  Hold study treatment.  
Upon resolution to ≤ Grade 1 or baseline, may consider resuming study 
treatment after discussion with the Novartis  Medical Monitor.  
Grade 4  See footnote**.  Otherwise, discontinue study treatment.  
Asymptomatic amylase and/or lipase elevation*** 
Grade 3 or Grade 4, not associated with symptoms or clinical manifestations of 
pancreatitis***  Continue study  treatment.  
If levels do not resolve to ≤ Grade 2 within ≤ 14 days after the initial report, 
hold study treatment.  
Upon resolution to ≤ Grade 2 , may resume study treatment  without dose 
modification , after discussion with the Novartis Medical Monitor.  
Pancreatitis  
Grade 2 / radiologic evidence  Hold study treatment.  
Manage per institutional practice.  
Upon resolution to ≤ Grade 1, may resume study treatment without dose 
modification, if no clinical evidence of pancreatitis and after discussion with 
the Novartis Medical Monitor.  
Grade 3 -4 Discontinue from treatment.  
CK elevation  
Grade 3-4 Monitor CK-MB isoenzyme, troponin (I or T), and creatinine.  
 ● If CK -MB and troponin (I or T) are normal, creatinine ≤  1.5 x baseline and 
patient asymptomatic, continue treatment.  
 ● If CK -MB and troponin (I or T) are abnormal or creatinine (> 1.5 x baseline 
and >  ULN) or patient symptomatic, delay treatment and explore alternative 
causes for elevated CK (for example myositis and rhabdomyolysis) 
according to local guidelines.  
 
After recovery of CK-MB, troponin (I or T) and creatinine to Grade 1  
or baseline, restart  treatment. Decrease MCS110 1 dose level.  
Cytokine Release Syndrome (CRS)  
Grade 2  See instructions for Grade 2 Infusion Reaction.  
Novartis  Confidential  Page 57  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
Toxicity  Dose Adjustment Rules*  
Grade 3 and Grade 4  Discontinue study treatment.  
Follow -up CRS as per institutional guidelines.  
Take blood for cytokine measurements as specified in Section  7.2.2.5.5  
Laboratory evaluations.  
Renal (creatinine)  
Grade 2  Hold study  treatment . 
Consider resuming study treatment without dose modification upon 
resolution to ≤ Grade 1 with appropriate management. . 
Grade 3 or 4  Discontinue study treatment.  
Endocrine  
Hypothyroidism or hyperthyroidism  
Grade 2  May continue study treatment without dose modification.  
Management according to institutional practice.  
Grade 3  Hold study treatment.  
Upon resolution to Grade ≤ 1 with appropriate management, may resume 
study treatment without dose modification.  
Grade 4  May resume therapy following resolution or control with physiologic hormone 
replacement.  
Other endocrine disorders  
Grade 2 and Grade 3  Hold study treatment.  
Upon resolution to Grade ≤ 1 with appropriate management, may resume 
study treatment without dose modification.  
Grade 4  Hold study treatment.  
Grade 4 treatment -related endocrinopathies, such as  
adrenal insufficiency, adrenocorticotropic hormone  
(ACTH) deficiency, hyper - or hypothyroidism, or glucose intolerance, which 
resolve or are adequately controlled with physiologic hormone replacement 
(corticosteroids, thyroid hormones) or glucose- controlling agents, 
respectively, may not require discontinuation after discussion with and 
approval from the Novartis Medical Monitor.  
Pulmonary (pneumonitis)  
Grade 1  Consider study  treatment hold.  
Manage per institutional practice.  
Consider resuming study treatment upon radiographic evidence of 
improvement.  
Grade 2  Hold study  treatment.  
Pulmonary and infection workup.  
Upon resolution to ≤ Grade 1, may resume study treatment without dose 
modificatio n 
Grade 3 or 4  Discontinue study treatment.  
Ocular (uveitis)  
Grade 1  Continue study treatment without dose modification.  
Ophthalmology consultation.  
Grade 2  Hold study  treatment . 
Urgent ophthalmology consultation.  
Upon resolution to ≤ Grade 1 may consider resuming study treatment without 
dose reduction after discussion with the Novartis Medical Monitor and in 
consultation with ophthalmology  
Novartis  Confidential  Page 58  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
Toxicity  Dose Adjustment Rules*  
Grade 3 or 4  Discontinue from treatment.  
Urgent ophthalmology consultation.  
Periorbital edema  
Grade 2  Delay treatment until resolved to ≤ Grade 1. Decrease MCS110 1 dose level.  
Grade 3 -4 Discontinue from treatment.  
Dermatology  (rash)  
Grade 1  Continue study treatment without dose modification. Topical steroids, 
antihistamines, topical emollients  
Grade 2  Consider holding study treatment.  
Topical or oral steroids, antihistamines.  
If study treatment is held and resolution to ≤ Grade 1, resume study 
treatment without dose modification.  
Grade 3 or Grade 4  Hold study  treatment . 
Manage per institutional practice.  
After resolution  to ≤ Grade 1, consider resuming study treatment after 
discussion with the Novartis Medical Monitor . 
Bullous dermatitis  Hold study  treatment . 
Grade 1-2 bullous dermatitis: discussion with the Novartis Medical Monitor is 
required before considering resuming study treatment.   
Grade 3 bullous dermatitis: consider resuming therapy after expert 
consultation and documented discussion with the Novartis medical monitor.  
Grade 4 bullous dermatitis:  discontinue study  treatment.  
Stevens -Johnson syndrome 
(SJS), or Lyell syndrome/toxic 
epidermal necrolysis (TEN)  Permanently discontinue study treatment.  
Cardiovascular  
ECG QTc -Interval prolonged; hypertension  
Grade 3  Hold study treatment.  
Upon resolution to Grade ≤ 1 or baseline (hypertension, QTc) or < 30 msec difference from baseline (QTc) within ≤ 7 days, may resume study treatment without dose modification after discussion with the Novartis Medical Monitor. 
Baseli ne ECG refers to the ECG(s) collected at screening  
Grade 4  Discontinue study treatment  
Other cardiovascular disorders  
Grade 2 (except myocarditis)  Hold study treatment.  
Upon resolution to Grade ≤ 1 or baseline, may resume study treatment 
without dose modification after discussion with the Novartis Medical Monitor. . 
Grade 2 myocarditis, or  
Grade ≥ 3 other cardiac disorders related to study 
treatment  Discontinue study treatment  
Musculoskeletal  
Grade 2 or Grade 3  Hold study treatment.  
Consider resuming study treatment without dose modification upon 
resolution to ≤ Grade 1 with appropriate management.  
Grade 4  Discontinue study treatment.  
In some cases, resuming study treatment may be considered after discussion with the Novartis Medical  Monitor and consultation with a 
rheumatologist.  
Novartis  Confidential  Page 59  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
Toxicity  Dose Adjustment Rules*  
Neurology  
Grade 1  Consider study treatment hold, particularly for clinical  
suspicion of Guillain-Barre syndrome, encephalitis, aseptic meningitis, 
transverse myelitis, or peripheral neuropathy.  
Grade 2  Hold study treatment.   
In some cases, resuming study treatment may be  
considered after discussion with the Novartis Medical  
Monitor.  
Grade 3 or Grade 4  Discontinue study treatment.  
Infusion Reaction  
Grade 1  Decrease infusion rate until recovery  
Grade 2  Stop infusion.  
 
Before restarting - administer oral pre-medication (e.g.1000 mg of 
acetaminophen/paracetamol, 50-100 mg diphenhydramine hydrochloride or 
alternative antihistamine), within 60 minutes of restarting the infusion.  
 
Restart in fusion at 50% of previous rate under continuous observation. 
Ensure that there is a minimum observation period of 1 hour prior to restarting the infusion(s).  
 If the AE recurs at the reinitiated slow rate of infusion, and despite oral pre-
medication, then discontinue patient from treatment.  
Grade 3 or 4  Discontinue infusion immediately, and discontinue study  treatment . 
Provide supplemental oxygen, fluids, and other resuscitative measures as needed. Monitor vital signs (e.g. blood pressure, pulse, respiration, and 
temperature) every 15 ± 5 minutes until resolution.  
Other laboratory adverse events, not specified elsewhere in table and not included in the 
consensus guidelines  
Grade 3  Hold study treatment.  
Upon resolution to ≤ Grade 1, resume study treatment without dose 
modification.  
Grade 4  Isolated Grade 4 electrolyte abnormalities not associated with clinical sequelae and corrected after appropriate management within 72 hours of their onset do not require discontinuation.  
In the case of Grade 4 electrolyte imbalances associated with clinical 
sequelae, or not resolved to ≤ Grade 1 within 72 hours despite appropriate 
management, discontinue study treatment.  
Other non- laboratory adverse events, not specified elsewhere in table and not included in 
the consensus guidelines  
Grade 2  Consider study treatment hold, at Investigator discretion.  
Upon resolution to ≤ Grade 1, resume study treatment without dose 
modification.  
Grade 3  Hold study treatment.  
Upon resolution to ≤ Grade 1, resuming study treatment must be discussed 
with the Novartis Medical Monitor.  
Grade 4  Discontinue from treatment.  
*Delay:  treatment may be delayed for 7 days due to AEs. If a scheduled dose of ongoing study drugs is 
delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at a lower dose level (if meeting the criteria for DLT) at the next scheduled dose ( Section 6.1.1
). 
Treatment: refers to both study drugs, unless one has been discontinued.  
Novartis  Confidential  Page 60  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
Toxicity  Dose Adjustment Rules*  
**Note: If Grade 3 or 4 hyper -bilirubinemia is due to the indirect (non-conjugated) component only, and 
hemolysis as the etiology has been ruled out as per institutional guidelines (e.g., review of peripheral blood 
smear a nd haptoglobin determination), then delay study treatment until resolved ≤ Grade 1, and resume study 
treatment at the discretion of the investigator.  
***Note: A CT scan or other imaging study to assess the pancreas, liver, and gallbladder must be performed 
within one week of the first occurrence of any ≥ Grade 3 of amylase and/or lipase.  
6.3.2  Follow -up for toxicities  
Patients whose treatment is interrupted or permanently discontinued due to an AE or clinically 
significant laboratory value, must be followed- up at least once a week (or more if clinically 
indicated) for 4 weeks, and subsequently at approximately 4- week in tervals, until resolution or 
stabilization of the event, whichever comes first. Appropriate clinical experts should be consulted as deemed necessary. Consensus management algorithms for immune -related AEs 
have been developed and are available to assist inv estigators in assessing and managing 
immune -related AEs (refer to Section 6.3.1) . In case of a toxicity suspected to be a cytokine 
release syndrome, the assessments outlined in Section 7.2.2.5.5  must be performed. 
All patients must be followed up for AEs and SAEs for 150 days after the last dose of PDR001 
or 90 days after the last dose of MCS110 for patients who stopped PDR001 and continued MCS110 alone for more than 60 days. 
6.3.3  Anticipated risks and safety concerns of the study drug  
Appropriate eligibility criteria and specific DLT definitions, as well as specific dose 
modification and stopping rules are included in this protocol. Recommended guidelines for prophylacti c or supportive treatment for expected toxicities, including management of study-
drug induced immune related adverse events, are provided in Table 6 -4. The risk to subjects in 
this trial may be minimized by compliance with the eligibility criteria and study procedures as well as, close clinical monitoring. There may be unforeseen risks with MCS110 in combination with PDR001 which could be serious. Refer to preclinical toxicity and or clinical data found in  
the MCS110 and PDR001 Investigator’s Brochure. 
6.4 Concomitant medications 
In general, concomitant medications and therapies deemed necessary for the supportive care  
(e.g. such as anti -emetics, anti -diarrhea) and safety of the patient are allowed. The 
adminis tration of bisphosphonates is permitted. 
The patient must be told to notify the investigational site about any new medications, herbal 
remedies and dietary supplements he/she takes after the start of the study treatment. All 
medications (other than study treatment) and significant non- drug therapies (including physical 
therapy, herbal/natural medications and blood transfusions) administered during the study must be listed on the Prior and Concomitant Medications or the Surgical and Medical Procedures eCRF. Prior antineoplastic therapies including medications, radiotherapy, and surgery are to be 
recorded on the separate Prior Antineoplastic Therapy eCRF during screening. Medication entries should be specific to trade name, dose and unit, the frequency and route of administration, the start and discontinuation date and the reason for therapy. 
Novartis  Confidential  Page 61  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
6.4.1  Permitted concomitant therapy requiring caution and/or action  
Therapeutic treatment with hematopoietic colony -stimulating growth factors G -CSF or GM -
CSF may only be initiated after the first two cycles in the dose escalation part of the study, 
unless the patient has already experienced a DLT. If available GM -CSF is preferred over G -
CSF ( Eyles 2006).  
Treatment with erythroid stimulating agents may not be initiated during the first two cycles in the dose escalation part of the study, unless the patient has already experienced a DLT. If a patient is using an erythroid stimulating agents prior to enrollment (at least 2 weeks before start of study treatment), they may continue at the same dose. 
Anticoagulants are permitted if the patient is already at stable doses of warfarin or taking stable 
doses of low molecular weight heparin for >2 weeks at time of first dose and INR  should be 
monitored as clinically indicated per investigator’s discretion. However, ongoing anticoagulant therapy should be temporarily discontinued to allow tumor biopsy according to the institutional guidelines. 
Anti-hypertensives are allowed as concomi tant medications; however, because transient 
hypotension has occurred during infusions of monoclonal antibodies, consideration should be 
given to withholding anti -hypertensive medications for 12 hours prior to infusion with MCS110 
and PDR001. 
Statins should be used with caution since CK elevations are commonly seen and transient CK 
elevations were noted in healthy volunteers and patients studies with MCS110. 
6.4.2  Prohibited concomitant therapy  
During the course of the study, patients may not receive other additional investigational drugs, 
agents, devices, chemotherapy, or any other therapies that may be active against cancer. Additionally, no other therapeutic monoclonal antibodies and no immunosuppressive medication may be administered while on this study. 
Prophylactic treatment with hematopoietic colony -stimulating growth factor G -CSF or GM -
CSF is prohibited since it may induce immune suppression and promote tumor growth 
(Eyles  2006).  
The use of systemic stero id therapy and other immunosuppressive drugs is not allowed, with 
the only exclusion of steroids for the treatment infusion reaction, irAEs or replacement -dose 
steroids in the setting of adrenal insufficiency. Systemic corticosteroids required for the cont rol 
of infusion reactions or irAEs must be tapered and be at doses ≤  10 mg/day of prednisone or 
equivalent before the next study drug administration. Systemic steroid therapy required during 
the course of the study to manage other concurrent medical conditions should be discussed with Novartis. 
The use of live vaccines is not allowed through the whole duration of the study. 
Novartis  Confidential  Page 62  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
6.5 Patient numbering, treatment assignment or randomization 
6.5.1  Patient numbering  
Each patient is identified in the study by a Subject Number (Subject No.), that is assigned when 
the patient is first pre -screened (if applicable) or when the patient is enrolled for screening. The 
subject number is retained as the primary identifier for the patient throughout his/her entire 
participation in  the trial. The Subject No. consists of the Center Number (Center No.) (as 
assigned by Novartis to the investigative site) with a sequential patient number suffixed to it, 
so that each subject is numbered uniquely across the entire database. Upon signing the informed consent form, the patient is assigned to the next sequential Subject No. available to the investigator through the Oracle Clinical RDC interface. Once assigned, the Subject No. must not be reused for any other subject and the Subject No. for that individual must not be changed, even if the patient is re -screened. If the patient fails to start treatment for any reason, the reason 
will be entered into the Screening Disposition page. 
6.5.2  Treatment assignment or randomization  
The assignment of a patient  to a particular cohort will be coordinated by the sponsor. No 
randomization will be performed in this study. 
6.6 Study drug preparation and dispensation 
PDR001 (100 mg powder for solution for infusion) will be administered first as a 30 minute 
intravenous infusion (up to 2 hour, if clinically indicated). MCS110 (7.5ml of 20 mg/ml concentrate in vial) will be administered intravenously as an 1 hour infusion (up to 2 hour, if clinically indicated). At least 30 min break should occur between the two infusions. 
Further instructions for the preparation and dispensation of MCS110 and PDR001 are described 
in the [Pharmacy Manual] . 
All dosages prescribed to the patient, all dose interruptions and all dose changes during the 
study must be recorded on the Dosage Administration Record CRF. 
6.6.1  Study drug packaging and labeling  
MCS110 is provided as open label bulk medication in a glass vial each containing 150 mg 
MCS110 as a 20 mg/ml concentrate solution for infusion. 
PDR001 100 mg powder for solution for infusion will be supplied as open label bulk 
medication.  
Medication labels will be coded, printed in the local language, and will comply with local regulatory requirements. The storage conditions for study drug will be provided on the medication label.  
6.6.2  Drug supply and stor age 
Study treatments must be received by designated personnel at the study site, handled and stored safely and properly, and kept in a secured location to which only the investigator and designated site personnel have access. Upon receipt, the study treatment should be stored according to the 
Novartis  Confidential  Page 63  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
instructions specified on the drug labels and in the MCS110 and PDR001 Investigator’s 
Brochure. 
6.6.3  Study drug compliance and accountability  
6.6.3.1  Study drug compliance  
Study treatment will be administered to the patient by the study site staff. Compliance will be 
assured by administration of the study treatment under the supervision of investigator or his/her designee.  
6.6.3.2  Study drug accountability  
The investigator or designee must maintain an accurate record of the shipment and dis pensing 
of study treatment in a drug accountability log. Drug accountability will be noted by the field monitor during site visits and at the completion of the study. 
At study close -out, and, as appropriate during the course of the study, the investigator will return 
all used and unused study treatment, packaging, drug labels, and a copy of the completed drug 
accountability log to the Novartis monitor or to the Novartis address provided in the investigator 
folder at each site.  
6.6.4  Disposal and destruction 
The s tudy drug supply can be destroyed at the local Novartis facility, Drug Supply group or 
third party, as appropriate 
Novartis  Confidential  Page 64  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110 Z2102 
 
7 Visit schedule and assessments  
7.1 Study flow and visit schedule 
Table 7 -1 lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be supported in the patient’s source 
documentation. The table (“Category” column) indicates which assessments produce data to be entered into the clinical database (D) or remain in source documents only (S). 
No CRF will be used as a source document. Screening/baseline evaluations must be performed ≤ 21 days before Cycle 1 Day 1, except for 
baseline radiological evaluations which must be done within 28 days. Assessments performed as part of the screening evaluations and within 3 days prior to the first dose of study treatment, are not required to be repeated on the first dosing day. 
Laboratory and radiological assessments performed as part  of standard of care prior to signing 
informed consent may be used if performed within 21 days and 28 days respectively, of Cycle 
1 Day 1. 
During the course of the study visits, test and/or procedures should occur on schedule whenever 
possible. A visit win dow of ± 7 days is allowed. If the infusion of MCS110 and/or PDR001 is 
delayed, the visits assessments will be shifted accordingly. On PK collection days the windows are provided in Section 7.2.3. 
Radiol ogical assessments must be performed ± 1 week of the scheduled date of the assessment.  
For Japan only, patients are required to be hospitalized during Cycle 1. 
Novartis  Confidential  Page 65  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
Table 7-1 Visit evaluation schedule  
 
 
 Screening 
Phase  Treatment Phase  Follow -
up   
Visit name  
Category  
Protocol Section  
Screening  
Cycle 1  Cycle 
2 Cycle 
3 Cycle 4  
Subsequent 
cycles  
EOT 
Safety F/U  
Disease 
Progression F/U  
Survival F/U  
Day of cycle    -21 to -1 1 2 4 8 15 1 15 1 1 2 4 8 15 1     
Obtain Informed 
Consent  D 7.1.1  X                   
Demography  D 7.1.1.2  X                   
Inclusion/ 
exclusion criteria  D 5.2 and 
5.3 X                   
Medical History  D 7.1.1.2  X                   
Diagnosis and 
extent of cancer  D 7.1.1.2  X                   
ER, PR, HER2, 
BRCA1 and BRCA2 status 
(TNBC)  D 7.1.1.2  X                   
Prior antineoplastic 
therapy  D 7.1.1.2  X                   
Novartis  Confidential  Page 66  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
 
 
 Screening 
Phase  Treatment Phase  Follow -
up   
Visit name  
Category  
Protocol Section  
Screening  
Cycle 1  Cycle 
2 Cycle 
3 Cycle 4  
Subsequent 
cycles  
EOT 
Safety F/U  
Disease 
Progression F/U  
Survival F/U  
Day of cycle    -21 to -1 1 2 4 8 15 1 15 1 1 2 4 8 15 1     
Prior/concomitant 
medications, surgery and medical 
procedures  D 7.1.1.2  
7.1.5  
and 6.4 X Continuous1   
Physical 
examination  S 7.2.2.1  X X   X X X X X X     X X    
Height  D 7.2.2.3  X                   
Weight  D 7.2.2.3  X X     X  X X     X X    
Vital signs  D 7.2.2.2  X X   X X X X X X     X X    
Performance 
status  D 7.2.2.4  X X     X  X X     X X    
Hematology  D 7.2.2.5.1  X X   X X X X X X   X  X X    
Chemistry  D 7.2.2.5.2  X X   X X X X X X   X  X X    
Coagulation  D 7.2.2.5.6  X Only if clinically significant  X    
Urinalysis  D 7.2.2.5.3  X X     X  X X     X X    
Thyroid function  D 7.2.2.5.4  X X     X  X X     X X    
Cytokines  
(E.g. IFN -γ; IL-6, 
IL-1, TNFα)  D 
7.2.2.5.5   X  In case of cytokine release syndrome     
Pregnancy test  D 7.2.2.5.7  X      X  X X     X X X2   
Novartis  Confidential  Page 67  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
 
 
 Screening 
Phase  Treatment Phase  Follow -
up   
Visit name  
Category  
Protocol Section  
Screening  
Cycle 1  Cycle 
2 Cycle 
3 Cycle 4  
Subsequent 
cycles  
EOT 
Safety F/U  
Disease 
Progression F/U  
Survival F/U  
Day of cycle    -21 to -1 1 2 4 8 15 1 15 1 1 2 4 8 15 1     
Virology  D 7.2.2.5.8  X                   
Antineoplastic 
therapies since discontinuation of 
study treatment  D 7.1.5                  X X7 X7 
Tumor evaluation as per RECIST 
v1.1 and as per irRC.  D 7.2.1  X 
Every 2 cycles from Cycle 3 Day 1 up to Cycle 9 Day 1 (C3D1, C5D1, C7D1, C9D1), then every 3 cycles 
until Cycle 18 Day 1 (C12D1, C15D1 C18D1). Assessment will be performed every 4 cycles thereafter, 
starting from Cycle 22 Day 1.  For disease progression f/u, every 9 weeks ± 1 week until week 51 after study start, then every 12 weeks± 
1 week until progression of disease per irRC, withdrawal of consent, or lost to follow -up.  
Tumor markers  D 7.2.1 X X    
12-leads ECG  D 7.2.2.6.1  X X        X      X    
Chest x -ray [for 
Japan only]  D 7.2.2.7  X    X               
Adverse events  D 8 Continuous     
Study drug 
administration  D 6.1.1   i.v. every 3 weeks for MCS110 and PDR001     
PK sampling  D 7.2.3   X X4 X4 X X4 X  X X X4 X4 X X4 X5     

Novartis  Confidential  Page 68  
Amended Protocol Version 05 ( Clean)  Protocol No. CMCS110Z2102 
 
 
 
 Screening 
Phase  Treatment Phase  Follow -
up   
Visit name  
Category  
Protocol Section  
Screening  
Cycle 1  Cycle 
2 Cycle 
3 Cycle 4  
Subsequent 
cycles  
EOT 
Safety F/U  
Disease 
Progression F/U  
Survival F/U  
Day of cycle    -21 to -1 1 2 4 8 15 1 15 1 1 2 4 8 15 1     
Immunogenicity 
(IG) sampling  D 7.2.3   X     X  X X     X5     
Survival contact  D 7.1.5                    X 
1 Concomitant medications are only collected until 30 day of follow -up or the start of antineoplastic therapy, whichever comes first.  
2 Urine pregnancy test should be performed every month during and at the end of 150 days safety follow -up (90 days in case patient is only taking MCS110 alone, for 
more than 60 days).  
 
4 Day 2, 4, 15 sampling times are only applicable to the Phase Ib part,  
5 Cycles 5 and 6 only,  
6 Only on C5D1  
7 In reference to Section 7.1.5 , the follow -up for  safety, disease progression and survival will not be performed for patients who transfer to another clinical study to 
continue provision of study treatment or an alternative treatment option.  For all other patients, the safety evaluation period will be completed but the disease -
progression and survival follow up will not be performed. 
 

Novartis  Confidential  Page 69  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 7.1.1  Screening 
The study IRB/IEC approved informed consent form must be signed and dated before any 
screening procedures are performed, except for laboratory and radiological evaluations performed as part of standard of care within the screening window. 
Patient s will be evaluated against study inclusion and exclusion criteria and safety assessments. 
For details of assessments, refer to Table 7 -1. Screening assessments must be repeated if 
performed outside of the specified screening window ( Section 7.1).  
7.1.1.1  Information to be collected on screening failures  
A patient who signed an Informed Consent Form but failed to be started on treatment for any 
reason will be considered a screen failure.  
The screening failure will be entered on the Screening Phase Disposition Page. 
The demographic information, informed consent, and Inclusion/Exclusion pages must also be 
completed for Screen Failure patients. No other data will be entered into the clinical database for patients who are screen failures, unless the patient experienced a SAE during screening (see Section 8.2 for SAE reporting details).  
7.1.1.2  Patient demographics and othe r baseline characteristics  
Data to be collected will include general patient demographics, relevant medical history and current medical conditions, diagnosis and extent of cancer, details of prior anti -neoplastic 
treatments, prior medication, procedures, significant non- drug therapies and any other 
assessments that are done for the purpose of determining eligibility for inclusion in the study. 
For patients with breast cancer, ER, PR and HER2 status will be collected. In addition BRCA1 
and BRCA2 genotype must be collected. 
7.1.2  Treatment period  
A treatment cycle is defined as 21 days for the purposes of scheduling procedures and 
evaluations. Please refer to Table 7 -1 for details of the timing of requ ired assessments and 
Section 7.1 for visit windows. 
Patients will be treated until they experience unacceptable toxicity, progressive disease per irRC 
and/or treatment is discontinued at the discretion of the investigator or the patient, as described in Section 7.1.3 and Section 4.3. 
Patients should not discontinue treatment based on progressive disease per RECIST v1.1. Accumulating evidence indicates that objective responses to immunotherapy follows delayed 
kinetics of weeks or months, and can be preceded by initial apparent radiological progression or appearance of new lesions or some enlarging lesions while other target lesions are regressing (“mixed response”) ( Wolchok 2009). It is therefore reasonable to allow for these possibilities 
and continue to treat the patient until progression is confirmed and found to be advancing at the next imaging assessment as per irRC. An outline of the irRC is provided in Appendix 2. 
Novartis  Confidential  Page 70  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 These considerations should be balanced by clinical judgment as to whether the patient is 
clinically deteriorating and unlikely to receive any benefit from continued treatment. 
Such deterioration will be assessed to have occurred after a clinical event that, in the 
Investigator’s opinion, is attributable to disease progression, is unlikely to reverse with continued study treatment and therefore indicates that the patient is not benefiting from study treatment and  cannot be managed by the addition of supportive care. 
The decision to continue or stop treatment should be discussed with the Novartis Medical Responsible and will be documented in the study files. 
The following criteria should be considered for treatment continuation decision making: 
• Patients with partial response or stable disease as well as patients with unconfirmed 
progressive disease (per irRC) should continue to receive study treatment until the next cycle.  
• Patients with confirmed irPD will discontin ue study drug(s) and enter the Follow-up 
period (see Section 7.1.5). Patients who have either a poor performance status or toxicity requiring both MCS110 and PDR001 discontinuation and do not have a confirmed irPD will enter the Follow -up period until confirmed irPD, initiation of a new treatment, 
completion of all Follow -up visits. Patients will then enter the Survival Follow -up period. 
• Patients with confirmed PD/irPD in stable or improved clinical status can remain under treatment, after discussion with Novartis, until there is a further progression or clinical deterioration under the following circumstances: 
• Absence of signs and symptoms (including worsening of laboratory values) indicating disease progressio n; 
• No decline in ECOG performance status; 
• Absence of rapid progression of disease; 
• Absence of progressive tumor at critical anatomical sites (e.g., cord compression) requiring urgent alternative medical intervention. 
7.1.3  Discontinuation of Study  Treatment  
Patients may voluntarily discontinue from the study treatment for any reason at any time. If a 
patient decides to discontinue from the study treatment, the investigator must make every effort (e.g. telephone, e -mail, letter) to determine the primary reason for  this decision and record this 
information in the patient’s chart and on the appropriate CRF pages. They may be considered withdrawn if they state an intention to withdraw, fail to return for visits, or become lost to follow-up for any other reason. 
The in vestigator should discontinue study treatment for a given patient if, on balance, he/she 
believes that continuation would be detrimental to the patient’s well-being. Study treatment may be discontinued if any of the following occur: 
• Adverse event  
• Lost to follow-up 
• Physician’s decision 
• Progressive disease per irRC (not per RECIST v1.1) 
Novartis  Confidential  Page 71  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 • Study terminated by Novartis 
• Subject/guardian decision 
• Protocol deviation 
Study treatment must be discontinued in case of pregnancy. 
At the time patients discontinue study treatment, a visit should be scheduled as soon as possible, 
and within 14 days of the last dose of study treatment or within 14 days of the decision to permanently discontinue study treatment, at which time all of the assessments listed f or the 
EOT visit will be performed ( Table 7 -1). If the decision to withdraw the patient occurs at a 
regularly scheduled visit, that visit may become the EOT visit rather than having the patient return fo r an additional visit. An End of Treatment Phase Disposition CRF page should be 
completed, giving the date and reason for stopping the study treatment. End of treatment/Premature withdrawal visit is not considered as the end of the study.  
Patients who discontinue study treatment should NOT be considered withdrawn from the study. They should return for the assessments indicated in Section 7.1.5. If they fail to return for these assessments for unknown reasons, every effort (e.g. telephone, email, letter) should be made to contact them as specified in Section 7.1.6. If a patient discontinues study treatment, but continues study assessments, the patient remains on study until such time as he/she completes protocol criteria for ending study assessments. At that time, the reason for study completion should be recorded on the Study Phase Completion Disposition CRF page. 
Patients who transfer into another study to continue provision of study treatment or an 
alternative treatment option will perform the end of treatment procedures.  
7.1.3.1  Replacement policy  
Phase Ib dose escalation part:  
Patients will not be repla ced on study. However, if a patient is considered as non- evaluable for 
dose determination and cannot be part of the Dose Determination Set (DDS), enrollment of a new patient to the current cohort will be considered if there is less than the required number of evaluable subjects. Enrollment of new subjects may be considered until at least the minimum number (3) or at most the maximum number (6) of evaluable subjects is achieved within the cohort. Minimum and maximum numbers of evaluable subjects per cohort are defined in Section 6.2.3. 
Phase II part:  
During the Phase II dose expansion part no replacements will be needed. 7.1.4  Withdrawal of Consent  
Patients  may voluntarily withdraw  consent to participate in  the study for any reason  at any 
time. Withdrawal of consent occurs  only when  a patient : 
• Does not want to participate in the study anymore, and 
• Does not allow further collection of personal data 
Novartis  Confidential  Page 72  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 In this situation,  the investigator  should m ake a reasonable effort  (e.g. telephone,  e-mail, lette r) 
to understand t he pri mary reason f or the patien t’s de cision to withdraw his/her consent and 
record this in formation.  
Study t reatment must be discontinued and no further assess ments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.  
Further attempts to  contact  the patie nt are not allowed  unless sa fety findings require 
communicating  or follow-up. 
All efforts should be made to complete the assessments prior to study withdrawal. A final 
evaluation at the time of the subject’s study withdrawal should be made as detailed in the assessment table.  
Novartis will continue to keep and use collected study information (including any data resul ting 
from the analysis of a subject’s samples until their time of withdrawal) according to applicable law. 
For US and Japan: All  biological sa mples not yet analyzed at the time of withdrawal may still 
be used for further testing/analysis in accordance with the terms of this protocol and of the 
informed consent form.  
For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no 
longer be used, unless permitted by applicable law. They will be stored according to applicable legal requirements.  
7.1.5  Follow -up period  
Safety Follow -up 
All patients must have safety evaluations until 150 days after the last dose of PDR001 or 90 days after the last dose of MCS110 (whichever the longer). The 30- , 90- and 150- day safety 
follow-up can be done by telephone call or visit.  
Concomitant medications will be collected until the 30 -day safety follow -up has been 
completed or the start of a new antineoplastic therapy, whichever occurs first.  
Data collected should be added to the Adverse Events CRF, the antineoplastic therapies since 
discontinuation of study treatment CRF, and the Concomitant Medications CRF.  
For a female participant of child bearing potential, a pregnancy test will be performed on a 
monthly basis after stopping the study treatment ( Section 7.2.2.5.7).  
For patients who transfer to another clinical study to continue provision of study treatment  or 
an alternative treatment option, as described in Section 4.3, the follow -up for safety will not be 
performed.  For all other patients, the safety evaluation period will be completed but the disease -
progression and survival follow up will not be performed. 
Disease progression follow -up period 
Patients who discontinue study treatment for  any reason other than death, disease progression 
per irRC, lost to follow -up, consent withdrawal, start of new cancer therapy or study 
Novartis  Confidential  Page 73  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 termination, should return for tumor evaluation assessments every 9 weeks until 51 weeks, then 
every 12 weeks until progression of disease per irRC, withdrawal of consent, lost to follow -up 
(Section 7.2.1), or until the end of the study is reached as described in Section 4 .3. 
If patients refuse to return for these visits or are unable to do so, every effort should be made to contact them or a knowledgeable informant by telephone to determine if the patient had disease progression. 
For patients who transfer to another clinical study or an alternative treatment option to continue 
provision of study treatment, the follow-up for disease progression will not be performed. 
Survival follow- up period 
Upon completion of the safety follow -up and disease progression follow -up (if appli cable), all 
patients enrolled in the Phase Ib and Phase II parts will be followed for survival every 3 months 
(can be done by telephone call) until death or until the end of the study is reached, as described 
in Section 4.3, unless they withdraw consent or are lost to follow-up. 
Antineoplastic therapies since discontinuation of study drug will be collected during this 
follow-up period. 
For patients who transfer to another clinical study or an alternative treatment option to continue 
provision of study treatment, the follow-up for survival will not be performed.  
7.1.6  Lost to f ollow- up 
For patie nts whose status is unclear  because they fail  to appear  for study visits without  stating 
an intention  to withdraw consent, the investigator should show "due diligence"  by contacting 
the patient, fa mily or  family physician as agreed in  the inform ed consent and by docum enting 
in the source docum ents steps  taken  to contact  the patient,  e.g. dates  of telephone calls, 
registered letters, etc. A patie nt should  not be considered  lost to follow-up until due diligence 
has been  completed. Patients  lost to follow-up should be recorded  as such on the appropriate 
Disposition  CRF.  
7.2 Assessment types  
7.2.1  Efficacy assessments 
Tumor response will be determined locally according to two sets of criteria: 
1. RECIST v1.1 ( Appendix 1) 
2. irRC ( Appendix 2) 
The local investigator’s assessment will be used for the analysis of response according to both 
RECIST v1.1 and irRC, and for treatment decision making (study discontinuation due to PD is 
per irRC). During the course of the study, Novartis may decide to have a  central review of the 
radiological assessments performed. In such case, the investigator’s staff will be instructed on how to send data from these radiological assessments to a Contract Research Organization (CRO) for central review when needed.  
At screen ing, all patients will undergo CT with i.v. contrast of the chest, abdomen and pelvis. 
If there is clinical evidence of disease in the neck, a CT with i.v. contrast of the neck will also 
Novartis  Confidential  Page 74  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 be performed. MRI should only be used to evaluate sites of disease that are not adequately 
imaged by CT. If a patient is intolerant of iodine -based contrast agents, CTs may be performed 
without contrast. MRI may be used to evaluate sites of disease where a CT without i.v. contrast is not adequate. Visible skin lesions and easily palpable subcutaneous tumors may be measured by physical examination using a ruler or calipers. Ultrasound should not be used to measure sites of disease. See Table 7 -2 for further details.  
Tumor assessments will be performed at the following time points until progression of disease per irRC or patient withdrawal:  
• Screening  
• Every 2 cycles from Cycle 3 Day 1 up to Cycle 9 Day 1, then every 3 cycles until Cycle18 Day 1 (1 year of treatment). Assessment will be performed every 4 cycles thereafter, starting from Cycle 22 Day1. 
• At the End of Treatment, if a scan was not conducted within 30 days prior to End of Treatment  
• After EOT, during disease progression follow-up, every 9 weeks (± 1 week) until week 51, then every 12 weeks (± 1 week), until progression of disease per irRC. 
• PR or CR, per both RECIST v1.1 and irRC, will be confirmed by a new assessment after at least 4 weeks. Also Progressive Disease (PD), as per irRC, will be confirmed after at least 4 weeks.  
If available, tumor markers collected as per local guidelines will be collected at the same time as RECIST tumor evaluation. 
Efficacy assessments should be performed ± 1 week from the calculated study day as described 
in Section 7.1. Disease progression follow -up should be performed as described in 
Section  7.1.5. 
Table 7-2 Disease assessment collection plan  
Procedure  Screening/Baseline  During Treatment/Follow -up 
Chest, abdomen and pelvis 
CT or MRI (with intravenous 
contrast enhancement)  Mandated  ● Every 6 weeks until end of cycle 8 (C3D1, 
C5D1, C7D1, C9D1)  
● Thereafter every 9 weeks (C12D1, 
C15D1, C18D1).  
● During year two, assessment can be performed every 4 cycles, starting from C22D1.  
● End of treatment, if not conducted within 
30 days prior to EOT.  
Tumor markers  If available as per local guideline Same time as CTor MRI tumor assessment, if available as per local 
guideline  
Brain CT or MRI  If clinically indicated If lesions were documented at baseline, follow same schedule as CT/MRI of chest, 
abdomen, and pelvis  
Localized bone CT, MRI or x-ray of other metastatic 
sites (eg neck or bone)  For any lesions already identified that are not visible on the chest, 
abdomen and pelvis CT or MRI  If lesions were documented at baseline, follow same schedule as CT/MRI of chest, 
abdomen, and pelvis  
Novartis  Confidential  Page 75  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Procedure  Screening/Baseline  During Treatment/Follow -up 
Color photography (with 
scale/ruler)  For any skin lesions present  If lesions were documented at baseline, 
follow same schedule as CT/MRI of chest, 
abdomen, and pelvis  
7.2.2  Safety and tolerability assessments  
Safety will be monitored by assessing physical examination, vital signs, body height and 
weight, performance status, hematology, chemistry, thyroid function, pregnancy, ECG, as well as collecting the AEs at every visit. For details on AE collection and reporting, refer to Section  8. 
7.2.2.1  Physical examination  
Physical examination will be performed according to Table 7 -1. 
At Screening and Cycle 1 Day 1, prior to treatment administration, a complete physical examination will be performed and will include the examination of general appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities and neuro logical. If indicated based on medical history and/or symptoms, rectal, 
external genitalia, breast, and pelvic exams will be performed.  
From Cycle 1 Day 8 onwards, a short physical examination will be performed. A short physical exam will include the examination of general appearance, vital signs (body temperature, blood pressure [BP] and pulse) and body sites as directed by symptoms. 
Significant findings that were present prior to the signature of the informed consent must be 
included in the Medical History CRF page. Significant new findings that begin or worsen after informed consent must be recorded on the Adverse Event CRF page. 
[For Japan only: oxygen saturation (SpO2) will be measured by pulse oximetry for Japanese 
patients every time physical examinat ion is performed as indicated in Table 7 -1.] 
7.2.2.2  Vital signs  
Vital signs (body temperature, pulse rate, blood pressure) must be performed before dosing and as indicated in Table 7 -1. 
Vital signs should be assessed on the scheduled day, even if study treatment is being withheld. More frequent examinations may be performed at the discretion of the Investigator if medically indicated, and will be recorded as unscheduled assessment.  
7.2.2.3  Height and weight  
Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram [kg] in indoor clothing, but without shoes) will be measured as indicated in Table 7 -1. 
7.2.2.4  Performance status  
ECOG performance status will be assessed according to Table 7 -1 and T able 7 -3. 
Novartis  Confidential  Page 76  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Table 7-3 ECOG performance status 
Grade  ECOG Status  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature (e.g., light house work, office work)  
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about 
more than 50% o f waking hours  
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours  
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair  
7.2.2.5  Laboratory evaluations  
Abnormal laboratory values that are clinically significant (e.g., require an interruption or delay 
of study treatment, lead to clinical symptoms, or require therapeutic intervention) must be documented in the Adverse Event eCRF. 
Novartis will be provided with a copy of the site’s local labor atory certification and tabulation 
of the normal ranges for each parameter required at study start and should be kept up to date on 
an ongoing basis. In addition, if at any time a patient has laboratory parameters obtained from a different outside laboratory, Novartis must be provided with a copy of the certification and a tabulation of the normal ranges for that laboratory. 
Table 7-4 Local/Central Clinical laboratory parameters collection plan  
Test Category  Test Name  
Hematology  Hematocrit, Hemoglobin, Platelets, White blood cells with differential (neutrophils, 
lymphocytes, monocytes, basophils, eosinophils, )  
Chemistry  Albumin, Alkaline phosphatase, ALT (SGPT), AST (SGOT), Bicarbonate, Calcium, 
Phosphate, Chloride, Magnesium, Creatinine, Glucose (non fasting), Creatine kinase, Lactate dehydrogenase (LDH), Total Bilirubin (also measure direct and indirect bilirubin if total bilirubin is > Grade 1), Blood Urea Nitrogen (BUN) or Urea, Uric Acid.  
 CK-MB isoenzyme, Troponin I/T, Aldolase or Myoglobin or other skeletal muscle 
marker - if required per local guidelines to rule out myositis/rhabdomyolysis (see 
Section  7.2.2.6.2 ) 
Cytokines *  IFN-γ, IL-6, IL-1,TNF -α 
Urinalysis  Macroscopic panel (Dipstick) (Bilirubin, Blood, Glucose, Ketones, White blood cells, pH, Protein, Specific Gravity)  
Myoglobin -if required to rule out myositis/rhabdomyolysis per local guidelines  
Coagulation  Prothrombin time (PT) or International normalized ratio [INR]), Partial thromboplastin 
time (PTT), Activated partial thromboplastin time (APTT)  
Thyroid  T3 [free], T4 [free], TSH  
Virology  HBV and HCV  
*To be performed by a Central Laboratory  
7.2.2.5.1  Hematology  
Hematology panel outlined in Table 7 -4 will be performed as per the assessment schedule in 
Table 7 -1. 
Novartis  Confidential  Page 77  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 7.2.2.5.2  Clinical chemistry  
Clinical chemistry panel outlined in Table 7 -4 will be performed as per the assessment schedule 
in Table 7 -1. 
7.2.2.5.3  Urine analysis  
Urine an alysis panel outlined in Table 7 -4 will be performed as per the assessment schedule in 
Table 7 -1. 
7.2.2.5.4  Thyroid function  
Thyroid function panel outlined in Table 7 -4 will be performed as per the assessment schedule 
in Table 7 -1. 
7.2.2.5.5  Cytokines  
Samples for the cytokine panel outlined in Table 7 -4 will be collected at the following time 
points: 
• Baseline (predose C1D1) 
• On an ad-hoc  basis, in case a patient has an adverse event suspected to be a cytokine 
release syndrome. In such case, this assessment should be performed at the following time 
points: 
a. within 5 hours (or as soon as possible) after the occurrence of the adverse event 
b. one week after the occurrence of the adverse event.  
Samples for cytokine panel assessment will be stored locally below - 70°C. The samples will be 
analyzed retrospectively in batches by the Novartis designated central laboratory. Immediate analysis of the sam ples by the central lab will be done only for patients who experienced an 
adverse event suspected to be a cytokine release syndrome and had follow -up samples collected.  
7.2.2.5.6  Coagulation  
Coagulation markers outlined in Table 7 -4 will be performed as per the assessment schedule in 
Table 7 -1. 
7.2.2.5.7  Pregnancy  
Pregnancy tests will be performed for women of child bearing potential per Table 7 -1. 
At screening, a serum pregnancy test must be performed within 3 days before the first dose. During the study (Day 1 of each Cycle starting with Cycle 2), and at the End of Treatment visit, a serum pregnancy test must also be pe rformed.  
A urine pregnancy test should be performed every month during and at the end of the safety follow- up period (i.e. 150 days after the last dose of PDR001 or 90 days after the last dose of 
MCS110 for patients who stopped PDR001 and continued MCS110 alone for more than 60 days). If the patient is not coming to the clinic during the safety follow-up, it can be performed at home or at a local doctor’s office, and the results will be communicated to the site staff. These follow-up pregnancy tests will be recorded only in the source documentation, not in the CRF. 
Novartis  Confidential  Page 78  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 7.2.2.5.8  Virology  
Virology panel outlined in Table 7 -4 will be performed as per the assessment schedule in 
Table 7-1. 
7.2.2.6  Cardiac assessments  
7.2.2.6.1  Electrocardiogram (ECG)  
A standard 12 lead ECG will be performed as per the assessment schedule in Table 7 -1 and 
Table 7 -5. Blood samples scheduled at the same time point should be taken after the ECGs are 
completed. The ECGs on C1D1, and C4D1 must be performed in triplicate. For the Screening, 
EOT and Unscheduled visits only one ECG per visit is required. 
Table 7-5 Local ECG collection plan  
Cycle  Day Time  
Screening  -21 to -1 Anytime  
1 1 *Pre-dose (0 hr)  
1 1 *1hr (±5 min) hour post last treatment administration  
4 1 *Pre-dose  
4 1 *1hr (±5 min) hour post last treatment administration  
EOT - Anytime  
Unscheduled**  - Anytime  
* ECGs performed in triplicate at these PK matched timepoints only.  
** A PK sample should be collected just after an ECG was performed due to an unexpected cardiac signal.  
Interpretation of the tracing must be made by a qualified physician and documented on the ECG CRF page. Each ECG tracing should be labeled with the study number, patient initials (where regulations permit) , patient number, date, and kept in the source documents at the study site. 
Clinically significant abnormalities present at screening should be reported on the Medical History CRF page. Clinically significant findings must be discussed with Novartis prior to enrolling the patient in the study. New or worsened clinically significant findings occurring after informed consent must be recorded on the Adverse Events CRF page. 
7.2.2.6.2  Cardiac and skeletal muscle markers.  
Due to known asymptomatic creatine kinase elevations associated with MCS1 10, additional 
labs will be analyzed to rule out cardiac muscle damage (CK -MB and Troponin I/T) or skeletal 
muscle damage (aldolase, myoglobin or other skeletal muscle marker per local guidelines). The 
muscle damage markers will be measured at baseline and  anytime during the study in case of 
CK elevation ≥5 x ULN.  
7.2.2.7  [For Japan only] Radiological examinations  
7.2.2.7.1   Chest x -ray 
A 2-view chest x -ray will be  performed at screening and Day 8 of Cycle 1.  
Novartis  Confidential  Page 79  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 7.2.3  Pharmacokinetics and immunogenicity assessments  
PK profiles to assess PK properties of MCS110 and PDR001 will be collected from all enrolled 
patients. However, only the patients from Phase Ib part will have additional PK collected on day 2, 4 and 15. 
Immunogenicity (IG) samples will also be collected to monitor appearance of anti -drug 
antibodies directed against MCS110 or PDR001. Please refer to Table 7 -6 and Table 7 -7 for 
details on PK and IG sample collections. If the dosing of Cycle 4 Day 1 is delayed, the PK sampling for the full PK profile should be 
delayed accordingly to match the scheduled time points for Cycle 4 as outlined in Table 7 -6 and 
Table 7 -7. After the primary CSR data cut -off date is reached, no additional PK and IG samples 
will be collected for the patients still on -going on the study. 
   
 
Table 7-6 Phase Ib Part: Pharmacokinetic blood collection log for MCS110, 
PDR001 and IG samples 
Cycle  Study 
day Analytes  Scheduled time point (Sampling 
window)  Total volume of 
Blood sample  
1 1 MCS110, PDR001 
and IG a Pre-dose b (0 hr)  6 mL  
1 1 MCS110, PDR001  1 hr (± 5 min) post end of C1D1 infusion 
dose c 4 mL  
1 2 MCS110, PDR001  24 hr (± 2 hr) post dose  4 mL  
1 4 MCS110, PDR001  72 hr(± 6 hr) post dose  4 mL  
1 8 MCS110, PDR001  168 hr (± 8 hr) post dose  4 mL  
1 15 MCS110, PDR001  336 hr (± 8 hr) post dose  4 mL  
2 1 MCS110, PDR001 
and IG a Pre-dose b of cycle 2 (0 hr)  6 mL  
3 1  MCS110, PDR001 
and IG a Pre-dosed b of cycle 3 (0 hr)  6 mL  
4 1  MCS110, PDR001 
and IG a Pre-dose b of cycle 4 (0 hr)  6 mL  
4 1 MCS110, PDR001  1 hr (± 5 min) post end of C4D1 infusion 
dose c 4 mL  
4 2 MCS110, PDR001  24 hr (± 2 hr) post dose of cycle 4  4 mL  
4 4 MCS110, PDR001  72 hr (± 6 hr) post dose of cycle 4  4 mL  
4 8 MCS110, PDR001  168 hr (± 8 hr) post dose of cycle 4  4 mL  
4 15 MCS110, PDR001  336 hr (± 8 hr) post dose of cycle 4  4 mL  
5 1 MCS110, PDR001 
and IG a Pre-dose b of cycle 5 (0 hr)  6 mL  
6 1 MCS110, PDR001 
and IG a Pre-dose b of cycle 6 (0 hr)  6 mL  
EOT  MCS110, PDR001 and IG a 6 mL  

Novartis  Confidential  Page 80  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Cycle  Study 
day Analytes  Scheduled time point (Sampling 
window)  Total volume of 
Blood sample  
Blood samples are to be collected from the arm opposite from infusion site, or alternatively, infusion site will 
need to be flushed with 10 mL of saline.  
a Immunogenicity (IG) (Anti -Drug [MCS110 or PDR001] Antibody): blood samples to be collected for anti -drug 
antibody together with PK samples  
b Pre-dose blood samples should be collected prior to start of infusion of any treatment  
c MCS110 sampling time is relative to the end of MCS110 infusion; PDR001 sampling time is relative to the end 
of PDR001 infusion 
Table 7-7 Phase II Part: Pharmacokinetic blood collection log for MCS110, 
PDR001 and IG samples 
Cycle  Study 
day Analytes  Scheduled time point (Sampling 
window)  Total volume of 
Blood sample  
1 1 MCS110, PDR001 
and IG a Pre-dose b (0 hr)  6 mL  
1 1 MCS110, PDR001  1 hr (± 5 min) post end of C1D1 infusion 
dose c 4 mL  
1 8 MCS110, PDR001  168 hr (± 8 hr) post dose  4 mL  
2 1 MCS110, PDR001 
and IG a Pre-dose b of cycle 2 (0 hr)  6 mL  
3 1  MCS110, PDR001 
and IG a Pre-dosed b of cycle 3 (0 hr)  6 mL  
4 1  MCS110, PDR001 
and IG a Pre-dose b of cycle 4 (0 hr)  6 mL  
4 1 MCS110, PDR001  1 hr (± 5 min) post end of C4D1 infusion 
dose c 4 mL  
4 8 MCS110, PDR001  168 hr (± 8 hr) post dose of cycle 4  4 mL  
5 1 MCS110, PDR001 
and IG a Pre-dose b of cycle 5 (0 hr)  6 mL  
6 1 MCS110, PDR001 
and IG a Pre-dose b of cycle 6 (0 hr)  6 mL  
Blood samples are to be collected from the arm opposite from infusion site, or alternatively, infusion site will 
need to be flushed with 10 mL of saline.  
a Immunogenicity (IG) (Anti -Drug [MCS110 or PDR001] Antibody): blood samples to be collected for anti -drug 
antibody together with PK samples  
b Pre-dose blood samples should be collected prior to start of infusion of any treatment  
c MCS110 sampling time is relative to the end of MCS110 infusion; PDR001 sampling time is relative to the end 
of PDR001 infusion 
7.2.3.1  Analytical method  
Bioanalysis for pharmacokinetic samples will employ the following validated assays: 
1. The assay to quantify MCS110 will be a validated ELISA assay. 
2. The assay to quantify PDR001 will be a validated LCMS assay. 
3. The assay to quantify and asses s the anti -MCS110 antibody will be a validated 
homogeneous ELISA. 
4. The assay to quantify and assess the anti-PDR001 antibody will be a validated 
homogeneous ELISA. 
Novartis  Confidential  Page 81  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 7.2.3.2  PK and immunogenicity sample handling, labeling, and shipping 
instructions  
A total of 4 mLs o f blood will be collected at each time point for MCS110 and PDR001 PK. 
After clotting and centrifugation, the resulting serum will be separated into 6 aliquots (3 for MCS110 and 3 for PDR001) and will be stored frozen until analysis . For time points when 
MCS110 and PDR001 PK and IG for both molecules are to be measured, a total of 6 mLs of 
blood will be collected at each time point. The samples will be prepared as serum and will be aliquoted into 12 aliquots (3 aliquots for each analyte MCS110 PK, PDR001 PK, MCS110 IG and PDR001 IG). Blood samples should be collected from the arm opposite from the investigational drug infusion, or from another site. Please see the [Laboratory Manual]  for 
detailed instructions about collection, handling and shipment of sample s. 
The actual collection date and time of each sample will be entered on the Pharmacokinetics/Immunogenicity Blood Collection eCRF pages. 

Novartis  Confidential  Page 82  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 

Novartis  Confidential  Page 83  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 8 Safety monitoring and reporting 
8.1 Adverse events  
8.1.1  Definitions and reporting 
An adverse event is defined as the appearance of (or worsening of any pre -existing) undesirable 
sign(s), symptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained. 
Abnormal laboratory values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinic ally significant, 
require therapy (e.g., hematologic abnormality that requires transfusion or hematological stem cell support), or require changes in study medication(s). 
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events CRF. Conditions that were already present at the time of informed consent should be recorded in the Medical History page of the patient’s CRF. Adverse event monitoring should be continued for 150 days after the last dose of PDR001 or 90 days  after the last dose of 
MCS110 for patients who stopped PDR001 and continued MCS110 alone for more than 60 days). 

Novartis  Confidential  Page 84  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 After initiation of new post -treatment antineoplastic therapy, only AEs suspected to be related 
to study treatment will be collected in the Ad verse Events CRF.  
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underlying signs and symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be reported as a separate Adverse Event.  
Adverse events will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the severity of mild, moderate, severe, and life- threatening, corresponding to Grades 1 - 4, will be 
used. CTCAE Grade 5 (death) will not be used in this study but is collected as a seriousness criteria; rather, information about deaths will be collected through a Death form. 
The occurrence of adverse events should be sought by non- directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study. Adverse events also may be detected when they are volunteered by the patient (subject) during the screening process or between visits, or through physical examination, laboratory test, or other assessments. As far as possible, each adverse event should be evaluated to determine: 
• The severity grade (CTCAE Grade 1 -4) 
• Its du ration (Start and end dates)  
• Its relationship to the study treatment (Reasonable possibility that AE is related: No, Yes)  
• Action taken with respect to study or investigational treatment (none, dose adjusted, 
temporarily interrupted, permanently discontinued, unknown, not applicable) 
• Whether medication or therapy was given (no concomitant medication/non-drug therapy, concomitant medication/non-drug therapy) 
• Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, recovered/resolved with sequalae, fatal, unknown) 
• Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1 
and which seriousness criteria have been met.  
All adverse events should be  treated appropriately. If a concomitant medication or non-drug 
therapy is given, this action should be recorded on the Adverse Event CRF. 
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the study treatment, the interventions required to treat it, and the outcome. 
Progression of malignancy (including fatal outcomes), if documented by use of appropriate 
method (for example, as per irRC or as per RECIST), should not be reported as a serious adverse event.  
Adverse events separate from the progression of malignancy (example, deep vein thrombosis at the time of  progression or hemoptysis concurrent with finding of disease progression) will 
be reported as per usual guidelines used for such events with proper attribution regarding relatedness to the drug. 
Novartis  Confidential  Page 85  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 8.1.2  Laboratory test abnormalities  
8.1.2.1  Definitions and reporting 
Labo ratory abnormalities that constitute an Adverse event in their own right (are considered 
clinically significant, induce clinical signs or symptoms, require concomitant therapy or require 
changes in study treatment), should be recorded on the Adverse Events  CRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low hemoglobin). Laboratory abnormalities that meet the criteria for Adverse Events should be followed until they have returned to normal or an adequate explanation of the abnormality is found. When an abnormal laboratory or test result corresponds to a sign/symptom of an already reported adverse event, it is not necessary to separately record the lab/test result as an additional event.  
Laboratory abnormal ities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically indicate a SAE unless it meets the definition of serious as defined below and/or as per investigator’s discretion. A dose hold or medication for the lab abnormality may be required by the protocol in which case the lab abnormality would still, by definition, be an adverse event and must be reported as such. 
8.2 Serious adverse events 
8.2.1  Definitions  
Serious adverse event (SAE) is defined as one of the following: 
• Is fatal or life -threatening  
• Results in persistent or significant disability/incapacity  
• Constitutes a congenital anomaly/birth defect 
• Is medically significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above 
• Requires inpatient hospitalization or prolongation of existing hospitalization, 
• Note that hospitalizations for the following reasons should not be reported as serious adverse events:  
• Routine treatment or monitoring of the studied indication, not associated with any deterioration in condition 
• Elective or pre-planned treatment for a pre-existing condition that is unrelated to the indication under study and has not worsened since signing the informed consent 
• Social reasons and respite care in the absence of any deterioration in the patient’s general condition 
• Note that treatment on an emergency outpatient basis that does not result in hospital admission and involves an event not fulfilling any of the definitions of a SAE given above is not a serious adverse event 
Progression of underlying malignancy is not reported as an adverse event if it is clearly consistent with the suspected progression of the underlying cancer as defined by RECIST or 
Novartis  Confidential  Page 86  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 irRC. Hospitalization due solely to the progression of underlying malignancy should NOT be 
reported as a serious adverse event.  
Clinical symptoms of progression may be reported as adverse events if the symptom cannot be determined as exclusively due to the progression of the underlying malignancy, or does not fit the expected pattern of progression for the disease under study. 
Symptomatic deterioration may occur in some patients. In this situ ation, progression is evident 
in the patient’s clinical symptoms, but is not supported by the tumor measurements. Or, the 
disease progression is so evident that the investigator may elect not to perform further disease assessments. In such cases, the deter mination of clinical progression is based on symptomatic 
deterioration. These determinations should be a rare exception as every effort should be made to document the objective progression of underlying malignancy. 
If there is any uncertainty about an adverse event being due only to the disease under study, it 
should be reported as an AE or SAE. 
8.2.2  Reporting 
To ensure patient safety, every SAE, regardless of suspected causality, occurring after the 
patient has provided informed consent and until at least 150 days after the patient has stopped study treatment must be reported to Novartis within 24 hours of learning of its occurrence (90 days for patients who stopped PDR001 and continued MCS110 alone for more than 60 days). 
If a patient starts a post treatment an tineoplastic therapy, then only SAEs suspected to be related 
to study treatment will be reported.  
Any SAEs experienced after this follow -up period should only be reported to Novartis if the 
investigator suspects a causal relationship to the study treatment . Recurrent episodes, 
complications, or progression of the initial SAE must be reported as follow -up to the original 
episode within 24 hours of the investigator receiving the follow -up information. An SAE 
occurring at a different time interval or otherwise  considered completely unrelated to a 
previously reported one should be reported separately as a new event. Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed  in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each specific study treatment (if there is more than one study treatment), complete the SAE Report Form in English [For Japan only: complete the SAE report form in English or Japanese], and submit the completed form within 24 hours to Novartis. Detailed instructions regarding the submission process and requirements for signatures are to be found in the investigator folder provided to ea ch site.  
Follow- up information is submitted in the same way as the original SAE Report. Each re -
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was broken or not, and whether the patient continued or withdrew from study participation. 
If the SAE is not previously documented in the Inves tigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the Novartis study treatment, an oncology Novartis 
Novartis  Confidential  Page 87  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Chief Medical Office and Patient Safety (CMO&PS) department associate may urgently require 
further information from the investigator for Health Authority reporting. Novartis may need to issue an Investigator Notification (IN), to inform all investigators involved in any study with the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions  (SUSARs) will be collected and reported to the competent authorities and relevant 
ethics committees in accordance with Directive 2001/20/EC or as per national regulatory requirements in participating countries. 
8.3 Pregnancies 
To ensure patient safety, each p regnancy occurring while the patient is on study treatment must 
be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications. After the mother has provided consent, the newborn will be followed-up for 12 months. 
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by the 
investigator to the oncology Novartis CMO&PS department. Pregnancy follow -up should be 
recorded on the same form and should include an assessment of the possible relationship to the investigational treatment and  any pregnancy outcome. Any SAE experienced during pregnancy 
must be reported on the SAE Report Form. 
For Korea only: Pregnancy outcomes should be collected for the female partners of any males 
who took study treatment in this study. Consent to report information regarding these  pregnancy 
outcomes should be obtained from the mother. 
8.4 Warnings and precautions 
No evidence available at the time of the approval of this study protocol indicated that special warnings or precautions were appropriate, other than those noted in the provided [Investigator Brochure]. Additional safety information collected between IB updates will be communicated in the form of Investigator Notifications. This information will be included in the patient informed consent and should be discussed with the patient during the study as needed. 
8.5 Data Monitoring Committee 
A formal data monitoring board will not be used for this study. This is an open- label, Phase 
Ib/II study in which patients will receive MCS110 in combination with PDR001. Novartis will have access to the Safety Data on a regular basis. Novartis will host investigator teleconferences on a regular basis during the study. Further, during the Phase Ib part of the study, Novartis and the investigators will meet at the end of each treatment c ohort to discuss and evaluate all of the 
gathered safety data. At the dose escalation teleconference the clinical course (safety information including both DLTs and all CTCAE Grade 2 or higher toxicity data during the first two cycles of treatment, and PK data) for each patient in the current dose cohort will be described in detail. Updated safety data on other ongoing patients, including data in later cycles, will be discussed as well.  
Novartis  Confidential  Page 88  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Dose escalation decisions will be based on a clinical synthesis of all relevant available data and 
not solely on DLT information. Selection of the actual dose for the next cohort of patients will be guided by the BLRM with EWOC and a medical review of relevant clinical, PK and laboratory data. Novartis and the investigator parties must reach a consensus on whether to declare MTD, escalate the dose any further, or whether to de- escalate and/or recruit an 
additional cohort of patients at the current dose level ( Section 10.4.2).  
During the Phase II part of the study individual patient data will be reviewed on an ongoing basis. Overall response rate (ORR) for Group 1, 3, 4 and clinical benefit rate (CBR) for Group 2 per RECIST v1.1 and irRC and aggregate safety data will be monitored quarterly by the study team across the duration of the trial. Enrollment of each of Group 1, 3 and 4 will be expanded up to approximately 40 patients when objective responses (CR or PR) per RECIST v1.1 or irRC  
are observed (≥ 3 of 20 patients i n each of the PD -1/PD- L1 therapy naïve groups or ≥ 2 of 20 
patients in the PD -1/PD- L1 therapy resistant group). In Group 2, enrollment may be expanded 
up to approximately 40 patients at RP2D if clinical benefit per RECIST v1.1 or irRC  (CR, PR 
or SD > 4 months) is observed in at least 3 pts. In addition, an exploratory group of 20 patients at a lower dose (1 mg/kg MCS110 in combination with PDR001 300 mg) may be opened if the above mentioned gating criteria is met (Group 2b). The decision of whether to expand a certain expansion group will be made at the time when the required number of responses is observed, or the last patient (out of 20 patients) has been on treatment for 6 months, whichever occurs earlier. The data review and analysis will be based on the  available investigator reported data 
in the clinical database at that time Section 10.7. 
9 Data collection and management  
9.1 Data confidentiality 
Information about study subjects will be kept confidential and mana ged under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following: 
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI. 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability to use all information collected prior to the revocation of subject authorization. For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect follow -up safety information (e.g. has the subject 
experienced any new or worsened AEs) at the end of their scheduled study period. 
The data collection system for this study uses built -in security features to encrypt all data for 
transmission in both directions, preventing unauthori zed access to confidential participant 
information. Access to the system will be controlled by a sequence of individually assigned 
user identification codes and passwords, made available only to authorized personnel who have completed prerequisite training . 
Novartis  Confidential  Page 89  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Prior to entering key sensitive personally identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify that this data is allowed to be collected. If the site indicates that country rules or ethics committee standards do not permit collection of these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the place of exact date of birth) to establish that the subject satisfies protocol age requirements and to enable appropria te age -related normal ranges to be used in assessing laboratory test results.  
9.2 Site monitoring 
Before study initiation, at a site initiation visit or at an investigator’s meeting, Novartis personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study, the field monitor will visit the site regularly to check the completeness of patient records, the accuracy of entries on the CRFs, the adherence to the protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits. 
The investigator must maintain source documents for each patient in the study, consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All informatio n recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a signed copy is given to the patient). 
The investigator must give the monitor access to all relevant  source documents to confirm their 
consistency with the CRF entries. Novartis monitoring standards require full verification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria and documentation of SAEs. Additional checks of the consistency of the source data with the CRFs are performed according to the study-specific monitoring plan. 
9.3 Data collection 
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter the data required by the protocol  into the Electronic Case Report Forms (eCRF). The eCRFs 
have been built using fully validated secure web- enabled software that conforms to 21 CFR Part 
11 requirements, Investigator site staff will not be given access to the EDC system until they have been  trained. Automatic validation programs check for data discrepancies in the eCRFs 
and, allow modification or verification of the entered data by the investigator staff. 
The Principal Investigator is responsible for assuring that the data entered into eCRF is 
complete, accurate, and that entry and updates are performed in a timely manner. 
PK  samples obtained during the course of 
the study will be collected from the Investigator sites and analyzed by a Novart is designated 
laboratory and/or contracted central laboratories. ECG data collected during the study will be 
reviewed locally by a cardiologist. During the course of the study, Novartis may decide to have a central review of the radiological assessments performed. In such case, the investigator’s staff will be instructed on how to send data from these radiological assessments to a Contract Research Organization (CRO) for central review when needed. Designated investigational site 

Novartis  Confidential  Page 90  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 staff will enter the information required by the protocol into the appropriate eCRF and/or 
designated laboratory requisition forms. Field monitors will review the eCRFs and laboratory paper requisition forms for accuracy and completeness and instruct site personnel to make any requi red corrections or additions. One copy of the requisition form will be forwarded to each 
analytical laboratory with the respective sample(s) by the field monitor or by the designated investigational site staff; and one copy will be retained at the investigational site.  
9.4 Database management and quality control 
For studies using eCRFs, Novartis personnel will review the data entered by investigational staff for completeness and accuracy. Electronic data queries stating the nature of the problem and requesting clarification will be created for discrepancies and missing values and sent to the investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data. 
Concom itant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employs the Anatomical Therapeutic Chemical classification 
system. Medical history/current medical conditions and adverse events will be coded using the Medical dictionary for regulatory activities (MedDRA) terminology.  
Samples and/or data will be processed centrally and the results will be sent electronically to Novartis. 
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copies 
of the patient data for archiving at the investigational site.  
10 Statistical methods and data analysis 
The data will be analyzed by Novartis and/or designated CRO. Any data analysis carried out 
independently by the investigator must  be submitted to Novartis before publication or 
presentation. 
It is planned that the data from participating centers in this protocol will be combined, so that 
an adequate number of patients will be available for analysis. The data will be summarized with respect to demographic and baseline characteristics, efficacy observations and measurements, safety observations and measurements, and all relevant PK and PD measurements using descriptive statistics (quantitative data) and contingency tables (qualitative data).  
The study data will be analyzed and reported based on all patients’ data of the Phase Ib and Phase II parts up to the time when all patients have potentially completed at least six cycles of treatment or discontinued the study. Any additional data for patients continuing to receive study treatment past the data cutoff date for the primary Clinical Study Report (CSR), as allowed by the protocol, will be reported at completion of the study as defined in Section 4.3. 
The following rules will be followed for reporting results unless stated otherwise: 
• Phase Ib dose escalation data: cohorts treated during the dose escalation with the same 
dose levels of MCS110 and PDR001 will be pooled into a single treatment group. All summaries, listings, figures and analyses will be performed by treatment group. 
Novartis  Confidential  Page 91  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 • Phase II data: All summaries, listings, figures for non-safety analysis will be reported by 
group. Safety analysis of Phase II will be reported by group and all patients. For Group 2, all summaries, listings, figures will be reported by dose level, when applicable. The groups are the following: 
• Group 1: TNBC (naive to PD-1/PD-L1 directed therapy) 
• Group 2: Pancreatic cancer (naive to PD -1/PD- L1 directed therapy) 
• Group 3: Endometrial cancer (naive to PD-1/PD-L1 directed therapy) 
• Group 4: Melanoma (resistant to PD-1/PD- L1 directed therapy)  
Categorical data will be presented as frequencies and percentages. For continuous data, mean, standard deviation, median, minimum, and maximum will be presented. 
Screen failure patients are those who signed the informed consent, but never started the study 
treatment for any reason. For these patients, the eCRF data collected (see Section 7.1.1.1) will 
not be included in analyses, but will be reported in the CSR as separate listings. 
10.1 Analysis sets  
10.1.1  Full Analysis Set  
The Full Analysis Set (FAS) comprises all patients who received at least one dose of MCS110 or PDR001. Patients will be analyzed according to the planned treatment combination. Unless otherwise specified, FAS is the default set used for all analyses.  
10.1.2  Safety Set  
The Safety Set (SS) includes all patients who have received at least one dose of MCS110 or PDR001. Pati ents will be classified according to treatment received, where treatment received 
is defined as:  
1. The treatment assigned if it was received at least once, or  
2. The first treatment received when starting therapy with study treatment if the assigned treatment w as never received.  
The safety set will be used for the safety summary of the study. 
10.1.3  Per-Protocol Set  
The Per Protocol Set (PPS) consists of a subset of FAS patients in the Phase II part who meet 
the following criteria:  
• Presence of at least one measurable l esion according to RECIST v1.1 as per Appendix 1  
• Have at least one post -baseline tumor assessment evaluable per RECIST v1.1, or have 
withdrawn due to clinical progression. 
• Have received the planned treatment  
• Have not been previously treated with PD-1 or PD- L1-directed therapy except patients in 
the melanoma pretreated group (Group 4), who must have previously received a PD-1 or PD-L1-directed therapy.  
Patients will be classified according to planned treatment.  
Novartis  Confidential  Page 92  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 The PPS will be used in the Phase II part of the study only and will define the patients used in 
the sensitivity analysis of the primary endpoint Section 10.4. If the PPS and the FAS are identical, the n analyses described by the PPS below will not be performed. 
10.1.4  Dose -determining analysis set  
The DDS consists of all patients from the safety set in the Phase Ib dose escalation part who either meet the following minimum exposure criterion and have sufficien t safety evaluations, 
or have experienced a DLT during first two cycles. 
A patient is considered to have met the minimum exposure criterion if he/she received two 
doses of MCS110 and PDR001 during the first two cycles. 
Patients who do not experience DLT during the first two cycles are considered to have sufficient 
safety evaluations if they have been observed for ≥ 42 days following the first dose, and are considered by both the Sponsor and Investigators to have enough safety data to conclude that a DLT did not occur. 
Patients who do not meet these minimum safety evaluation requirements nor experience a DLT 
will be regarded as ineligible for the DDS and an additional patient may be recruited (see Section 7.1.3.1).  
10.1.5  Pharmacokinetic analysis set  
The Pharmacokinetic analysis set (PAS) includes all subjects who provide an evaluable PK profile. A profile is considered evaluable if all of the following conditions are satisfied: 
• Subject receives the planned treatment  
• Subject provides at least one primary PK parameter  
Note : patients will be removed from the estimation of certain PK parameters on an individual 
basis depending on the number of available blood samples. These patients will be identified at 
the time of the analyses  
10.2 Patient demographics/other baseline characteristics 
Demographic and other baseline data (including disease characteristics) will be listed in detail.  
Qualitative data (e.g. performance status) and quantitative data (e.g. weight) will be summarized by appropriate descriptive statistics for each treatment cohort in Phase Ib and for each group in Phase II. 
10.3 Treatments (study treatment, concomitant therapies, 
compliance) 
For each of MCS110 and PDR001, the actual dose and durati on in days of treatment as well as 
the dose intensity (actual dose received/actual duration) and relative dose intensity (the ratio of dose intensity to planned dose/planned duration) will be listed and summarized by means of descriptive statistics by trea tment group. Categories for relative dose intensity of MCS110 or 
PDR001 will be specified as < 0.5, ≥ 0.5 - < 0.75, ≥ 0.75 - < 0.9, ≥ 0.9 - < 1.1 and ≥ 1.1. The 
number and proportion of patients within each category will be presented by treatment group. 
Novartis  Confidential  Page 93  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Concomitant medications and significant non- drug therapies prior to and after the start of the 
study treatment will be listed by patient and summarized by ATC term and treatment group. 
The reason for discontinuation from treatment will be summarized and list ed, along with dates 
of first and last dose of MCS110 and PDR001 (if applicable), duration of exposure to MCS110 
and PDR001 (if applicable) and date of discontinuation for each patient. 
Compliance with the protocol will be assessed by the number and propor tion of patients with 
protocol deviations. Protocol deviations will be identified prior to database lock and will be 
listed and summarized.  
10.4 Primary objective 
Phase Ib  
The primary objective of the Phase Ib part is to  characterize the safety and tolerability  of 
MCS110 given in combination with PDR001 and to identify a recommended dose for Phase II . 
Phase II  
The primary objective of the Phase II part of this study is to estimate the anti -tumor activity of 
the combination of MCS110 with PDR001 in each expansion group. 
10.4.1  Variable  
Phase Ib  
The primary variables of Phase Ib are:  
• Safety: Incidence and severity of AEs and SAEs, including changes in laboratory values, 
vital signs, and ECGs; 
• Tolerability: Dose interruptions, reductions, and dose intensity; 
• Incidence of DLTs in the first two cycles of study treatment 
Phase II  
For TNBC, endometrial carcinoma and melanoma the primary variable of Phase II is the Overall 
Response Rate (ORR), defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) based on local Investigator assessment, as 
defined in RECIST v1.1. Estimation of the true ORR in this part of the study will be based upon the observed BOR for patients in the FAS, using a Bayesian analysis. 
For pancreatic patients, the primary variable of Phase II is the Clinical Benefit Rate (CBR), 
defined as the proportion of patients with a best overall response of complete response (CR) or 
partial response (PR) (with at least two assessments 4 weeks apart) or stable disease (SD) > 4 months based on local Investigator assessment, as defined in RECIST v1.1. 
Novartis  Confidential  Page 94  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 10.4.2  Statistical hypothesis, model, and method of analysis  
10.4.2.1  Phase Ib  
10.4.2.1.1  Identification of a recommended dose  
The dose escalation part of this study will be guided by a Bayesian analysis of first two cycles 
dose limiting toxicity (DLT) data for MCS110 and PDR001 in combination. The Bayesian analysis will be based on a model with three parts, representing: 
• Single agent MCS110 : logit(π
1(d1)) = log(α 1) + β 1log(d 1/d1*); d 1* = 5 mg/kg Q3W 
• Single agent PDR001: logit(π 2(d2)) = log(α 2) + β 2log(d 2/d2*); d 2* = 300 mg Q3W 
• Interaction: Odds(π 12(d1,d2))) = π 12(d1,d2)/(1- π12(d1,d2)) 
= exp(η(d 1/d1*)(d 2/d2*))(π 1(d1)+ π 2(d2) – π1(d1) π2(d2))/((1 - π1(d1))(1- π2(d2))), 
where logit(π.(d.)) = log[π.(d.)/{1- π.(d.)}], d 1* = 5 mg/kg and d 2*= 300 mg are the reference 
doses of MCS110 and PDR001 respectively, α 1, α2, β1, β2 > 0 and - ∞ < η < ∞.  
Single agent toxicity is modelled using logistic regression for the probability of a patient 
experiencing a DLT against log -dose. The odds of a DLT are then calculated under no 
interaction for the two single agent toxicities, and interaction is accounted for by adjusting these odds with an additional model parameter (odds multiplier). Details of  the model are given in 
(Appendix 3).  
Assessment of patient risk  
After each cohort of patients, the posterior distribution for the risk of DLT for new patients at combination doses of interest will be evaluated. The posterior distributions will be summarized 
to provide the posterior probability that the risk of DLT lies within the following intervals: 
Under -dosing:  [0 , 0.16)  
Targeted toxicity:  [0.16 , 0.33)  
Excessive toxicity:  [0.33 , 1]  
The escalation with overdose control (EWOC) principle  
Dosing decisions are guided by the escalation with overdose control principle  
(Rogatko 2007). A combination dose may only be used for newly enrolled pat ients if the risk 
of excessive toxicity at that combination dose is less than 25%. 
Prior distributions  
For each single agent model, a mixture prior was derived. For MCS110, this study uses a 
mixture prior consisting of two components. Component 1 is the distribution derived based on dose- DLT data. The assigned weight for Component 1 is 80%. Component 2 allows for a higher 
toxicity case. The assigned weight for Component 2 is 20%. For PDR001, this study uses a mixture prior consisting of three components. Component 1 and 2 are derived based on dose -
DLT data. The assigned total weight for Component 1 and 2 is 80%. Component 3 allows for a higher toxicity case. The assigned weight for Component 3 is 20%. 
Novartis  Confidential  Page 95  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 A meta -analytic -predictive (MAP) approach was used to derive Component 1 of the prior 
distribution for the single agent MCS110 model parameters, and Component 1 and 2 of the prior 
distribution for the single agent PDR001 model parameters. The MAP prior for  the logistic 
model parameters for this study is the conditional distribution of the parameters given the historical data (see Spiegelhalter 2004, Neuenschwander 2010, Neuenschwander 2014). MAP 
priors are derived from hierarchical models, which take into account possible differences between the studies.  
For this study, available clinical data were taken from the following clinical studies:  
For MCS110: [CMCS110A2101]  first-in-human MCS110 study. This study is completed. 
[CMCS110X2201]  a Phase II study in PVNS patients. This study is ongoing. 
For PDR001: [CPDR001X2101]  first-in-human PDR001 oncology study. This study is 
ongoing. 
For each of the single agent prior, an additional high toxic component is introduced to allow for 
a higher toxicity case. A full description of the application of the MAP approach to derive the prior distributions of the single agent MCS110 and PDR001 model parameters is given in (Appendix 3) 
The prior distribution for the interaction parameter was based upon prior understanding of possible drug safety interactions ( Section 1.3.3). This prior allows for the possibility of either 
synergistic or antagonistic interaction, and is fully described in ( Appendix 3 ). 
Starting dose  
The starting dose is 3 mg/kg for MCS110, and 100 mg for PDR001 which will be administered every 3 weeks (see Section 6.2.1). For this dose the prior risk of excessive toxicity is 10.4%, which satisfies the EWOC criterion. A full assessment of the prior risk to patients is given in (Appendix 3). Before first patient first visit (FPFV), the BLRM will be updated with additional 
PDR001 single agent data (if available) to ensure the starting dose still satisfies EWOC.  
Listing of DLTs  
DLTs will be listed, and their incidence summarized by primary system organ class and worst grade (CTCAE version 4.03). Listings and summaries will be based on the DDS. 
10.4.2.1.2  Safety analyses 
Analyses set and grouping for the analyses  
For all safety analyses, the safety set will be used. All listings and tables will be presented by 
treatment group. 
The overall observation period will be divided into three mutually exclusive segments: 
1. pre-treatment period: from day of patient’s informed consent to the day before first dose 
of study treatment 
2. on-treatment period: from day of first dose of study medication to 30 days after the last 
dose of study treatment 
Novartis  Confidential  Page 96  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 3. post-treatment period: from 31 days a fter date of last administration of study treatment  
Safety summaries will primarily be based on all data from the on -treatment period.  Following 
last administration of study treatment, adverse events (including serious adverse events), and 
new antineoplastic therapies are collected for a period of 150 days.  Following start of new antineoplastic therapy, only treatment related adverse events will be collected.  Select summaries of related adverse events will be produced for the combined on -treatment and po st-
treatment periods for patients receiving PDR001. 
Adverse events (AEs)  
Summary tables for AEs have to include only AEs that started or worsened during the on-
treatment period, the treatment- emergent AEs. However, all safety data (including those from 
the pre and post -treatment periods) will be listed and those collected during the pre -treatment 
and post- treatment period are to be flagged.  
The incidence of treatment -emergent AEs (new or worsening from baseline) will be 
summarized by system organ class and or preferred term, severity (based on CTCAE grades), type of AE, relation to study treatment by treatment group. 
Deaths reportable as SAEs and non -fatal SAEs will be listed by patient and tabulated by type 
of AE and treatment group. Specific safety event categories (SEC) may be considered. Such categories consist of one or 
more well -defined safety events which are similar in nature and for which there is a specific 
clinical interest in connection with the study treatment(s), which is specified in case retrieval strategy (CRS). SEC will be specified in the statistical analysis plan (SAP) and finalized prior to database lock.  
For each specified SEC, number and percentage of patients with at least one event part of the SEC will be reported. 
Laboratory abnormali ties 
For laboratory tests covered by the Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.03 the study’s biostatistical and reporting team will grade laboratory data accordingly. For laboratory tests covered by CTCAE, a  Grade 0 will be assi gned for all non-
missing values not graded as 1 or higher. Grade 5 will not be used. 
For laboratory tests where grades are not defined by CTCAE, results will be graded by the 
low/normal/high classifications based on laboratory normal ranges . 
The following by- treatment summaries will be generated separately for hematology, 
biochemistry and urinary laboratory tests: 
• Frequency table for newly occurring on- treatment grades 3 or 4 (see below for details).  
• Shift tables using CTCAE grades to compare baseline to the worst on- treatment value.  
• Listing of all clinically relevant laboratory data with values flagged to show the 
corresponding CTCAE grades and the classifications relative to the laboratory normal ranges.  
Novartis  Confidential  Page 97  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 In addition to the above mentioned tables and listings,  analyses may be 
specified in the SAP.  
ECG  
• shift table baseline to worst on -treatment result for overall assessments  
• listing of ECG evaluations 
• listing of ECG evaluations for all patients with at least one abnormality  
Vital signs  
Definitions of notably abnormal results will be specified in the SAP.  
• Listing of vital signs  
• shift table baseline to worst on -treatment result 
10.4.2.1.3  Tolerability  
Tolerability of study treatment will be assessed by summarizing the number of treatment dose 
interruptions and dose reductions. Reasons for dose interruptions and dose reductions will be listed by patient and summarized ( Section 10.3).  
10.4.2.2  Phase II  
A Bayesian design will be used in order to estimate ORR (Group 1, 3 and 4) or CBR (Group 2) for each of the following groups in the Phase II part of the study. 
• Group 1: MCS110+PDR001, TNBC (naïve to PD-1/PD- L1 directed therapy)  
• Group 2: MCS110+PDR001, Pancreatic adenocarcinoma (naïve to PD-1/PD -L1 directed 
therapy) 
• Group 3: MCS110+PDR001, Endometrial carcinoma (naïve to PD-1/PD- L1 directed 
therapy) 
• Group 4: MCS110+PDR001, Melanoma (progressed on previous PD-1/PD-L1 therapy) 
Groups 1, 3 and 4 will enroll approximately 20 patients, and may be extended to approximately 
40 patients (if at least 3 patients have an objective response for Group 1 and 3; and if at least 2 patients have an objective response for Group 4). In Group 2, 20 patients will be enrolled at 
RP2D, and enrollment may be extended to approximately 40 patients if clinical benefit is observed in at least 3 pts. In addition, an exploratory group of 20 patients at a lower dose (1 mg/kg MCS110 in combination with PDR001 300 mg) may be opened if the above mentioned gating criterion is met (Group 2b). See timing of the decision- making in Section 4.2.  The 
primary analysis will be performed when all patients have completed at least 6 cycles of treatment or discontinued prior to that time fo r any reason.  
Group 1, 3: Minimally informative unimodal Beta prior distribution is defined such that the prior mean ORR is set to be equal to 30% and the parameters of the minimally informative Beta prior distribution of ORR have been set up as following: 
• a/(a+b) = 0.3  
• a = 0.43 

Novartis  Confidential  Page 98  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 • b = 1. 
At primary analysis, this prior distribution will be updated with all the data available from the 
patients in the FAS. See sample size estimation in Section 10.8. 
Once updated, the estimate ORR and proba bility of ORR lies in the following categories will 
be reported: 
• [0%, 15%) unacceptable efficacy  
• [15%, 30%) moderate efficacy 
• [30%, 100%] clinically relevant efficacy 
If the observed ORR is equal to or greater than 30% (i.e. ≥ 12 responses (CR or PR) of out 40 
patients) then this will be considered as preliminary evidence of antitumor activity of MCS110+PDR001 in the respective patient group naive to PD-1/PD-L1 directed therapy. 
Note that, for a sample size of n = 40, if the observed ORR is 30% then the posterior probability 
of true ORR greater than 20% is 93.0%. 
Group 2:  Minimally informative unimodal Beta prior distribution is defined such that the prior 
mean CBR is conservatively set to be equal to 15% and the parameters of the minimally 
informative Beta prior distribution of CBR have been set up as following: 
• a/(a+b) = 0.15  
• a = 0.18 
• b = 1. 
At primary analysis, this prior distribution will be updated with all the data available from the 
patients in the FAS. See sample size estimation in Section 10.8. 
If the lower MCS110 dose level is explored (Group 2b), a separate model with the same prior 
assumption will be used to estimate CBR.  
Once updated, the estimate CBR and probability of CBR lies in the following categories will 
be reported: 
• [0%, 7.5%) unacceptable efficacy 
• [7.5%, 15%) moderate efficacy 
• [15%, 100%] clinically relevant efficacy 
Observed CBR will be analyzed by dose level. If the observed CBR is equal to or greater than 
15% (i.e. ≥ 6 responses (CR, or PR, or SD for at least 4 months) out of 40 patients at RP2D; or ≥ 3 responses (CR, or PR, or SD for at least 4 months) out of 20 patients at lower dose group (Group 2b) then this will be considered as preliminary evidence of antitumor activity of MCS110+PDR001 in the pancreatic patient group naive to PD-1/PD-L1 directed therapy. 
Note that, for a sample size of n = 40, if the observed ORR is 15% then the posterior probability 
of true CBR greater than 7.5% is 93.5%; for a sample size of n = 20, if the observed ORR is 15% then the posterior probability of true CBR greater than 7.5% is 84.3%. 
Novartis  Confidential  Page 99  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Group 4  
Minimally informative unimodal Beta prior distribution is defined such that the prior mean 
ORR is conservatively set to be equal to 15% and the pa rameters of the minimally informative 
Beta prior distribution of ORR have been set up as following: 
• a/(a+b) = 0.15  
• a = 0.18 
• b = 1. 
At primary analysis, this prior distribution will be updated with all the data available from the 
patients in the FAS. See sample size estimation in Section 10.8. 
Once updated, the estimate ORR and proba bility of ORR lies in the following categories will 
be reported: 
• [0%, 7.5%) unacceptable efficacy 
• [7.5%, 15%) moderate efficacy 
• [15%, 100%] clinically relevant efficacy 
If the observed ORR is equal to or greater than 15% (i.e. ≥ 6 responses (CR or PR) of out 40 
patients) then this will be considered as preliminary evidence of antitumor activity of MCS110+PDR001 in the respective patient group resistant to PD-1/PD-L1 directed therapy. 
Note that, for a sample size of n = 40, if the observed ORR is 15% then the posterior probability 
of true ORR greater than 7.5% is 93.5%. 
10.4.3  Handling of missing values/censoring/discontinuations  
Continuing events (e.g., AEs, concomitant medication, etc.) will be summarized using the data 
cut-off date as the date of completion, with  a flag to indicate within listings that the event is 
continuing. For patients who discontinue the study with ongoing events, the discontinuation date will be used as the completion date of the event. 
The reason for discontinuation from study will be summarized and listed, along with dates of 
first and last study drug treatment, duration of exposure to study drug treatment and date of discontinuation for each patient. 
Other missing data will simply be noted as missing on appropriate tables/listings.  
10.4.4  Support ive analyses  
For the Phase II part, the primary analysis on ORR may be repeated using PPS. Additional 
exploratory and supportive analyses will be performed if appropriate as defined in the SAP. 
10.5 Secondary objective 
10.5.1  Key secondary objective  
Not applicable.  
Novartis  Confidential  Page 100  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 10.5.2  Other secondary efficacy objectives  
Tumor response will be determined per local investigators’ assessment, according to RECIST 
v1.1 and irRC. Response related efficacy assessments will be defined and analyzed based on both RECIST v1.1 and irRC. For the purpose of this study, C linical benefit rate (CBR) is 
defined as the proportion of patients with a best overall response of CR or PR , or an overall lesion response of SD which lasts for more than  4 months . 
Secondary efficacy endpoints include:  
• Phase Ib part: ORR, PFS, CBR, DOR and DCR per RECIST v1.1 and per immune related 
Response Criteria (irRC)  
• Phase II part: (1) For Group 1, 3, 4, ORR per irRC, PFS, DOR, DCR, CBR per RECIST v1.1 and per irRC; (2) For Group 2, CBR per irRC, PFS, DOR, DCR, ORR per RECIST v1.1 and per irRC 
For all secondary efficacy parameters, data will be listed, summarized, or analyzed by treatment group for the Phase Ib part, and by disease group (groups 1 to 4) for Phase II patients treated at the MTD/ RP2D.  
ORR, CBR and DCR will be summa rized with accompanying 90% confidence interval. 
PFS, along with DOR for patients who experience a CR or PR at any time on study will be listed by patient.  PFS will be analyzed using Kaplan- Meier estimates (including graphical 
representation) with 90% CIs of median survival for each treatment group/disease group. 
OS data will be listed for all patients enrolled in the Phase Ib and Phase II parts. Descriptive  
statistics for OS endpoint (e.g., median OS and 90% CI of the Kaplan- Meier estimates) will be 
provided as appropriate by treatment group and furthermore by disease group for patients 
treated at the MTD/RP2D in the Phase II part.  
Individual lesion measurements and overall response assessments will be listed by patient and assessment date. Best overall response per RECIST v1.1 and per irRC will be listed and tabulated.  
Any additional analyses of efficacy endpoints will be described in the SAP. 
10.5.3  Safety objectives  
Another secondary objective is to further characterize the safety and tolerability of MCS110 in 
combination with PDR001 during Phase II part. Safety and tolerability analyses as described in 
Section 10.4.2.1.2 and Section 10.4.2.1.3 will be performed. 
10.5.4  P harmacokinetics  
The pharmacokinetic parameters will be determined by profile using noncompartmental 
method(s) for both MCS110 and PDR001 as presented in Table 10 -1, and PAS will be used in 
all pharmacoki netic data analysis and PK summary statistics.  
Novartis  Confidential  Page 101  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Table 10 -1 Pharmacokinetic Parameters to be analyzed  
AUClast  The AUC from time zero to the last measurable concentration sampli ng time (tlast) (mass x 
time x volume -1) 
AUCinf  The AUC from time zero to infinity (mass x time x volume -1) 
Cmax  The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration 
after single dose administration (mass x volume -1) 
Tmax  The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug 
concentration after single dose administration (time)  
T1/2 The elimination half -life associated with the terminal slope ( λz) of a semi logarithmic 
concentration -time curve (time). Use qualifier for other half -lives 
CL The total body clearance of drug from the plasma (volume x time -1) 
Vz The apparent volume of distribution during terminal phase (associated with λz) (volume)  
AR Accumulation Ratio=Cm ax (multiple Dose)/Cmax (single dose)  
Descriptive statistics of all pharmacokinetic parameters will include arithmetic and geometric 
mean, median, SD, and CV, geometric CV, minimum and maximum. Zero concentrations will not be included in the geometric mean calculation. Since Tmax is generally evaluated by a nonparametric method, median values and ranges will be given for this parameter. 
Summary statistics will be presented for MCS110 and PDR001 serum concentrations at each 
scheduled time point. Descriptive graphical plots of individual serum concentration versus time profiles and mean concentration versus time profiles will be generated. 
Missing concentration values will be reported as is in data listings. Concentration values below 
Lower limit of quantitation will be handled as zero in summary statistics, and reported as is in 
data listings. Any missing pharmacokinetic parameter data will not be imputed.  
The presence of immunogenicity for MCS110 and PDR001, at each scheduled time point, will be listed by treatment group, disease and patient. Overall immunogenicity will be summarized.  
More details will be provided in SAP or separate analysis plan. 

Novartis  Confidential  Page 102  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 

Novartis  Confidential  Page 103  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 10.7 Interim analysis  
No formal interim analyses are planned.  
Phase Ib  
However, in Phase Ib, the dose -escalation design foresees that decisions based on the current 
data are taken before the end of the study. More precisely, after each cohort in the dose 
escalation part, the next dose will be chosen depending on the observed data (based on safety, tolerability, PK and PD, guided by the recommendations from the BLRM of DLT using EWOC, and recommendations from participating investigators). Details of this procedure and the process for communication with Investigators are provided in Sectio n 6.2.3. 
Phase II  
Data from patients in the Phase II part will be reviewed on an ongoing basis to monitor the safety and tolerability of the RP2D in that part of the study. The sample size in any of Group 1, 3 or 4  may be extended to approximately 40 pati ents (if ≥ 3 of 20 patients in each of the PD -
1/PD- L1 therapy naïve groups or ≥ 2 of 20 patients in the PD -1/PD- L1 therapy resistant group 
have tumor responses of CR or PR per RECIST v1.1 or irRC ). In Group 2, 20 patients will be 
enrolled at RP2D, and enrolment may be expanded up to approximately 40 patients if at least 3 pts with CR, PR or SD > 4 months per RECIST v1.1 or irRC  are observed. In addition, an 
exploratory group of 20 patients at a lower dose (1 mg/kg MCS110 in combination with PDR001 300 mg) may be opened if the above mentioned gating criterion is met (Group 2b). The decision of whether to expand a certain expansion group will be made at the time when the required number of responses is observed, or the last patient (out of 20 patients) has been on treatment for at least 6 months, whichever occurs earlier.  The Investigators and Novartis  will 
make the decision based on a synthesis of all relevant data available including safety, PK and PD information. 
10.8 Sample size calculation  
Phase Ib  
Cohorts of 3 to 6 evaluable patients will be enrolled in the dose -escalation Phase including at 
least six patients at the MTD/RP2D level, as described in Section 6.2.3. Multiple cohorts may 

Novartis  Confidential  Page 104  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 be sequentially enrolled to the same dose level. Additional cohorts of 3 to 6 patients may be 
enrolled at any dose level below the estimated MTD/RP2D for further elaboration of safety and pharmacokinetic parameters as required. At least 15  patients are expected to be treated in the  
dose escalation Phase for the model to have reasonable operating characteristics relating to its estimation of MTD.  
Phase II  
Approximately 20 patients will initially be enrolled to each of groups 1, 3 and 4. Enrollment may be expanded up to approximately 40 patients in these groups if objective responses (CR or 
PR) per RECIST v1.1 or irRC  are observed (≥ 3 of 20 patients in each of the PD -1/PD- L1 
therapy naïve groups or ≥ 2 of 20 patients in the PD -1/PD- L1 therapy resistant group) 
(Section  2.2).  In Group 2, 20 patients will be enrolled at RP2D, and enrolment may be 
expanded up to approximately 40 patients if at least 3 pts with CR, PR or SD > 4 months per RECIST v1.1 or irRC  are observed. In addition, an exploratory group of 20 patients at a lower 
dose (1 mg/kg MCS110 in combination with PDR001 300 mg) may be opened if the above mentioned gating criterion is met (Group 2b). The operating characteristics of the designs are provided in Table 10 -2 (for Group 1, 3), Table 10 -3 (for Group 4), and Table 10 -4 (for Group 
2 at RP2D), Table 10 -5 (for Group 2b). 
Table 10 -2 Operating characteristics of the design (Group 1, 3)  
True ORR  Probability to observe >=3 
responses in first 20 
patients  Group 1: TNBC  
Group 3: Endometrial cancer  
probability to observe an ORR ≥ 30% with 40 patients  
(Overall success rate)  
15% 59.5%  1.2%  
20% 79.4%  8.7%  
25% 90.9%  28.4%  
30% 96.5%  55.8%  
40% 99.6%  92.8%  
50% 100.0%  99.7%  
Table 10 -3 Operating characteristics of the design (Group 4)  
True ORR  Probability to observe >=2 
responses in first 20 
patients  Groups 4: resistant melanoma  
probability to observe an ORR ≥ 15% with 40 patients  
(Overall success rate)  
7.5%  44.9%  7.1%  
15% 82.4%  54.2%  
20% 93.1%  81.5%  
30% 99.2%  98.6%  
40% 99.9%  99.9%  
50% 100.0%  100%  
Novartis  Confidential  Page 105  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Table 10 -4 Operating characteristics of the design (Group 2 at RP2D)  
True 
CBR  Probability to observe >=3 
responses (CR, PR or SD > 4 
months) in first 20 patients  Group 2: Pancreatic cancer  
probability to observe a CBR ≥ 15% with 40 patients  
7.5%  18.6%  5.5%  
15% 59.5%  46.1%  
20% 79.4%  73.4%  
30% 96.5%  96.1%  
Table 10 -5 Operating characteristics of the design (Group 2b)  
True CBR  Groups 2b: Pancreatic cancer  
probability to observe a CBR ≥ 15% with 20 patients  
7.5%  18.6%  
15% 59.5%  
20% 79.4%  
30% 96.5%  
10.9 Power for analysis of key secondary variables 
Not applicable.  
11 Ethical considerations and administrative procedures  
11.1 Regulatory and ethical compliance 
This clinical study was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC and US Code of Federal Regulations Title 21), and with the ethical principles laid down in the Declaration of Helsinki. 
11.2 Responsibilities of the investigator and IRB/IEC/REB 
The protocol and the proposed informed consent form must be reviewed and approved by a properly constituted Institutional Review Board/Independent Ethics Committee/Research Ethics Board (IRB/IEC/REB) before study start. Prior to study start, the investigator is required to sign a protocol signature page confirming his/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to Novartis monitors, auditors, Novartis Clinical Quality Assura nce representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory authorities as required. 
11.3 Informed consent procedures 
Eligible patients may only be included in the study after providing written (witnessed, where required by law or regulati on), IRB/IEC/REB-approved informed consent 
Informed consent must be obtained before conducting any study- specific procedures (i.e. all of 
the procedures described in the protocol). The process of obtaining informed consent should be 
Novartis  Confidential  Page 106  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 documented in the patient source documents. The date when a subject’s Informed Consent was 
actually obtained will be captured in their CRFs. 
Novartis will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study and complies with the ICH GCP guideline and regulatory requirements. Any changes to this ICF suggested by the investigator must be agreed to by Novartis before submission to the IRB/IEC/REB, and a copy of the approved version must be provided to the Novartis monitor after IRB/IEC/REB approval. 
Women of child bearing potential should be informed that taking the study medication may 
involve unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate  in the study they must adhere to the contraception requirement for the 
duration of the study. If there is any question that the patient will not reliably comply, they should not be entered in the study. 
11.4 Discontinuation of the study 
Novartis reserves the r ight to discontinue this study under the conditions specified in the clinical 
study agreement. Specific conditions for terminating the study are outlined in  
Section 4.4. 
11.5 Publication of study protocol and results 
Novartis is committed to following high ethical standards for reporting study results for its innovative medicine, including the timely communication and publication of clinical trial results, whatever their outcome. Novartis assures that the key design elements of this protocol will be posted on the publicly accessible database, e.g. clinicaltrials.gov , before study start. In 
addition, results of interventional clinical trials in adult patients are posted on novartisclinicaltrials.com, a publicly  accessible database of clinical study results within 1 year 
of study completion  
(i.e., LPLV) and those for interventional clinical trials involving pediatric patients within 6 
months of study completion. 
Novartis follows the ICMJE authorship guidelines (icmje.org) and other specific guidelines of 
the journal or congress to which the publication will be submitted. 
Authors will not receive remuneration for their writing of a publication, either directly from 
Novartis or through the professional medical writing agency. Author(s) may be requested to present poster or oral presentation at scientific congress; however, there will be no honorarium provided for such presentations. 
As part of its commitment to full transparency in publications, Novartis supports th e full 
disclosure of all funding sources for the study and publications, as well as any actual and 
potential conflicts of interest of financial and non -financial nature by all authors, including 
medical writing/editorial support, if applicable.  
For the Novartis Guidelines for the Publication of Results from Novartis -sponsored Research, 
please refer to www.novartis.com. 
Novartis  Confidential  Page 107  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 11.6 Study documentation, record keeping and retention of 
documents 
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements for the protection of confidentiality of subjects. As part of participating in a Novartis -sponsored 
study, each site will permit authorized re presentatives of the sponsor(s) and regulatory agencies 
to examine (and when required by applicable law, to copy) clinical records for the purposes of quality assurance reviews, audits and evaluation of the study safety and progress. 
Source data are all in formation, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x- rays, and subject files and records kept 
at the pharmacy, at the laboratories, and medico -technical departments involved in the clinical 
trial. 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site Principal Investigator. The study case report form (CRF) is the primary data collection instrument for the study. The investigator should ensure the accuracy, completeness , legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported on the CRF, that are derived from source documents, should be consistent with the source documents or the discrepancies should be explained. All data requested on the CRF must be recorded. Any missing data must be explained. Any change or correction to a paper CRF should be dated, initialed, and explained (if necessary) and should not obscure the original entry. For electronic CRFs an audit trail will be maintained by the system. The investigator should retain 
records of the changes and corrections to paper CRFs. 
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by applicable regulations and/or guidelines. The investigator/institution should take measures to prevent accidental or premature destruction of these documents.  
Essential documents (written and electronic) should be retained for a period of not less than fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written permission to dispose of them or, requires their retention for an additional period of time because of applicable laws, regulati ons and/or guidelines. 
11.7 Confidentiality of study documents and patient records 
The investigator must ensure anonymity of the patients; patients must not be identified by names in any documents submitted to Novartis. Signed informed consent forms and patient  enrollment 
log must be kept strictly confidential to enable patient identification at the site.  
Novartis  Confidential  Page 108  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 11.8 Audits and inspections 
Source data/documents must be available to inspections by Novartis or designee or Health 
Authorities.  
11.9 Financial disclosures 
Financial di sclosures should be provided by study personnel who are directly involved in the 
treatment or evaluation of patients at the site - prior to study start. 
12 Protocol adherence  
Investigators ascertain they will apply due diligence to avoid protocol deviations. Under no circumstances should the investigator contact Novartis or its agents, if any, monitoring the study to request approval of a protocol deviation, as no authorized deviations are permitted. If the investigator feels a protocol deviation would improve the conduct of the study this must be considered a protocol amendment, and unless such an amendment is agreed upon by Novartis and approved by the IRB/IEC/REB it cannot be implemented. All significant protocol deviations will be recorded and reported in the CSR. 
12.1 Amendments to the protocol 
Any change or addition to the protocol can only be made in a written protocol amendment that must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. Only amendments that are requi red for patient safety may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety of any patient included in this study, even if this action represents a deviation from the protocol. In such cases, Novartis should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations (e.g. UK requires the notification of urgent safety measures within 3 days) but not later than 10 working days. 
Novartis  Confidential  Page 109  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 13 References (available upon request)  
Aharinejad, S., et al. (2007). "Target validation using RNA interference in solid tumors." 
Methods Mol Biol 361: 227-238. 
Brahmer JR, Lacchetti C, Schnei der BJ et al (2018) Management of Immune- Related Adverse 
Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of 
Clinical Oncology Clinical Practice Guideline. J Clin Oncol; Epub ahead of print. 
Cassier, P:A: et al (2014) Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients 
with locally advanced pigmented villonodular synovitis (PVNS), Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts. Vol 32, No 15_suppl (May 20 Supplement): 10504 
Dai, C., et al.  (2001). "Monocyte chemoattractant protein-1 expression in renal tissue is 
associated with monocyte recruitment and tubulo- interstitial lesions in patients with lupus 
nephritis." Chin Med J (Engl) 114(8): 864-868. DeNardo, D. G., et al. (2011). "Leukocyte complexity predicts breast cancer survival and 
functionally regulates response to chemotherapy." Cancer Discov 1(1): 54-67. 
Diem, S., et al. (2016). "Serum lactate dehydrogenase as an early marker for outcome in 
patients treated with anti- PD-1 therapy in m etastatic melanoma." Br J Cancer 114(3): 256-
261. 
Emens LA, Braiteh FS, Cassier P et al. (2015) Inhibition of PD-L1 by MPDL3280A leads to 
clinical activity in patients with metastatic triple -negative breast cancer (TNBC) Cancer Res 
August 1, 75; 2859 
Eyles , J. L., et al. (2006). "Granulocyte colony-stimulating factor and neutrophils --forgotten 
mediators of inflammatory disease " Nat Clin Pract Rheumatol, 2, 500-10. 
Freeman, G. J. (2008). "Structures of PD-1 with its ligands: sideways and dancing cheek to 
cheek." Proc Natl Acad Sci U S A 105(30): 10275-10276. 
Gabrilovich, D. I. and S. Nagaraj (2009). "Myeloid-derived suppressor cells as regulators of 
the immune system." Nat Rev Immunol 9(3): 162-174. 
Gettinger, S. N., et al. (2015). "Overall Survival and Long-Term Safety of Nivolumab (Anti-
Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously 
Treated Advanced Non- Small-Cell Lung Cancer." J Clin Oncol. 
Gomez- Roca, CA et al. (2015). Phase I study of RG7155, a novel anti-CSF1R antibody, in 
patients with advanced/metastatic solid tumors. J Clin Oncol 33, 2015 (suppl; abstr 3005) 
Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from 
Immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol; 28:iv119–iv142. 
Hamid O and Carvejal RD (2013a) Anti- programmed death -1 and anti- programmed death -
ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther; 13:847-61. 
Novartis  Confidential  Page 110  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Hamid O, Robert C, Daud A, et al (2013b) Safety and tumor responses with lambrolizumab 
(anti-PD-1) in melanoma. N Engl J Med; 369:134–44. 
Jiang, X. (2015). Macrophage- produced IL -10 limits the chemotherapy efficacy in breast 
cancer. J Zhejiang Univ Sci B, 16, 44-5.Keir, M. E., et al. (2008). "PD-1 and its ligands in tolerance and immunity." Annu Rev Immunol 26: 677-704. 
Keir, ME, Butte, MJ, Freeman, GJ, et al (2008) PD-1 and its ligands in tolerance and 
immunity. Ann Rev Immunol: 26:677–704. 
Kelderman, S., et al. (2014). "Acquired and intrinsic resistance in cancer immunotherapy." 
Mol Oncol 8(6): 1132-1139. 
Krishnamurthy S, Korenblat K and Scott M (2009) Persistent Increase in Aspartate 
Aminotransferase in an Asymptomatic Patient. Clinical Chemistry 55(8)1573–1577 
Kuang, D. M., et al. (2009). "Activated monocytes in pe ritumoral stroma of hepatocellular 
carcinoma foster immune privilege and disease progression through PD-L1." J Exp Med 
206(6): 1327-1337. 
Kubler, K., et al. (2014). Prognostic significance of tumor- associated macrophages in 
endometrial adenocarcinoma. Gynecol Oncol, 135, 176-83. Li, J., et al (2006). Conditional deletion of the colony stimulating factor- 1 receptor (c -fms 
proto-oncogene) in mice. Genesis, 44, 328-35. Mangsbo SM, Sandin LC, Anger K, et al (2010) Enhanced tumor eradication by combining 
CTLA -4 or PD-1 blockade with CpG therapy. J Immunother; 33:225–35. 
Mielgo, A. and Schmid, MC. (2013). Impact of tumour associated macrophages in pancreatic 
cancer. BMB Rep, 46, 131-8. 
Mkrtichyan M, Najjar YG, Raulfs EC, et al (2011) Anti- PD-1 synergizes with 
cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. 
Eur J Immunol; 41:2977–86. 
Murphy K (2011) Janeway’s Immunobiology. 8th ed; New York: Garland Science. Nanda R, Chow L, Dees E, et al (2014) A phase Ib study of pembrolizumab (MK-3475) in 
patients with advanced triple-negative breast cancer. San Antonio Breast Cancer Symposium: 
Abstract S1 -09. 
Nanda, R., et al. (2016). "Pembrolizumab in Patients With Advanced Triple- Negative Breast 
Cancer: Phase Ib KEYNOTE -012 Study." J Clin Oncol. 
Neuenschwander B, et al. (2010) Summarizing Historical Information on Controls in Clinical Trials. Clinical Trials; 7:5 -18. 
Neuenschwander B, et al. (2014). A Bayesian Industry Approach to Phase I Combination 
Trials in Oncology. In Statistical Methods in Drug Combination Studies. Zhao W and Yang H 
(eds), Chapman & Hall/CRC, 2014. 
Novartis  Confidential  Page 111  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Priceman, S. J., et al. (2010). "Targeting distinct tumor- infiltrating myeloid cells by inhibiting 
CSF-1 receptor: combating tumor evasion of antiangiogenic therapy." Blood 115(7): 1461-
1471. 
Pyonteck, S. M., et al. (2013). "CSF-1R inhibition alters macrophage polarization and blocks 
glioma progression." Nat Med 19(10): 1264-1272. 
Radi, Z. A., et al. (2011). "Increased serum enzyme levels associated with kupf fer cell 
reduction with no signs of hepatic or skeletal muscle injury". Am J Pathol, 179, 240-7. Ries C, Cannarile M, Hoves S, et al. (2014) Targeting tumor- associated macrophages with 
anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25(6):846-59 
Riley, J. L. (2009). "PD-1 signaling in primary T cells." Immunol Rev 229(1): 114-125. Rizvi, N. A., et al. (2015). "Activity and safety of nivolumab, an anti- PD-1 immune 
checkpoint inhibitor, for patients with advanced, refractory squamous non- small-cell lung 
cancer (CheckMate 063): a phase 2, single-arm trial." Lancet Oncol 16(3): 257-265. Robert C, Ribas A, Wolchok JD, et al (2014) Anti-programmed- death -receptor- 1 treatment 
with pembrolizumab in ipilimumab -refractory advanced melanoma: a randomised dose-
comparison cohort of a phase 1 trial. Lancet; 384:1109-17. Rogatko A, Schoeneck D, Jonas W, et al (2007) Translation of innovative designs into phase I 
trials. J Clin Oncol; 25:4982-6. 
Rosenblatt, J, Glotzbecker B, Mills H, et al (2011) PD-1 blockade by CT-011, anti- PD-1 
antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion 
vaccine. J Immunother; 34:409–18. 
Ruffell B, Chang-Strachan, Chan V, et al. (2014) Macrophage IL-10 Blocks CD8+ T Cell-
Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral 
Dendritic Cells. Cancer Cell 26, 623–637 
Ruffell, B. and. Coussens L. M (2015). "Macrophages and therapeutic resistance in cancer." 
Cancer Cell 27(4): 462-472. 
Rugo HS, Sharma N , Reebel L, et  al. (2014) Phase Ib study of PLX3397, a CSF1R inhibitor, 
and paclitaxel in patients with advanced solid tumors. Annals of Oncology 25 (suppl_4): 
iv146-iv164. 10.1093/annonc/mdu331 
Segal NH, Antonia SJ, Brahmer JR, et al (2014) Preliminary data from a multi-arm expansion 
study of MEDI4736, an anti- PD-L1 antibody. J Clin Oncol (Meeting Abstracts); 
32(15s):3002. 
Sica, A., Schioppa, T., Mantovani, A. & Allavena, P. 2006. Tumour- associated macrophages 
are a distinct M2 polarised population promoting tumour progression: potential targets of anti-
cancer therapy. Eur J Cancer, 42, 717-27. 
Spiegelhalter DJ, et al. (2004) Bayesian Approaches to Clinical Trials and Health -Care 
Evaluation. John Wiley & Sons, New York. 
Novartis  Confidential  Page 112  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Tarhini, Aa. et al (2012). Differing patterns of circulating regulatory T cells and myeloid-
derived suppressor cells in metastatic melanoma patients receiving anti -CTLA4 antibody and 
interferon -alpha or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother, 35, 
702-10. 
Topalian SL, Hodi SF, Brahmer JR, et al (2012) Safety, Activity, and Immune Correlates of 
Anti–PD-1 Antibody in Cancer. N Engl J Med; 366: 2443-54. 
Topalian, S. L., et al. (2014). "Survival, durable tumor remission, and long- term safety in 
patients with advanced melanoma receiving nivolumab." J Clin Oncol 32(10): 1020-1030. 
Wainberg, Z. et al (2017). First- in-human phase 1 dose escalation and expansion of a novel 
combination, anti–CSF -1 receptor (Cabiralizumab) plus anti –PD-1 (Nivolumab), in patients 
with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 5(Suppl 3):89 Wang W, Lau R, Yu D, et al (2009) PD-1 blockade reverses the suppression of melanoma 
antigen -specific CTL by CD4+ CD25(Hi) regulatory T cells. Int. Immunol. 21, 1065–77. 
Weber, J. S., et al. (2015). "Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti- CTLA -4 treatment (CheckMate 037): a randomised, 
controlled, open-label, phase 3 trial." Lancet Oncol 16(4): 375-384. 
Wolchok JD, Hoos A, O'Day S et al (2009) Guidelines for the Evaluation of Immune Therapy 
Activity in Solid Tumors: Immune -Related Response Criteria. Clin Cancer Res; 15:7412 -20. 
Wolchok, Jd., et al. (2013). Four- year survival rates for patients with metastatic melanoma 
who received ipilimumab in phase II clinical trials. Ann Oncol, 24, 2174-80. 
Yuan ZY, et al. (2014) High infiltration of tumor- associated macrophages in triple- negative 
breast cancer is associated with a higher risk of distant metastasis. OncoTargets and Therapy 
7:1475–1480 
Zhou, W., et al. (2014). "LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when 
LKB1 Is Inactivated." Genes Dis 1(1): 64-74. 
Zhu, Y., et al. (2014). "CSF1/CSF1R blockade reprograms tumor- infiltrating macrophages 
and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models." 
Cancer Res 74(18): 5057-5069. 
Novartis  Confidential  Page 113  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 14 Appendices  
14.1 Appendix 1: Guidelines for Response, Duration of Overall 
Response, TTF, TTP, Progression-Free Survival and Overall 
Survival (based on RECIST 1.1) 
Harmoniz ation of Efficacy Analysis of Solid Tumor Studies  
Document type:  TA Specific Guideline  
Document status:  Version 3.1:  29-Nov-2011  
Version 3:0:  19-Oct-2009  
Version 2:0:  18-Jan-2007  
Version 1:0:  13-Dec-2002  
Release date:  29-Nov-2011  
List of Contributors  
Authors (Version 3.1):   
 
Authors (Version 3):   
Authors (Version 2):   
Authors (Version 1):   

Novartis  Confidential  Page 114  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Glossary  
CR Complete response  
CRF Case Report Form  
CSR  Clinical Study Report  
CT Computed tomography  
DFS Disease -free survival  
eCRF  Electronic Case Report Form  
FPFV  First patient first visit  
LPLV  Last patient last visit  
MRI Magnetic resonance imaging  
OS Overall survival  
PD Progressive disease  
PFS Progression -free survival  
PR Partial response  
RAP Reporting and Analysis Plan  
RECIST  Response Evaluation Criteria in Solid Tumors  
SD Stable disease  
SOD  Sum of Diameter  
TTF Time to treatment failure  
TTP Time to progression  
UNK  Unknown  
14.1.1  Introduction 
The purpose of this document is to provide the working definitions and rules necessary for a 
consistent and efficient analysis of efficacy for oncology studies in solid tumors. This document is based on the RECIST cri teria for tumor responses ( Therasse et al 2000 ) and the revised 
RECIST 1.1 guidelines ( Eisenhauer et al 2009).  
The efficacy assessments described in Section 14.1.2 and the definition of best response in 
Section 14.1.3.1 are based on the RECIST 1.1 criteria but  also give more detailed instructions 
and rules for determination of best response. Section 14.1.3.2 is summarizing the “time to 
event” variables and rules which are mainly derived from internal discussions  and regulatory 
consultations, as the RECIST criteria do not define these variables in detail. Section 14.1.4 of this guideline describes data handling and programming rules. This section is to be  referred to 
in the RAP (Reporting and Analysis Plan) to provide further details needed for programming. 
14.1.2  Efficacy assessments 
Tumor evaluations are made based on RECIST criteria ( Therasse et al 2000 ), New Guidelines 
to Evaluate the Response to Treatment in Solid Tumors, Journal of National Cancer Institute, 
Vol. 92; 205- 16 and revised RECIST guidelines (version 1.1) ( Eisenhauer et al 2009 ) European 
Journal of Cancer; 45:228-247. 
Novartis  Confidential  Page 115  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 14.1.2.1  Definitions  
14.1.2.1.1  Disease measurability  
In order to evaluate tumors throughout a study, definitions of measurability are required in order 
to classify lesions appropriately at baseline. In defining measurability, a distinction also needs to be made between nodal lesions (pathological lymph nodes) and non-nodal lesions. 
• Measurable disease - the presence of at least one measurable nodal or non -nodal lesion. 
If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be 
confirmed by cytology/histology. 
For patients without measurable disease see Section 14.1.3.2.8 
Measurable lesions  (both nodal and non-nodal) 
• Measurable non -nodal - As a rule of thumb, the minimum size of a measurable non-nodal 
target lesion at baseline should be no less than double the slice thickness or 10mm 
whichever is greater - e.g. the minimum non- nodal lesion size for CT/MRI with 5mm cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16 mm.  
• Lytic bone lesions or mixed lytic- blastic lesions with identifiable soft tis sue components, 
that can be evaluated by CT/MRI, can be considered as measurable lesions, if the soft tissue component meets the definition of measurability.  
• Measurable nodal lesions (i.e. lymph nodes) - Lymph nodes ≥ 15 mm in short axis can be 
considered for selection as target lesions. Lymph nodes measuring ≥ 10 mm and <15 mm 
are considered non -measurable. Lymph nodes smaller than 10 mm in short axis at 
baseline, regardless of the slice thickness, are normal and not considered indicative of disease.  
• Cystic lesions : 
• Lesions that meet the criteria for radiographically defined simple cysts (i.e., spherical structure with a thin, non-irregular, non-nodular and non-enhancing wall, no septations, and low CT density [water-like] content) should not be considered as malignant lesions (neither measurable nor non- measurable) since they are, by 
definition, simple cysts.  
• ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of measurability described above. However, if noncystic lesions are present in the same patient, these are preferred for selection as target lesions.  
• Non-measurable lesions - all other lesions are considered non-measurable, including small 
lesions (e.g. longest diameter <10 mm with CT/MRI or pathological lymph nodes with ≥  
10 to < 15 mm short axis), as well as truly non-measurable lesions e.g., blastic bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory breast disease, lymphangitis cutis/pulmonis, abdominal masses/abdominal organomegaly identified by physical exam that is not measurable by reproducible imaging techniques. 
Novartis  Confidential  Page 116  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 14.1.2.1.2  Eligibility based on measurable disease  
If no measurable lesions are identified at baseline, the patient may be allowed to enter the study 
in some situations (e.g. in Phase III studies where PFS is the primary endpoint). However, it is recommended that patients be excluded from trials where the main focus is on the Overall Response Rate (ORR). Guidance on how patients with just non- measurable disease at baseline 
will be evaluated for response and also handled in the statistical analyses is given in Section  14.1.3.2.8. 
14.1.2.2  Methods of tumor measurement - general guidelines  
In this document, the term “contrast” refers to intravenous (i.v.) contrast. 
The following considerations are to be made when evaluating the tumor: 
• All measurements should be taken and recorded in metric notation (mm), using a ruler or 
calipers. All baseline evalu ations should be performed as closely as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the treatment.  
• Imaging-based evaluation is preferred to evaluation by clinical examination when both methods have been used to assess the antitumor effect of a treatment.  
• For optimal evaluation of patients, the same methods of assessment and technique should be used to characterize each identified and reported lesion at baseline and during follow-up. Contrast-enhanced CT of chest, abdomen and pelvis should preferably be performed using a 5 mm slice thickness with a contiguous reconstruction algorithm. CT/MRI scan slice thickness should not exceed 8 mm cuts using a contiguous reconstruction algorithm. If, at baseline, a patient i s known to have a medical contraindication to CT contrast or 
develops a contraindication during the trial, the following change in imaging modality will be accepted for follow -up: a non-contrast CT of chest (MRI not recommended due to 
respiratory artifacts ) plus contrast-enhanced MRI of abdomen and pelvis. 
• A change in methodology can be defined as either a change in contrast use (e.g. keeping the same technique, like CT, but switching from with to without contrast use or vice- versa, 
regardless of the justification for the change) or a change in technique (e.g. from CT to MRI, or vice-versa), or a change in any other imaging modality. A change in methodology will result by default in a UNK overall lesion response assessment . However, another 
response assessme nt than the Novartis calculated UNK response may be accepted from 
the investigator or the central blinded reviewer if a definitive response assessment can be justified, based on the available information. 
• FDG -PET : can complement CT scans in assessing progression (particularly possible for 
‘new’ disease). New lesions on the basis of FDG-PET imaging can be identified according to the following algorithm: 
• Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD 
based on a new lesion. 
• No FDG -PET at baseline with a positive FDG -PET at follow -up: 
• If the positive FDG- PET at follow -up corresponds to a new site of disease confirmed by 
CT, this is PD.  
Novartis  Confidential  Page 117  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 • If the positive FDG- PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow-up CT are needed to determine if there is truly progression occurring at 
that Site (if so, the date of PD will be the date of the initial abnormal CT scan).  
• If the positive FDG- PET at follow -up corresponds to a pre-existing site of disease on C T 
that is not progressing on the basis of the anatomic images, this is not PD. 
• Chest x -ray: Lesions on chest x- ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by aerated lung. However, CT is preferable. 
• Ultrasound : When the primary endpoint of the study is objective response evaluation, 
ultrasound (US) should not be used to measure tumor lesions. It is, however, a possible alternative to clinical measurements of superficial palpable lymph nodes, subcutaneous lesions and thyroid nodules. US might also be useful to confirm the complete disappearance of superficial lesions usually assessed by clinical examination.  
• Endoscopy and laparoscopy: The utilization of endoscopy and laparoscopy for objective tumor evaluation has not yet been fully and widely validated. Their uses in this specific context require sophisticated equipment and a high level of expertise that may only be available in some centers. Therefore, the utilization of such techniques for objective tumor response should be restricted to validation purposes in specialized centers. However, such techniques can be useful in confirming complete pathological response when biopsies are obtained. 
• Tumor markers : Tumor markers alone cannot be used to assess response. However, 
some disease specific and more validated tumor markers (e.g. CA -125 for ovarian cancer, 
PSA for prostate cancer, alpha-FP, LDH and Beta- hCG for testicular cancer) can be 
integrated as non- target disease. If markers are initially above the upper normal lim it they 
must normalize for a patient to be considered in complete clinical response when all lesions have disappeared. 
• Cytology and histology: Cytology and histology can be used to differentiate between PR and CR in rare cases (i.e., after treatment to dif ferentiate between residual benign lesions 
and residual malignant lesions in tumor types such as germ cell tumors). Cytologic confirmation of neoplastic nature of any effusion that appears or worsens during treatment is required when the measurable tumor has met the criteria for response or stable disease. Under such circumstances, the cytologic examination of the fluid collected will permit differentiation between response and stable disease (an effusion may be a side effect of the treatment) or progressiv e disease (if the neoplastic origin of the fluid is confirmed). 
• Clinical examination : Clinical lesions will only be considered measurable when they are 
superficial (i.e., skin nodules and palpable lymph nodes). For the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is recommended.  
14.1.2.3  Baseline documentation of target and non -target lesions  
For the evaluation of lesions at baseline and throughout the study, the lesions are classified at baseline as  either target or non- target lesions:  
• Target lesions : All measurable lesions (nodal and non-nodal) up to a maximum of five 
lesions in total (and a maximum of two lesions per organ), representative of all involved 
Novartis  Confidential  Page 118  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 organs should be identified as target lesions and recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). Each target le sion must be uniquely and sequentially numbered on the CRF 
(even if it resides in the same organ).  
Minimum target lesion size at baseline  
• Non-nodal target : Non -nodal target lesions identified by methods for which slice 
thickness is not applicable (e.g. clinical examination, photography) should be at least 10 mm in longest diameter. See Section 14.1.2.1.1. 
• Nodal target : See Section 14.1.2.1.1. 
A sum of diameters (long axis for non- nodal lesions, short axis for nodal) for all target lesions 
will be calculated and reported as the baseline sum of diameters (SOD). The baseline sum of diameters will be used as reference by which to characterize the objective tumor response. Each target lesion identified at baseline must be followed at each subsequent evaluation and documented on eCRF. 
• Non-target lesions : All other lesions are considered non-target lesions, i.e. lesions not 
fulfilling the criteria for target lesions at baseline. Presence or absence or worsening of 
non-target lesions should be assessed throughout the study; measurements of these lesions are not required. Multiple non- target  lesions involved in the same organ can be assessed as 
a group and recorded as a single item (i.e. multiple liver metastases). Each non- target 
lesion identified at baseline must be followed at each subsequent evaluation and documented on eCRF. 
14.1.2.4  Follow -up evaluation of target and non- target lesions  
To assess tumor response, the sum of diameters for all target lesions will be calculated (at baseline and throughout the study). At each assessment response is evaluated first separately for the target (Table 14 -1) and non- target lesions ( Table 14 -2) identified at baseline. These 
evaluations are then used to calculate the overall lesion response considering both the target and 
non-target lesions together ( Table 14 -3) as well as the presence or absence of new lesions.  
14.1.2.4.1  Follow- up and recording of lesions  
At each visit and for each lesion the actual date of the scan or procedure which was used for the evaluation of each specific lesion should be recorded. This applies to target and non- target 
lesions as well as new lesions that are detected. At the assessment visit all of the separate lesion evaluation data are examined by the investigator in order to derive the overall visit response. Therefore all such data applicable to a particular visit should be associated with the same assessment number.  
Non-nodal lesions  
Following treatment, lesions may have longest diamet er measurements smaller than the image 
reconstruction interval. Lesions smaller than twice the reconstruction interval are subject to substantial “partial volume” effects (i.e., size may be underestimated because of the distance of 
Novartis  Confidential  Page 119  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 the cut from the longest  diameter; such lesions may appear to have responded or progressed on 
subsequent examinations, when, in fact, they remain the same size). 
If the lesion has completely disappeared, the lesion size should be reported as 0 mm. Measurements of non- nodal target  lesions that become 5 mm or less in longest diameter are 
likely to be non- reproducible. Therefore, it is recommended to report a default value of 5 mm, 
instead of the actual measurement. This default value is derived from the 5 mm CT slice 
thickness (but should not be changed with varying CT slice thickness). Actual measurement should be given for all lesions larger than 5 mm in longest diameter irrespective of slice thickness/reconstruction interval. 
In other cases where the lesion cannot be reliably meas ured for reasons other than its size (e.g., 
borders of the lesion are confounded by neighboring anatomical structures), no measurement 
should be entered and the lesion cannot be evaluated. 
Nodal lesions  
A nodal lesion less than 10 mm in size by short axis is considered normal. Lymph nodes are not 
expected to disappear completely, so a “non -zero size” will always persist.  
Measurements of nodal target lesions that become 5 mm or less in short axis are likely to be non-reproducible. Therefore, it is recommended to report a default value of 5 mm, instead of 
the actual measurement. This default value is derived from the 5 mm CT slice thickness (but should not be changed with varying CT slice thickness).Actual measurement should be given for all lesions larger tha n 5 mm in short axis irrespective of slice thickness/reconstruction 
interval.  
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be considered normal for response purpose determination. The lymph node measurements wil l 
continue to be recorded to allow the values to be included in the sum of diameters for target lesions, which may be required subsequently for response determination. 
14.1.2.4.2  Determination of target lesion response  
Table 14 -1 Response criteria for target lesions  
Response Criteria  Evaluation of target lesions  
Complete Response (CR):  Disappearance of all non -nodal target lesions. In addition, any pathological lymph 
nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1 
Partial Response (PR):  At least a 30% decrease in the sum of diameter of all target lesions, taking as 
reference the baseline sum of diameters.  
Progressive Disease (PD):  At least a 20% increase in the sum of diameter of all measured target lesions, 
taking as reference the smallest sum of diameter of all target lesions recorded at 
or afte r baseline. In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm2. 
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions 
which would qualify for PD.  
Unknown (UNK)  Progression has not been documented and one or more target lesions have not 
been assessed or have been assessed using a different method than baseline.3 
Novartis  Confidential  Page 120  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 1. SOD for CR may not be zero when nodal lesions are part of target lesions  
2. Following an initial CR, a PD cannot be assigned if all non- nodal target lesions are still not present and all nodal 
lesions are <10 mm in size. In this case, the target lesion response is CR  
3. Methodology change See Section 14.1.2.2  
Notes on target lesion response  
Reappearance of lesions : If the lesion appears at the same anatomical location where a target 
lesion had previously disappeared, it is advised that the time point of lesion disappearance (i.e., 
the “0 mm” recording) be re -evaluated to make sure that the lesion was not actually present 
and/or not visualized for technical reasons in this previous assessment. If it is not possible to change the 0 value, then the investigator/radiologist has to decide between the following three possibilities:  
• The lesion is a new lesion, in which case the overall tumor assessment will be considered as progressive disease 
• The lesion is clearly a reappearance of a previously disappeared lesion, in w hich case the 
size of the lesion has to be entered in the CRF and the tumor assessment will remain based on the sum of tumor measurements as presented in Table 14 -1 above (i.e., a PD will be 
determined if there is at least 20% increase in the sum of diameters of all  measured target 
lesions, taking as reference the smallest sum of diameters of all target lesions recorded at or after baseline with at least 5 mm increase in the absolute sum of the diameters ). Proper 
documentation should be available to support this decision. This applies to patients who have not achieved target response of CR. For patients who have achieved CR, please refer to last bullet in this section.  
• For those patients who have only one target lesion at baseline, the reappearance of the target lesion which disappeared previously, even if still small, is considered a PD. 
• Missing measurements : In cases where measurements are missing for one or more target 
lesions it is sometimes still possible to assign PD based on the measurements of the remaining lesions. For example, if the sum of diameters for 5 target lesions at baseline is 100 mm at baseline and the sum of diameters for 3 of those lesions at a post- baseline visit 
is 140 mm (with d ata for 2 other lesions missing) then a PD should be assigned. However, 
in other cases where a PD cannot definitely be attributed, the target lesion response would be UNK.  
• Nodal lesion decrease to normal size: When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” size they should still have a 
measurement recorded on scans. This measurement should be reported even when the nodes are normal in order not to overstate progression should it be based on increase in the size of nodes. 
• Lesions split : In some circumstances, disease that is measurable as a target lesion at 
baseline and appears to be one mass can split to become two or more smaller sub-lesions. When this occurs, the diameters (long axis - non-nodal lesion, short axis - nodal lesions) of the two split lesions should be added together and the sum recorded in the diameter field on the case report form under the original lesion number. This value will be included in the sum of diameters when deriving target lesion response. The individual split lesions will not be considered as new lesions, and will not automatically trigger a PD designation. 
Novartis  Confidential  Page 121  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 • Lesions coalesced : Conversely, it is also possible that two or more lesions which were 
distinctly separate at baseline become confluent at subsequent visits. When this occurs a 
plane between the original lesions may be maintained that would aid in obtaining diameter measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the maximal diameters (long axis - non-nodal lesion, short axis - nodal lesions) of the “merged lesion” should be used when calculating the sum of diameters for target lesions. On the case report form, the diameter of the “merged lesion” should be recorded for the size of one of the original lesions while a size of “0”mm should be entered for the remaining lesion numbers which have coalesced.  
• The measurements for nodal lesions , even if less than 10 mm in size, will contribute to 
the calculation of target le sion response in the usual way with slight modifications. 
• Since lesions less than 10 mm are considered normal, a CR for target lesion response should be assigned when all nodal target lesions shrink to less than 10 mm and all non-nodal target lesions have disappeared.  
• Once a CR target lesion response has been assigned a CR will continue to be appropriate (in the absence of missing data) until progression of target lesions. 
• Following a CR, a PD can subsequently only be assigned for target lesion response if either a non -nodal target lesion “reappears” or if any single nodal lesion is at least 10 mm 
and there is at least 20% increase in sum of the diameters of all nodal target lesions relative to nadir with at least 5 mm increase in the absolute sum of the dia meters.  
14.1.2.4.3  Determination of non- target lesion response  
Table 14 -2 Response criteria for non- target lesions  
Response Criteria  Evaluation of non -target lesions  
Complete Response (CR):  Disappearance of all non -target lesions. In addition, all lymph nodes assigned a 
non-target lesions must be non -pathological in size (< 10 mm short axis)  
Progressive Disease (PD):  Unequivocal progression of existing non -target lesions.1 
Non-CR/Non -PD: Neither CR nor PD  
Unknown (UNK)  Progression has not been documented and one or more non -target lesions have 
not been assessed or have been assessed using a different method than baseline.  
1. Although a clear progression of non -target lesions only is exceptional, in such circumstances, the opinion of the 
treating physician does prevail and the progression status should be confirmed later on by the review panel (or 
study chair).  
Notes on non- target lesion response  
• The response for non- target lesions is CR only if all non-target non-nodal lesions which 
were evaluated at baseline are now all absent and with all non -target nodal lesions 
returned to normal size (i.e. < 10 mm). If any of the non- target lesions are still present, or 
there are any abnormal nodal lesions (i.e. ≥  10 mm) the response can only be ‘ Non-
CR/Non -PD’ unless any of the lesions was not assessed (in which case response is UNK ) 
or there is unequivocal progression of the non- target lesions (in which case  response is 
PD). 
• Unequivocal progression : To achieve “unequivocal progression” on the basis of non-
target disease there must be an overall level of substantial worsening in non- target disease 
Novartis  Confidential  Page 122  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 such that, even in presence of CR, PR or SD in target disease, the overall tumor burden 
has increased sufficiently to merit discontinuation of therapy. A modest “increase” in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression status. The designation of overall progression solely on the basis of change in non-target disease in the face of CR, PR or SD of target disease is therefore expected to be 
rare. In order for a PD to be assigned on the basis of non- target lesions, the increase in the 
extent of the disease must be substantial even in cases where there is no measurable disease at baseline. If there is unequivocal progression of non- target lesion(s), then at least 
one of the non-target lesions must be assigned a status of “Worsened”. Where possible, similar rule s to those described in Section 14.1.2.4.2 for assigning PD following a CR for 
the non- target lesion response in the presence of non -target lesions nodal lesions should be 
applied. 
14.1.2.4.4  New lesions  
The appearance of a new lesion is always associated with Progressive Disease (PD) and has to be recorded as a new lesion in the New Lesion CRF page.  
• If a new lesion is equivocal , for example because of its small size, continued therapy and 
follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new lesion, then progression should be declared using the date of the first observation of the lesion 
• If new disease is observed in a region which was not scanned at baseline  or where the 
particular baseline scan is not available for some reason, then this should be considered as a PD. The one exception to this is when there are no baseline scans at all available for a patient in which case the response should be UNK, as for any of this patient's assessment (see Section 14.1.2.5).  
• A lymph node is considered as a “new lesion”  and, therefore, indicative of progressive 
disease if the short axis increases in size to ≥  10 mm for the first time in the study plus 5 
mm absolute increase.  
FDG -PET : can complement CT scans in assessing progression (particularly possible for 
‘new’ disease). See Section 14.1.2.2. 
14.1.2.5  Evaluation of overall lesion response  
The evaluation of overall lesion response at each assessment is a composite of the target lesion response, non- target lesion response and presence of new lesions as shown below in  
Table 14 -3. 
Table 14 -3 Overall lesion response at each assessment  
Target lesions  Non-target lesions  New Lesions  Overall  
lesion response  
CR CR No CR1 
CR Non-CR/Non -PD3 No PR 
CR, PR, SD  UNK  No UNK  
PR Non-PD and not UNK  No PR1 
SD Non-PD and not UNK  No SD1, 2 
UNK  Non-PD or UNK  No UNK1 
Novartis  Confidential  Page 123  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
1. This overall lesion response also applies when there are no non-target lesions identified at baseline.  
2. Once confirmed PR was achieved, all these assessments are considered PR.  
3. As defined in Section 14.1.2.4  
If there are no baseline scans available at all, then the overall lesion response at each assessment 
should be considered Unknown (UNK). 
If the evaluation of any of the target or non -target lesions identified at baseline could not be 
made during follow-up, the overall status must be ‘unknown’ unless progression was seen. In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended that the residual lesion be investigated (fine needle aspirate/biopsy) to confirm the CR. 
14.1.3  Efficacy definitions  
The following definitions primarily relate to patients who have measurable disease at baseline. 
Section 14.1.3.2.8 outlines the special co nsiderations that need to be given to patients with no 
measurable disease at baseline in order to apply the same concepts.  
14.1.3.1  Best overall response 
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.  
The best overall res ponse will usually be determined from response assessments undertaken 
while on treatment. However, if any assessments occur after treatment withdrawal the protocol should specifically describe if these will be included in the determination of best overall response and/or whether these additional assessments will be required for sensitivity or supportive analyses. As a default, any assessments taken more than 30 days after the last dose of study treatment will not be included in the best overall response der ivation. If any alternative 
cancer therapy is taken while on study any subsequent assessments would ordinarily be excluded from the best overall response determination. If response assessments taken after withdrawal from study treatment and/or alternative therapy are to be included in the main endpoint determination, then this should be described and justified in the protocol. 
Where a study requires confirmation of response (PR or CR), changes in tumor measurements 
must be confirmed by repeat assessments th at should be performed not less than 4 weeks after 
the criteria for response are first met.  
Longer intervals may also be appropriate. However, this must be clearly stated in the protocol. The main goal of confirmation of objective response is to avoid overestimating the response rate observed. In cases where confirmation of response is not feasible, it should be made clear when reporting the outcome of such studies that the responses are not confirmed. 
• For non- randomized trials where response is the primary  endpoint, confirmation is needed. 
Novartis  Confidential  Page 124  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 • For trials intended to support accelerated approval, confirmation is needed 
• For all other trials, confirmation of response may be considered optional. 
The best overall response for each patient is determined from the sequence of overall (lesion) 
responses according to the following rules: 
• CR = at least two determinations of CR at least 4 weeks apart before progression where 
confirmation required or one determination of CR prior to progression where confirmation not required  
• PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) where confirmation required or one determination of PR prior to progression where confirmation not required 
• SD = at least one SD assessment (or better) > 6 weeks after randomization/start of treatment (and not qualifying for CR or PR). 
• PD = progression ≤  12 weeks after randomization/ start of treatment (and not qualifying 
for CR, PR or SD).  
• UNK = all other cases (i.e. not qualifying for confirmed CR or PR and without SD after more than 6 weeks or early progression within the first 12 weeks) 
Overall lesion responses of CR must stay the same until progression sets in, with the exception of a UNK status. A patient who had a CR cannot subsequently have a lower status other than a PD, e.g. PR or SD, as this would imply a progression based on one or more lesions reappearing, in which case the status would become a PD.  
Once an overall lesion response of PR is observed (which may have to be a confirmed PR depending on the study) this assignment must stay the same or improve over time until progression sets in, with the exception of an UNK status. However, in studies where 
confirmation of response is required, if a patient has a single PR ( ≥30% reduction of tumor 
burden compared to baseline) at one assessment, followed by a <30% reduction from baseline 
at the next assessment (but not ≥ 20% increase from previous smallest sum), the objective status 
at that assessment should be SD. Once a confirmed PR was seen, the overall lesion response 
should be considered PR (or UNK) until progression is documented or the lesions totally disappear in which case a CR assignment is applicable. In studies where confirmation of response is not required after a single PR the overall lesion response should still be considered PR (or UNK) until progression is documented or the lesion totally disappears in which case a CR assignment is applicable.  
Example: In a case where confirmation of response is required the sum of lesion diameters is 200 mm at baseline and then 140 mm - 150 mm - 140 mm - 160 mm - 160 mm at the subsequent 
visits. Assuming that non -target lesions did not progress, the overall lesion response would be 
PR - SD - PR - PR - PR. The second assessment with 140 mm confirms the PR for this patient. 
All subsequent assessments are considered PR even if tumor measurements decrease only by 20% compared to baseline (200 mm to 160 mm) at the following assessments. 
If the patient progressed but continues study treatment, further assessments are not considered 
for the determination of best overall response. 
Novartis  Confidential  Page 125  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Note: these cases may be described as a separate finding in the CSR but not included in the 
overall response or disease control rates. 
The best overall response for  a patient is always calculated, based on the sequence of overall 
lesion responses. However, the overall lesion response at a given assessment may be provided 
from different sources:  
• Investigator overall lesion response 
• Central Blinded Review overall lesio n response 
• Novartis calculated overall lesion response (based on measurements from either Investigator or Central Review)  
The primary analysis of the best overall response will be based on the sequence of investigator overall lesion responses. 
Based on the  patients’ best overall response during the study, the following rates are then 
calculated:  
Overall response rate (ORR)  is the proportion of patients with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in some pr otocols or publications. 
Disease control rate  (DCR)  is the proportion of patients with a best overall response of CR or 
PR or SD.  
Another approach is to summarize the progression rate at a certain time point after baseline. In 
this case, the following definition is used: 
Early progression rate (EPR)  is the proportion of patients with progressive disease within 
8 weeks of the start of treatment.  
The protocol should define populations for which these will be calculated. The timepoint for 
EPR is study specific. EPR is used for the multinomial designs of Dent and Zee (2001)  and 
counts all patients who at the specified assessment (in this example the assessment would be at 8 weeks ± window) do not have an overall lesion response of SD, PR or CR. Patients with an unknown (UNK) assessment at that time point and no PD before, will not be counted as early progressors in the analysis but may be included in the denominator of the EPR rate, depending on the analysis population used. Similarly when examining overall response and disease control, patients with a best overall response assessment of unknown (UNK) will not be regarded as “responders” but may be included in the denominator for ORR and DCR calculation depending on the analysis population (e.g. populations based on an ITT approach). 
14.1.3.2  Time to event variables  
14.1.3.2.1  Progression- free survival  
Usually in all Oncology studies, patients are followed for tumor progression after 
discontinuation of study medication for reasons other than progression or death. If this is not used, e.g. in Phase I or II studies, this should be clearly stated in the protocol. Note that randomized trials (preferably blinded) are recommended where PFS is to be the primary endpoint. 
Novartis  Confidential  Page 126  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Progressio n-free survival  (PFS)  is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event, progression- free survival is censored at the date of last adequate 
tumor assessment.  
14.1.3.2.2  Overall survival  
All patients should be followed until death or until patient has had adequate follow -up time as 
specified in the protocol whichever comes first. The follow-up data should contain the date the patient was  last seen alive / last known date patient alive, the date of death and the reason of 
death (“Study indication” or “Other”). 
Overall survival (OS)  is defined as the time from date of randomization/start of treatment to 
date of death due to any cause. If a patient is not known to have died, survival will be censored 
at the date of last known date patient alive.  
14.1.3.2.3  Time to progression  
Some studies might consider only death related to underlying cancer as an event which indicates progression. In this case the variable “Time to progression” might be used. TTP is defined as PFS except for death unrelated to underlying cancer. 
Time to progression (TTP)  is the time from date of randomization/start of treatment to the 
date of event defined as the first documented progression or death due to underlying cancer. If 
a patient has not had an event, time to progression is censored at the date of last adequate tumor assessment.  
14.1.3.2.4  Time to treatment failure 
This endpoint is often appropriate in studies of advanced disease where early discontinuation is typically related to intolerance of the study drug. In some protocols, time to treatment failure may be considered as a sensitivity analysis for time to progression. The list of discontinuation reasons to be considered or not as trea tment failure may be adapted according to the specificities 
of the study or the disease. 
Time to treatment failure (TTF)  is the time from date of randomization/start of treatment to 
the earliest of date of progression, date of death due to any cause, or date of discontinuation due 
to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to treatment failure for patients who did not experience treatment failure will be censored at last adequate tumor assessment.  
14.1.3.2.5  Duration of response  
The analysis of the following variables should be performed with much caution when restricted to responders since treatment bias could have been introduced. There have been reports where a treatment with a significantly higher response rate had a significantly shorter duration of response but where this probably primarily reflected selection bias which is explained as follows: It is postulated that there are two groups of patients: a good risk group and a poor risk group. Good risk patients tend to get into response readily (and relatively quickly) and tend to 
remain in response after they have a response. Poor risk patients tend to be difficult to achieve 
Novartis  Confidential  Page 127  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 a response, may have a longer time to respond, and tend to relapse quickly when they do 
respond. Potent  agents induce a response in both good risk and poor risk patients. Less potent 
agents induce a response mainly in good risk patients only. This is described in more detail by Morgan (1988) . 
It is recommended that an analysis of all patients (both responders and non- responders) be 
performed whether or not a “responders only” descriptive analysis is presented. An analysis of responders should only be performed to provide descriptive statistics and even then interpreted with caution by evaluating the results in the context of the observed response rates. If an inferential comparison between treatments is required this should only be performed on all patients (i.e. not restricting to “responders” only) using appropriate statistical methods such as the techniques described in Ellis et al (2008) . It should also be stated in the protocol if duration 
of response is to be calculated in addition for unconfirmed response. 
For summary statistics on “responders” only the following definitions are appropriate. (Specific 
definitions for an all -patient analysis of these endpoints are not appropriate since the status of 
patients throughout the study is usually taken into account in the analysis). 
Duration of overall response (CR or PR) : For patients with a CR or PR (which may have to 
be confirmed the start date is the date of first documented response (CR or PR) and the end date 
and censoring is defined the sa me as that for time to progression.  
The following two durations might be calculated in addition for a large Phase III study in which a reasonable number of responders is seen.  
Duration of overall complete response (CR) : For patients with a CR (which may have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is defined the same as that for time to progression. 
Duration of stable disease (CR/PR/SD) : For patients with a CR or PR (which may have to be 
confirmed) o r SD the start and end date as well as censoring is defined the same as that for time 
to progression. 
14.1.3.2.6  Time to response  
Time to overall response (CR or PR)  is the time between date of randomization/start of 
treatment until first documented response (CR or PR). The response may need to be confirmed 
depending on the type of study and its importance. Where the response needs to be confirmed then time to response is the time to the first CR or PR observed. 
Although an analysis on the full population is preferred a descriptive analysis may be performed 
on the “responders” subset only, in which case the results should be interpreted with caution 
and in the context of the overall response rates, since the same kind of selection bias may be introduced as described for duration of response in Section 14.1.3.2.5. It is recommended that an analysis of all patients (both responders and non-responders) be performed whether or not a “responders only” descriptive analysis is pr esented. Where an inferential statistical comparison 
is required, then all patients should definitely be included in the analysis to ensure the statistical test is valid. For analysis including all patients, patients who did not achieve a response (which may have to be a confirmed response) will be censored using one of the following options. 
Novartis  Confidential  Page 128  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 • at maximum follow -up (i.e. FPFV to LPLV used for the analysis) for patients who had a 
PFS event (i.e. progressed or died due to any cause). In this case the PFS event is the 
worst possible outcome as it means the patient cannot subsequently respond. Since the statistical analysis usually makes use of the ranking of times to response it is sufficient to assign the worst possible censoring time which could be observed in the study which is equal to the maximum follow -up time (i.e. time from FPFV to LPLV)  
• at last adequate tumor assessment date otherwise. In this case patients have not yet progressed so they theoretically still have a chance of responding 
Time to overall com plete response (CR)  is the time between dates of randomization/start of 
treatment until first documented CR. Similar analysis considerations including (if appropriate) censoring rules apply for this endpoint described for the time to overall response endpoint.  
14.1.3.2.7  Definition of start and end dates for time to event variables  
Assessment date  
For each assessment (i.e. evaluation number), the assessment date  is calculated as the latest of 
all measurement dates (e.g. X -ray, CT-scan) if the overall lesion response a t that assessment is 
CR/PR/SD/UNK. Otherwise - if overall lesion response is progression - the assessment date is 
calculated as the earliest date of all measurement dates at that evaluation number.  
Start dates  
For all “time to event” variables, other than duration of response, the randomization/ date of 
treatment start will be used as the start date.  
For the calculation of duration of response the following start date should be used: 
• Date of first documented res ponse is the assessment date of the first overall lesion 
response of CR (for duration of overall complete response) or CR / PR (for duration of 
overall response) respectively, when this status is later confirmed. 
End dates  
The end dates which are used to c alculate ‘time to event’ variables are defined as follows:  
• Date of death (during treatment as recorded on the treatment completion page or during follow-up as recorded on the study evaluation completion page or the survival follow-up page).  
• Date of progression is the first assessment date at which the overall lesion response was recorded as progressive disease.  
• Date of last adequate tumor assessment is the date the last tumor assessment with overall lesion response of CR, PR or SD which was made before an event or a censoring reason occurred. In this case the last tumor evaluation date at that assessment is used. If no post-baseline assessments are available (before an event or a censoring reason occurred) the date of randomization/start of treatment is used . 
• Date of next scheduled assessment is the date of the last adequate tumor assessment plus the protocol specified time interval for assessments. This date may be used if back-dating 
Novartis  Confidential  Page 129  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 is considered when the event occurred beyond the acceptable time window for the next 
tumor assessment as per protocol (see Section 14.1.3.2.8).  
Example  (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months - missing - missing - PD. Date of next scheduled assessment 
would then correspond to 9 months. 
• Date of discontinuation is the date of the end of treatment visit. 
• Date of last contact is defined as the last date the patient was known to be alive. This 
corresponds to the latest date for either the visit date, lab sample date or tumor assessment date. If available, the last known date patient alive from the survival follow-up page is used. If no survival follow-up is available, the date of discontinuation is used as las t 
contact date.  
• Date of secondary anti -cancer therapy is defined as the start date of any additional 
(secondary) antineoplastic therapy or surgery. 
14.1.3.2.8  Handling of patients with non- measurable disease only at baseline  
It is possible that patients with only non- measurable disease present at baseline are entered into 
the study, either because of a protocol violation or by design (e.g. in Phase III studies with PFS as the primary endpoint). In such cases the handling of the response data requires special consideration with respect to inclusion in any analysis of endpoints based on the overall response evaluations. 
It is recommended that any patients with only non- measurable disease at baseline should be 
included in the main (ITT) analysis of each of these endpoints. Although the text of the definitions described in the previous sections primarily relates to 
patients with measurable disease at baseline, patients without measurable disease should also be incorporated in an appropriate manner. The overall response f or patients with measurable 
disease is derived slightly differently according to Table 14 -4. 
Table 14 -4 Overall lesion response at each assessment: patients with non -target 
disease only  
Non-target lesions  New Lesions  Overall lesion response  
CR No CR 
Non-CR/Non -PD1 No Non-CR/non -PD 
UNK  No UNK  
PD Yes or No  PD 
Any Yes PD 
1 As defined in Section 14.1.2.4  
In general, the non- CR/non -PD response for these patients is considered equivalent to an SD 
response in endpoint determination. In summary tables for best overall response patients with only non-measurable disease may be highlighted in an appropriate fashion e.g. in particular by displaying the specific numbers with the non-CR/non- PD category.  
In considering how to incorporate data from these patients into the analysis the importance to each endpoint of being able to identify a PR and/or to determine the occurrence and timing of progression needs to be taken into account. 
Novartis  Confidential  Page 130  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 For ORR  it is recommended that the main (ITT) analysis includes data from patients with only 
non-measurable disease at baseline, handling patients with a best response of CR as 
“responders” with respect to ORR and all other pat ients as “non -responders”.  
For PFS , it is again recommended that the main ITT analyses on these endpoints include all 
patients with only non- measurable disease at baseline, with possible sensitivity analyses which 
exclude these particular patients. Endpoints such as PFS which are reliant on the determination 
and/or timing of progression can incorporate data from patients with only non- measurable 
disease.  
14.1.3.2.9  Sensitivity analyses  
This section outlines the possible event and censoring dates for progression, as we ll as addresses 
the issues of missing tumor assessments during the study. For instance, if one or more assessment visits are missed prior to the progression event, to what date should the progression event be assigned? And should progression event be ignored if it occurred after a long period of a patient being lost to follow -up? It is important that the protocol and RAP specify the 
primary analysis in detail with respect to the definition of event and censoring dates and also include a description of one or more sensitivity analyses to be performed. 
Based on definitions outlined in Section 14.1.3.2.7, and using the draft FDA guideline on 
endpoints (Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, April 2005) as a reference, the following analyses can be considered: 
Table 14 -5 Options for event dates used in PFS, TTP, duration of response  
Situation  Options for end -date (progression or 
censoring)1 
(1) = default unless specified differently in 
the protocol or RAP  Outcome  
A No baseline assessment  (1) Date of randomization/start of treatment3 Censored  
B Progression at or before next scheduled 
assessment  (1) Date of progression  
(2) Date of next scheduled assessment2 Progressed  
Progressed  
C1 Progression or death after exactly one 
missing assessment  (1) Date of progression (or death)  
(2) Date of next scheduled assessment2 Progressed  
Progressed  
C2 Progression or death after two or more  
missing assessments  (1) Date of last adequate assessment2 
(2) Date of next scheduled assessment2 
(3) Date of progression (or death)  Censored  
Progressed  
Progressed  
D No progression  (1) Date of last adequate assessme nt Censored  
E Treatment discontinuation due to ‘Disease 
progression’ without documented 
progression, i.e. clinical progression based 
on investigator claim  (1) N/A  
(2) Date of discontinuation (visit date at which 
clinical progression was determined)  Ignored  
Progressed  
F New anticancer therapy given  (1) Date of last adequate assessment  
(2) Date of secondary anti -cancer therapy  
(3) Date of secondary anti -cancer therapy  
(4) N/A  Censored  
Censored  
Event  
Ignored  
G Deaths due to reason other th an 
deterioration of ‘Study indication’  (1) Date of last adequate assessment  Censored 
(only TTP and 
duration of 
response)  
Novartis  Confidential  Page 131  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 1.=Definitions can be found in Section 14.1.3.2.7  
2.=After the last adequate tumor assessment. “Date of next scheduled assessment” is defined in 
Section  14.1.3.2.7 . 
3.=The rare exception to this is if the patient dies no later than the time of the second scheduled assessment as 
defined in the protocol in which case this is a PFS event at the date of death.  
The primary analysis and the sensitivity analyses must be specified in the protocol. Clearly 
define if and why options (1) are not used for situations C, E and (if applicable) F. 
Situations C (C1 and C2): Progression or death after one or more missing assessments: The 
primary analysis is usually using options (1) for situations C1 and C2, i.e. 
• (C1) taking the actual progression or death date, in the case of only one missing 
assessment.  
• (C2) censoring at the date of the last adequate assessment, in the case of two or more consecutive missing assessments.  
In the case of two or missing assessments (situation C2), option (3) may be considered joint ly 
with option (1) in situation C1 as sensitivity analysis. A variant of this sensitivity analysis consists of backdating the date of event to the next scheduled assessment as proposed with option (2) in situations C1 and C2. 
Situation E: Treatment discontinuation due to ‘Disease progression’ without documented 
progression : By default, option (1) is used for situation E as patients without documented PD 
should be followed for progression after discontinuation of treatment. However, option (2) may be used as  sensitivity analysis. If progression is claimed based on clinical deterioration instead 
of tumor assessment by e.g. CT -scan, option (2) may be used for indications with high early 
progression rate or difficulties to assess the tumor due to clinical deterioration. 
Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protocol. However, option (1), i.e. censoring at last adequate assessment may be 
used as a default in this case.  
Additional suggestions for se nsitivity analyses  
Other suggestions for additional sensitivity analyses may include analyses to check for potential bias in follow -up schedules for tumor assessments, e.g. by assigning the dates for censoring and 
events only at scheduled visit dates. The latter could be handled by replacing in Table 14 -5 the 
“Date of last adequate assessment” by the “Date of previous scheduled assessment (from baseline)”, with the following definition: 
• Date of previous s cheduled assessment (from baseline)  is the date when a tumor 
assessment would have taken place, if the protocol assessment scheme was strictly 
followed from baseline, immediately before or on the date of the last adequate tumor assessment.  
In addition, analyses could be repeated using the Investigators’ assessments of response rather than the calculated response. The need for these types of sensitivity analyses will depend on the individual requirements for the specific study and disease area and have to be  specified in the 
protocol or RAP documentation. 
Novartis  Confidential  Page 132  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 14.1.4  Data handling and programming rules  
The following section should be used as guidance for development of the protocol, data 
handling procedures or programming requirements (e.g. on incomplete dates). 
14.1.4.1  Study/pr oject specific decisions  
For each study (or project) various issues need to be addressed and specified in the protocol or 
RAP documentation. Any deviations from protocol must be discussed and defined at the latest in the RAP documentation. 
The proposed primary analysis and potential sensitivity analyses should be discussed and 
agreed with the health authorities and documented in the protocol (or at the latest in the RAP documentation before database lock). 
14.1.4.2  End of treatment phase completion  
Patients may voluntarily withdraw from the study treatment or may be taken off the study 
treatment at the discretion of the investigator at any time. For patients who are lost to follow -
up, the investigator or designee should show "due diligence" by documenting in the sour ce 
documents steps taken to contact the patient, e.g., dates of telephone calls, registered letters, 
etc. 
The end of treatment visit and its associated assessments should occur within 14 days of the last study treatment.  
Patients may discontinue study treatment for any of the following reasons: 
• Adverse event(s)  
• Lost to follow-up 
• Physician decision 
• Pregnancy  
• Protocol deviation 
• Subject/guardian decision 
• Death  
• Progressive disease per irRC (not per RECIST)  
• Study terminated by the sponsor 
14.1.4.3  End of post -treatment follow -up (study phase completion)  
End of post -treatment follow -up visit will be completed after discontinuation of study treatment 
and post- treatment evaluations but prior to collecting survival follow -up. 
Patients may provide study phase completion information for one of the following reasons: • Adverse event  
• Lost to follow-up 
• Physician decision 
• Pregnancy  
• Protocol deviation 
Novartis  Confidential  Page 133  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 • Technical problems  
• Subject/guardian decision 
• Death  
• New therapy for study indication 
• Progressive disease  
• Study terminated  by the sponsor 
14.1.4.4  Medical validation of programmed overall lesion response  
As RECIST is very strict regarding measurement methods (i.e. any assessment with more or 
less sensitive method than the one used to assess the lesion at baseline is considered UNK) an d 
not available evaluations (i.e. if any target or non- target lesion was not evaluated the whole 
overall lesion response is UNK unless remaining lesions qualified for PD), these UNK assessments may be re-evaluated by clinicians at Novartis or external experts. In addition, data review reports will be available to identify assessments for which the investigators’ or central reader’s opinion does not match the programmed calculated response based on RECIST criteria. This may be queried for clarification. However, the investigator or central reader’s response assessment will never be overruled.  
If Novartis elect to invalidate an overall lesion response as evaluated by the investigator or central reader upon internal or external review of the data, the calculated overall lesion response at that specific assessment is to be kept in a dataset. This must be clearly documented in the RAP documentation and agreed before database lock. This dataset should be created and stored as part of the ‘raw’ data.  
Any discontinuation due to ‘Disease progression’ without documentation of progression by RECIST criteria should be carefully reviewed. Only patients with documented deterioration of symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or study evaluation. 
14.1.4.5  Programming rules  
The following should be used for programming of efficacy results: 14.1.4.5.1  Calculation of ‘time to event’ variables  
Time to event = end date - start date + 1 (in days)  
When no post -baseline tumor assessments are available, the date of randomization/start of 
treatment will be used as end date (duration = 1 day) when time is to be censored at last tumor 
assessment, i.e. time to event variables can never be negative.  
14.1.4.5.2  Incomplete assessment dates  
All in vestigation dates (e.g. X-ray, CT scan) must be completed with day, month and year. 
If one or more investigation dates are incomplete but other investigation dates are available, this/these incomplete date(s) are not considered for calculation of the assessment date (and 
Novartis  Confidential  Page 134  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 assessment date is calculated as outlined in Section 14.1.3.2.7). If all measurement dates have 
no day recorded, the 1st of the month is used. 
If the month is not completed, for any of the investigations, the respective assessment will be considered to be at the date which is exactly between previous and following assessment. If a previous and following assessment is not available, this assessment will not be used for any calculation.  
14.1.4.5.3  Incomplete dates for last known date patient alive or death  
All dates must be completed with day, month and year. If the day is missing, the 15
th of the 
month will be used for incomplete death dates or dates of last contact. 
14.1.4.5.4  Non-target lesion response  
If no non- target lesions are identified at baseline (and therefore not followed throughout the 
study), the non- target lesion response at each assessment will be considered ‘not applicable 
(NA)’.  
14.1.4.5.5  Study/project specific programming  
The standard analysis programs need to be adapted for each study/project. 14.1.4.5.6  Censoring reason  
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study evaluation completion page and the survival page. 
For survival the following censoring reasons are possible: 
• Alive  
• Lost to follow-up 
For PFS and TTP (and therefore duration of responses) the following censoring reasons are 
possible: 
• Ongoing without event 
• Lost to follow-up 
• Withdrew consent 
• Adequate assessment no longer available*  
• Event documented after two or more missing tumor assessments (option 
• Death due al, see Table 14 -5) to reason other than underlying canc er (only used for TTP 
and duration of response)  
• Initiation of new anti- cancer therapy  
*Adequate assessment is defined in Section 14.1.3.2.7. This reason is applicable when adequate 
evaluations are missing for a specified period prior to data cut -off (or prior to any other 
censoring reason) corresponding to the unavailability of two or more planned tumor assessments prior to the cut -off date. The following clarifications concerning this reason should 
also be noted: 
Novartis  Confidential  Page 135  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 • This may be when there has been a definite decision to stop evaluation (e.g. 
reason=“Sponsor decision” on study evaluation completion page), when patients are not followed for progression after treatment completion or when only UNK assessments are available just prior to data cut- off). 
• The reason "Adequate assessment no longer available" also prevails in situations when another censoring reason (e.g. withdrawal of consent, loss to follow-up or alternative anti-cancer therapy)  has occurred more than the specified period following the last adequate 
assessment.  
• This reason will also be used to censor in case of no baseline assessment. 
14.1.5  References (available upon request)  
Dent S, Zee (2001) application of a new multinomial phase II stopping rule using response and early progression, J Clin Oncol; 19: 785-791 
Eisenhauer E, et al (2009) New response evaluation criteria in solid tumors: revised RECIST 
guideline (version 1.1). European Journal of Cancer, Vol.45: 228-47 
Ellis S, et al (2 008) Analysis of duration of response in oncology trials. Contemp Clin Trials 
2008; 29: 456-465 FDA Guidelines: 2005 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, April 2005 
FDA Guidelines: 2007 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, May 2007 
Morgan TM (1988) Analysis of duration of response: a problem of oncology trials. Cont Clin 
Trials; 9: 11 -18 
Therasse P, Arbuck S, Eisenhauer E, et al (2000) New Guidelines to Evaluate the Response to 
Treatmen t in Solid Tumors, Journal of National Cancer Institute, Vol. 92; 205-16 
Novartis  Confidential  Page 136  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 14.2 Appendix 2: Guidelines for immune-related Response Criteria 
(irRC) using one-dimensional measurements (simulating RECIST 
1.1) 
14.2.1  Introduction 
The currently used immune -related response criteria (irRC) uses unidimensional measurements 
to assess tumor response and it is an adaptation of the original irRC published by Wolchok 
(Wolchok 2009, Nishino 2013).  
The purpose of this document is to summarize the irRC guidelines in details focusing on differences in tumor response assessments between irRC and RECIST v1.1. 
The primary difference between irRC and RECIST 1.1 is the definition of progressive disease. 
The definitions of baseline target/non target lesions, number of lesions selected at baseline, the criteria for lesion measurement method of evaluation of response and definition of response are the same for irRC and RECI ST 1.1 and are available in the RECIST 1.1 guidelines 
(Appendix 1).  
14.2.2  New lesions and non- target lesions  
In irRC a new lesion does not automatically indicate progressive disease. 
New measurable lesions ar e added to the sum of diameters of the previously existing target 
lesions, and the sum of diameters is followed at each subsequent tumor assessment. New measureable lesions are defined using the same criteria as for baseline target lesions in 
RECIST v1.1. New measurable lesions shall be prioritized according to size, and the largest lesions shall be selected as new measurable lesions. Up to five new measurable (and a maximum of two per organ) are allowed  in total and will be included in the overall tumor as sessment.  
Non-target lesions (baseline and new non- measurable lesions) are used primarily for 
determination of Complete Response (CR). The RECIST v1.1 definitions for the assessment of non-target lesions apply. A CR requires that all non- target lesions dis appear (both those present 
at baseline and any new non- measurable lesions that have appeared during the study). If after 
worsening a non- target lesion becomes measurable, it should still be followed as a non- target 
lesion. Worsening of non -target lesions a nd new non- measurable lesions only indicate disease 
progression if there is unequivocal evidence of disease progression ( Table 14 -6). 
14.2.3  Follow -up evaluation of target and non- target lesions  
To assess tumor  response, the sum of diameters for all target lesions is calculated (at baseline 
and throughout the study). The diameters of any new measurable lesions are included in the sum of diameters at each assessment to provide the total tumor burden. At each asse ssment, 
percent change in the sum of diameters is calculated and compared to baseline or to nadir in order to evaluate the target lesion response (including new measurable lesions) ( Section 14.2.4). 
This evaluation combined with the status of non- target lesions (baseline and new non-
measurable lesions) is then used to determinate the overall lesion response ( Table 14 -6). The 
thresholds for irPR and irP D assessment are the same as for RECIST v1.1.  
Novartis  Confidential  Page 137  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 14.2.4  Definitions of response categories and evaluation of overall lesion 
response  
In irRC, the overall response is primarily based on target lesions (baseline and new measurable lesions). The non- target lesions only contribute to define irCR, and irPD in the case of 
unequivocal progression, as shown below in Table 14-6. 
Like in RECIST 1.1, irCR and irPR must be confirmed at a new assessment after at least 4 
weeks. Unlike RECIST 1.1, irPD also requires confirmation at a new assessment after at least 4 weeks.  
The response categories are defined as follows: 
• Immune related Complete Response (irCR): Disappearance of all non -nodal target lesions 
and non-target lesions in two consecutive observations not less than 4 weeks apart. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm. (Sum of diameters may be greater than zero at the time of CR, if nodal lesions are included as target lesions). 
• Immune related Partial Response (irPR): At least a 30% decrease in the sum of diameters of all target lesions including new target lesions in two consecutive observations not less 
than 4 weeks apart, taking as reference the baseline sum of diameters.  
• Immune related Progressive Disease (irPD): At least a 20% increase in the sum of diameters of all  measured target lesions including new measurable lesions. The irPD must 
be confirmed in a second evaluation not less than 4 weeks later, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Worsening of non-target lesions (existing or new) only indicate PD when there is unequivocal evidence of progression, confirmed in a second evaluation not less than 4 weeks later. 
• Immune related Stable Disease (irSD): Neither a sufficient shrinkage to qualify for irPR or irCR, nor an increase in lesions which would qualify for irPD. 
• Unknown (UNK): Progression has not been documented and one or more target lesions have not been assessed or have been assessed using a method significantly different from baseline that prevents reasonable comparison to the prior assessments. 
Table 14 -6 Overall response at each assessment  
Target and new measurable lesions 
(Tumor burden), * (%)  Non-target lesions  
(both baseline and new non -
measurable)  Overall  
lesion response  
- 100 Absent  irCRa 
- 100 Stable/not evaluated  irPRa 
≤-30 b Absent/Stable/not evaluated  irPRa 
>-30 b and<+20 c Absent/Stable/not evaluated  irSD 
≥+20 c Any irPDa 
Any Unequivocal progression  irPDa 
Novartis  Confidential  Page 138  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Target and new measurable lesions 
(Tumor burden), * (%)  Non-target lesions  
(both baseline and new non -
measurable)  Overall  
lesion response  
* the longest diameter of new measurable lesions is included in the calculation of the sum of longest diameters.  
a To be confirmed after at least 4 weeks.  
b From baseline  
c From nadir  
If the evaluation of any of the target lesions could not be made during follow -up, the overall 
status must be ‘unknown’ unless progression was documented. 
If the evaluation of any non -target lesions is not made, and all target lesions disappeared, irCR 
cannot be determined and overall response must be “irPR”. In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended that the residual lesion be investigated (fine needle aspirate/biopsy) to confirm the irCR. 
14.2.5  Only non- measurable disease at baseline  
For patients with only non- measurable disease at baseline,  unequivocal progression of non-
target lesions will constitute an irPD (i.e. worsening of the overall tumor burden which is 
substantial enough to lead to discontinuation or change of therapy). In addition, the appearance of new lesions (measurable or non-m easurable) consistent with unequivocal progression taking 
into account the overall disease burden will constitute an irPD. The absence of all non- target 
lesions and no new lesions will qualify for irCR. Otherwise the overall response will be considered as irNon -CR/Non -PD (irNCRNPD) similar to RECIST 1.1. Confirmation of irPD 
and irCR as specified above in Section 14.2.4 is required. If any baseline non-target lesion or a new lesion observed at an earlier post -baseline evaluation was not/could not be assessed at a 
later post -baseline tumor evaluation then the overall response will be irUNK. No confirmation 
is required for irNCRNPD.  
14.2.6  References (available upon request)  
Bohnsack O, Ludajic K, Hoos A (2014) Adaptation of the immune- related response criteria: 
irRECIST. ESMO 2014; Abstract 4958 visible at: //webges.com/cslide/library/esmo/browse/search/eTT#9faE02tu. 
Nishino M, Giobbie-Hurder A, Gargano M, et al (2013) Developing a Common Language for 
Tumor Response to Immunotherapy: Immune- Related Response Criteria Using 
Unidimensional Measurements. Clin Cancer Res ; 19:3936-3943. 
Wolchok JD, Hoos A, O'Day S et al (2009) Guidelines for the Evaluation of Immune Therapy 
Activity in Solid Tumors: Immune -Related Response Criteria. Clin Cancer Res; 15:7412 -20. 
Novartis  Confidential  Page 139  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 14.3 Appendix 3: Statistical Details for the Phase Ib Part: Bayesian 
logistic regression model (BLRM): prior and design properties 
for hypothetical data scenarios 
This appendix provides details of the statistical model, the derivation of prior distributions from 
historical and pre -clinical data, the results of the Bayesian analyses and respective dosing 
decisions for some hypothetical data scenarios, and a simulation study of the operating characteristics of the model.  
14.3.1  Statistical Models  
The statistical model comprises single -agent toxicity parts, which allow the incorporation of 
single-agent toxicity data, and an interaction part. 
14.3.1.1  Single agent part  
Let 𝜋𝜋
1(𝑑𝑑1) be the risk of DLT for MCS110 given as a single agent at dose 𝑑𝑑 1; 𝜋𝜋2(𝑑𝑑2) be the 
risk of DLT for PDR001 given as a single agent at dose 𝑑𝑑2. These single agent dose -DLT 
models are logistic: 
MCS110: logit�𝜋𝜋1(𝑑𝑑1)� =  log (𝛼𝛼1) +  𝛽𝛽1 log(𝑑𝑑1𝑑𝑑1∗⁄) 
PDR001: logit�𝜋𝜋2(𝑑𝑑2)� =  log (𝛼𝛼2) +  𝛽𝛽2 log(𝑑𝑑2𝑑𝑑2∗⁄) 
where 𝑑𝑑1∗= 5 mg/kg and 𝑑𝑑2∗= 300 mg (reference doses) are used to scale the doses of MCS110 
and PDR001, respectively. Hence, 𝛼𝛼1 and 𝛼𝛼2 (>0) are the single -agent odds of a DLT at 𝑑𝑑1∗ and 
𝑑𝑑2∗, respectively; and 𝛽𝛽1 and 𝛽𝛽2 (>0) are the increase in the log -odds of a DLT by a unit increase 
in log-dose. 14.3.1.2  Interaction  
Under the situation of no interaction, the risk of a DLT at dose 𝑑𝑑
1 of MCS110 and dose 𝑑𝑑2 of 
PDR001 is: 
𝜋𝜋120(𝑑𝑑1,𝑑𝑑2)= 1− �1−𝜋𝜋1(𝑑𝑑1)��1−𝜋𝜋2(𝑑𝑑2)� 
To allow for interaction between MCS110 and PDR001, an odds multiplier is introduced. The 
risk of DLT for combination dose (𝑑𝑑1,𝑑𝑑2) is then given by: 
odds�𝜋𝜋12(𝑑𝑑1,𝑑𝑑2)�=exp(𝜂𝜂12×𝑑𝑑1𝑑𝑑1∗⁄ ×𝑑𝑑2𝑑𝑑2∗⁄)×odds�𝜋𝜋120(𝑑𝑑1,𝑑𝑑2)� 
where odds (𝜋𝜋) =𝜋𝜋(1−𝜋𝜋)⁄ ; and 𝜂𝜂 12 is the log -odds ratio between the interaction and no 
interaction model at reference doses. Here 𝜂𝜂12= 0 corresponds to no interaction, with 𝜂𝜂 12> 0 
and 𝜂𝜂12< 0 representing synergistic and antagonistic toxicity respectively. 
14.3.2  Prior specifications  
The Bayesian approach requires t he specification of prior distributions for all model parameters, 
which include the single agent parameters log(𝛼𝛼1), log(𝛽𝛽1) for MCS110, log (𝛼𝛼2), log (𝛽𝛽2) for 
PDR001, and the interaction parameter 𝜂𝜂 12. A meta -analytic -predictive (MAP) approach was 
used to derive the prior distribution for the single- agent model parameters.  
Novartis  Confidential  Page 140  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 14.3.2.1  Prior distribution for the logistic parameters  
For each of MCS110 and PDR001 single agent, a mixture prior was derived. 
A MAP approach was used to incorporate the dose -DLT data from  [CMCS110A2101]  (first -
in-human MCS110 study in prostate cancer patients)  and [CMCS110X2201]  (a Phase II study 
in PVNS patients, with the cutoff date Nov 28, 2015) for MCS110; and [CPDR001X2101]  
(first-in-human PDR001 oncology study, with the cutoff date Nov 28, 2015) for PDR001. To 
make the prior more robust, an additional mixture component corresponding to high toxicity 
was introduced. 
14.3.2.1.1  Description of the meta- analytic -predictive (MAP) approach  
The aim of the MAP approach is to derive a prior distribution f or the logistic parameters 
�log(𝛼𝛼∗),  log (𝛽𝛽∗)� of the new trial using DLT data from historical studies.  
Let 𝑟𝑟𝑑𝑑𝑑𝑑 and 𝑛𝑛𝑑𝑑𝑑𝑑 be the number of patients with a DLT, and the total number of patients at dose 
𝑑𝑑 in historical trial 𝑠𝑠 (𝑠𝑠= 1, … ,𝑆𝑆). The corresponding probability of a DLT is 𝜋𝜋 𝑑𝑑𝑑𝑑. The model 
specifications for the derivation of the MAP prior are as follows: 
𝑟𝑟𝑑𝑑𝑑𝑑 | 𝜋𝜋𝑑𝑑𝑑𝑑 ~ Bin (𝜋𝜋𝑑𝑑𝑑𝑑,𝑛𝑛𝑑𝑑𝑑𝑑) 
logit (𝜋𝜋𝑑𝑑𝑑𝑑)=log(𝛼𝛼𝑑𝑑) +  𝛽𝛽𝑑𝑑 log(𝑑𝑑/𝑑𝑑∗) 
 �𝑙𝑙𝑙𝑙𝑙𝑙(𝛼𝛼𝑑𝑑),𝑙𝑙𝑙𝑙𝑙𝑙(𝛽𝛽𝑑𝑑)� � 𝜇𝜇,𝜓𝜓 ~ BVN (𝜇𝜇,𝜓𝜓), s = 1, … , 𝑆𝑆 
�𝑙𝑙𝑙𝑙𝑙𝑙(𝛼𝛼∗),𝑙𝑙𝑙𝑙𝑙𝑙(𝛽𝛽∗)� � 𝜇𝜇,𝜓𝜓 ~ BVN (𝜇𝜇,𝜓𝜓) 
The parameters 𝜇𝜇 = (𝜇𝜇1,𝜇𝜇2) and 𝜓𝜓 are the mean and between -trial covariance matrix for the 
logistic parameters, the latter with standard deviations τ1, τ2, and correlation ρ. The parameters 
τ1 and τ2 quantify the degree of between trial heterogeneity. The following priors will be used 
for these parameters:  
• normal priors for 𝜇𝜇1 and 𝜇𝜇2, 
• log-normal priors for τ1 and τ2, and 
• a uniform prior for ρ. 
The MAP prior for single -agent model parameters in the new trial, � log(α∗),log(β∗)�, is the 
predictive distribution  
�𝑙𝑙 𝑙𝑙𝑙𝑙 (𝛼𝛼∗),𝑙𝑙𝑙𝑙𝑙𝑙(𝛽𝛽∗)� � (𝑟𝑟𝑑𝑑𝑑𝑑,𝑛𝑛𝑑𝑑𝑑𝑑∶ 𝑠𝑠= 1, … ,𝑆𝑆) 
Since the predictive distribution is not available analytically, MCMC is used to simulate values 
from this distribution. This is implemented using JAGS version 3.12. The sample from this distribution is then approximated by a mixture of bivariate normal (BVN) distributions. BVN mixtures with increasing numbers of mixture components are fitted to the sample using the expectation -maximization (EM) algorithm ( Dempster 1977). The  optimal number of 
components of the mixture is then identified using the Akaike information criterion (AIC) (Akaike 1974).  
Novartis  Confidential  Page 141  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 14.3.2.1.2   Single agent MCS110  
For MCS110, this study uses a mixture prior consisting of two components. Component 1 is 
the distribution derived based on dose -DLT data from [CMCS110A2101]  (first -in-human 
MCS110 study in prostate cancer patients)  and [CMCS110X2201]  (a Phase II study in PVNS 
patients)  by MAP approach ( Section 14.3.2.1.1). The assigned weight for Component 1 is 80%. 
Component 2 allows for a higher toxicity case. The assigned weight for Component 2 is 20%. 
Component 1:  
For the MAP model for MCS110, reference dose 𝑑𝑑1∗= 5 mg/kg is used, and data from 𝑆𝑆 = 2 
historical studies is available. ( Table 14 -8 and Table 14 -9) [CMCS110A2101]  is a Phase I study 
with 3 prostate cancer patients with bone metastasis receiving 0.01 mg/kg MCS110 in a once 
every 2 week dosing schedule on a 28- day cycle for 3 cycles. [CMCS110X2201]  is a Phase II 
proof of concept study in patients with PVNS (pigmented villonodular synovitis). As of Nov-
28-2015, there are 18 patients treated with single dose of MCS110 at 10 mg/kg. 
Weakly informative normal priors are assumed for 𝜇𝜇1 and 𝜇𝜇2, with means corresponding to a 
risk of DLT of 10% at the reference dose, and a doubling in dose leading to a doubling in the 
odds of the risk of a DLT, respectively. Priors for τ1 and τ2 are assigned such that (1) their 
medians correspond to large between trial heterogeneity, and (2) their uncertainty (95% prior 
interval) cover plausi ble between -trial standard deviations ( Neuenschwander 2014).  
The prior distributions for the model used for deriving the MAP priors are specified in Table 14 -7. 
Table 14 -7 Prior distributions for the parameters of the MAP model used to derive 
the prior for the single -agent MCS110 model parameters  
Parameter  Prior distributi on 
𝜇𝜇1 N(mean = logit(0.10), sd = 2)  
𝜇𝜇2 N(mean = 0, sd=1)  
τ1 log-normal(mean = log(1), sd = log(2)/1.96)  
τ2 log-normal(mean = log(0.500), sd = log(2)/1.96)  
ρ uniform( -1,1) 
Historical data  
Table 14 -8 Historical data from [CMCS110A2101]  
Dose level of MCS110 (mg/kg)  Number DLTs/Number of evaluable patients  
0.01 0/3 
Table 14 -9 Historical data from [CMCS110X2201]  
Dose level of MCS110 (mg/kg)  Number DLTs/Number of evaluable patients  
10 0/18 
Component 2:  
This weakly informative bivariate normal prior allows for a case with higher toxicity.  
Novartis  Confidential  Page 142  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 • For the intercept parameter log(α 2), the prior mean of -1.658 is derived based on the a-
priori median of an assumed 16% DLT rate at the reference dose d 2*= 5 mg/kg. By setting 
the standard deviation =2, the respective 95% a-priori interval for probability of DLT at 
dose 5 mg/kg is wide (0.4%, 90.6%), which represents weak prior information. 
• For the log- slope parameter log(β 2), the prior mean of 0 and prior standard deviation of 1 
allow for very flat to very steep slopes. Therefore, it is a weakly informative prior. The interpretation is as follows: when tripling the dose, the odds of having a DLT are multiplied by a factor of 3
β. 
• The Component 2 is set to be (-1.658, 0, 2, 1, 0) 
14.3.2.1.3  Single agent PDR0 01 
For PDR001, this study uses a mixture prior consisting of three components. Component 1and 2 are derived based on dose -DLT data from First- in-human PDR001 oncology study 
[CPDR001X2101]  by MAP approach ( Section 14.3.2.1.1). The assigned total weight for 
Component 1 and 2 is 80%. Component 3 allows for a higher toxicity case. The assigned weight for Component 3 is 20%. 
Component 1 and 2  
For the MAP model for PDR001, reference dose 𝑑𝑑
2∗=300 mg is used, and data from 𝑆𝑆= 1 
historical study is available . (Table 14 -11) [CPDR001X2101]  is a Phase I study with two dose 
schedules: three cohorts of patients on a Q2W schedule; and two cohorts on a Q4W schedule. 
PDR001 dose levels in Q2W and Q4W dosing schedules are converted to Q3W by finding out the dose level in Q3W which provides equivalent area under the curve (AUC
0-6weeks ) for dose 
levels in Q2W and Q4W regimens studied in [CPDR001X2101]  trial. Using the popPK model 
developed from [CPDR001X2101]  PK data following steps are conducted: (1) Target AUCs 
are simulated for studied dose levels in [CPDR001X2101]  trial at their respective regimens for 
AUC 0-6weeks ; (2) Corresponding Q3W AUC 0-6weeks  are generated for dose levels every 10 mg on 
Q3W regimen; i.e 50 through 2000 mg with every 10 mg interval; (3) The dose level on Q3W regimen that minimized the absolute difference between target AUC and Q3W AUC
0-6weeks  are 
selected as candidate dose.  
After the dose conversion is performed as described above, PDR001 single agent data is then 
used to derive MAP prior. Firstly, weakly informative priors are assumed for 𝜇𝜇1 and 𝜇𝜇2, with 
means corresponding to a risk of DLT at the reference dose of 10%, and a doubling in dose 
leading to a doubling in the odds of the risk of a DLT, respectively. Priors for τ1 and τ2 are 
assigned such that (1) their medians correspond to substantial between trial heterogeneity, and 
(2) their uncertainty (95% prior interval) cover plausible  between -trial standard deviations 
(Neuenschwander 2014). PDR001 data was then used to update the prior described above. 
The prior distributions for the model used for deriving the MAP priors are specifi ed in  
Table 14 -10. 
Novartis  Confidential  Page 143  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Table 14 -10 Prior distributions for the parameters of the MAP model used to derive 
the prior for the single -agent PDR001 model parameters  
Parameter  Prior distribution  
𝜇𝜇1 N(mean = logit(0.10), sd = 2)  
𝜇𝜇2 N(mean = 0, sd=1)  
τ1 log-normal(mean = 0.500, sd = log(2)/1.96)  
τ2 log-normal(mean = 0.250, sd = log(2)/1.96)  
ρ uniform( -1,1) 
Historical data  
Table 14 -11 Historical data from [CPDR001X2101]  
Dose 
schedule  Dose level  
(mg/kg)  Flat dose  
(mg)  Equivalent dose level in Q3W 
(mg)*  Total Number of DLT 
/Number of evaluable 
patients  
Q2W  1 80 110 0/16 
Q2W  3 240 330 0/12 
Q2W  10 800 1110  0/3 
Q4W  3 240 220 0/6 
Q4W  5 400 360 0/6 
* Equivalent dose level in Q3W is calculated based on simulation described under Component 1 and 2  
Component 3:  
This weakly informative bivariate normal prior allows for a case with higher toxicity.  
• For the intercept parameter log(α 2), the prior mean of -1.099 is derived based on the a-
priori median of an assumed 25% DLT rate at the reference dose d 2*= 300 mg. By setting 
the standard deviation =2, the respective 95% a-priori interval for probability of DLT at 
dose 300 mg/kg is wide (0.7%, 94.4%), which represents weak prior information. 
• For the log- slope parameter log(β 2), the prior mean of 0 and prior standard deviation of 1 
allow for very flat to very steep slopes. Therefore, it is a weakly informative prior. The interpretation is as follows: when tripling the dose, the odds of having a DLT are multiplied by a factor of 3
β. 
• The Component 3 is set to be (-1.099, 0, 2, 1, 0) 
All the information to derive the prior distributions for the model parameters is provided in Table 14 -13. 
14.3.2.2  Prior distribution for the interaction parameters  
Although no interaction is expected, considerable uncertainty remains. A normal prior distribution for the interaction parameter η
12 is to be derived to reflect the current uncertainty 
about the toxicity profile of the combination of MCS110 and PDR001. The risk of significant positive interactio n between MCS110 and PDR001 cannot be totally excluded. The interaction 
parameter η
12 was chosen accordingly but with a degree of uncertainty in order to allow for the 
Novartis  Confidential  Page 144  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 possibility that the interaction may be positive or negative. Therefore the following as sumption 
is made for the interaction parameter:  
• 𝜂𝜂12 is normally distributed, with mean 0 , and standard deviation 2.803; 
• At the starting dose of d 1start=3 mg/kg and d 2start=100 mg the corresponding distribution for 
the odds ratio has mean 1 and a 97.5th percentile of 3.00, i.e. 3-fold increase in odds of 
DLT due to interaction compared to no interaction. 
Since the interaction is dose -dependent (see model definition in Section 10.4.2), the prior for 
the interaction parameter has a simple interpretation only at the anticipated combination 
reference dose of MCS110 = 5 mg/kg and PDR001 = 300 mg. Table 14 -12 shows the prior 
median and 95% confidence interval of fold increase in odds of DLT due to interaction compared to no interaction at all provisional dose levels, as well as the reference dose level.  
Table 14 -12 A priori intera ction at the provisional and reference dose levels  
MCS110  
(mg/kg, Q3W)  PDR001  
(mg, Q3W)  
 100 300 
3 1 
(0.333, 3.000)  1 
(0.037,27.000)  
5 1 
(0.160, 6.240)  1 
(0.004, 243.000)  
10 1 
(0.026, 38.941)  1 
(0.000,59049.000)  
* Presented are median (95% confidence interval). The prior median of fold increase in odds of DLT with 95% 
confidence interval at the combination reference dose level is highlighted in bold.  
14.3.2.3  Summary of prior distributions  
The prior distributions of the model parameters are summarized in Table 14 -13. 
Prior summaries for DLT rates for are summarized in Table 14 -14. 
Table 14 -13 Prior distribution for the model parameters  
Parameter  Mean  Standard deviations  correlation  weight  
Single agent MCS110 prior  
BVN Mixture �log(𝛼𝛼1), log(𝛽𝛽1)� 
Component 1  
(MAP prior)  (-4.302 , -0.356)  (1.852, 1.030)  -0.050  0.80 
Component 2  
(high toxicity)  (-1.658 , 0)  (2, 1)  0 0.20 
Single agent PDR001 prior  
BVN Mixture �log(𝛼𝛼2), log(𝛽𝛽2)� 
Component 1  
(MAP prior)  (-5.166 , -0.582)  (1.454, 0.956)  -0.275  0.43 
Component 2  
(MAP prior)  (-4.115 , -0.008)  (1.083, 0.647)  -0.212  0.37 
Component 3  
(high toxicity)  (-1.099 , 0)  (2, 1)  0 0.20 
Novartis  Confidential  Page 145  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Parameter  Mean  Standard deviations  correlation  weight  
Interaction parameter  
Normal  
𝜂𝜂12 0 2.803  N/A N/A 
Table 14 -14 Summary of prior distribution of DLT rates  
MCS110  
dose 
(mg/kg)  Prior probabilities that P(DLT) is in the 
interval  : 
Mean  SD Quantiles  
[0, 0.16)  [0.16, 0.33)  [0.33,1]  2.5%  50% 97.5%  
 In combination with PDR001 100 mg  
3 0.803  0.093  0.104  0.111  0.187  0.001  0.03 0.747  
5 0.74 0.11 0.15 0.145  0.22 0.001  0.044  0.845  
10 0.604  0.117  0.279  0.244  0.309  0.001  0.082  0.981  
 In combination with PDR001 300 mg  
3 0.687  0.112  0.201  0.183  0.262  0.001  0.052  0.932  
5 0.601  0.104  0.295  0.256  0.328  0 0.074  0.988  
10 0.516  0.063  0.421  0.381  0.418  0 0.131  1 
Note: bold values indicate dose combinations not meeting the overdose criterion.  
14.3.3  Hypothetical on- study scenarios  
To illustrate the performance of the Bayesian model used to guide dose escalation, hypothetical 
dose escalations scenarios following the provisional dose levels specified in Table 6 -2 are 
displayed. In each case, the maximum dose that can be used in the next cohort of patients is shown. This maximum dose is determined using the model based assessment of the risk of DLT in future patients and the dose escalation rules as described in Section 6.2.3. In practice a dose below the maximum might be chosen based on additional safety, PK or PD information (Section  6.2.3).  
Table 14 -15 shows on-study dosing recommendations for some hypothetical data scenarios. 
Note that the next dose combination is selected in concordance with the provisional dose levels specified in Section 6.2.2 of the protocol wherever it is allowed, to mimic possible on-study 
escalation steps.  
Table 14 -15 Dose decisions recommended by BLRM under EWOC  
Scenario  Dose 
combination 
MCS110 
(mg/kg)/PDR001 
(mg)  Number of  Next dose level  
patients  DLTs  Dose  
(mg/kg / 
mg) P(Target 
toxicity)  P(excessive 
toxicity)  Median 
P(DLT)  
1 Cohort1:3/100  3 0 3/300  0.101  0.097  0.031  
2 Cohort1:3/100  3 1 3/100  0.260  0.219  0.150  
3 Cohort1:3/100  3 2 STOP     
4 Cohort1:3/100  
Cohort2:3/100  3 
5 1 
0 3/300  0.189  0.212  0.110  
5 Cohort1:3/100  
Cohort2:3/300  3 
5 0 
0 5/300  0.075  0.061  0.014  
Novartis  Confidential  Page 146  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Scenario  Dose 
combination MCS110 
(mg/kg)/PDR001 
(mg)  Number of  Next dose level  
patients  DLTs  Dose  
(mg/kg / 
mg) P(Target 
toxicity)  P(excessive 
toxicity)  Median 
P(DLT)  
6 Cohort1:3/100  
Cohort2:3/300  3 
5 0 
1 3/300   
0.256  0.092  0.109  
7 Cohort1:3/100  
Cohort2:3/300  3 
5 0 
2 3/100  0.175  0.043  0.075  
8 Cohort1:3/100  
Cohort2:3/300  
Cohort3:3/300  3 
5 
4 0 1 
0 5/300  0.199  0.200  0.110  
9 Cohort1:3/100  
Cohort2:3/300  
Cohort3:5/300  3 5 
4 0 0 
0 10/300  0.055  0.104  0.003  
10 Cohort1:3/100  
Cohort2:3/300  
Cohort3:5/300  3 5 
4 0 0 
1 5/300  0.263  0.125  0.119  
11 Cohort1:3/100  
Cohort2:3/300  
Cohort3:5/300  3 5 
4 0 0 
2 3/300  0.255  0.030  0.110  
12 Cohort1:3/100  
Cohort2:3/300  
Cohort3:3/300  
Cohort4:5/300  3 5 
4 
3 0 
1 
0 
1 3/300  0.222  0.015  0.102  
13 Cohort1:3/100  
Cohort2:3/300  
Cohort3:5/300  
Cohort4:3/300  3 
5 
4 
3 0 
0 
2 
1 3/300  0.380  0.048  0.144  
14 Cohort1:3/100  
Cohort2:3/300  
Cohort3:5/300  
Cohort4:10/300  3 
5 4 
6 0 0 0 
1 10/300  0.244  0.086  0.101  
15 Cohort1:3/100  
Cohort2:3/300  
Cohort3:5/300  
Cohort4:10/300  3 5 4 
6 0 0 0 
2 5/300  0.081  0.002  0.067  
16 Cohort1:3/100  
Cohort2:3/300  
Cohort3:5/300  
Cohort4:10/300  
Cohort5:5/300  3 5 4 6 
3 0 0 0 2 
1 5/300  0.163  0.005  0.094  
Note that the overdose criterion is defined as P(over) < 0.25.  
*Additional dose levels may be added if allowed by the BLRM.  
Within Table 14 -15, it can be seen that the model generally leads to decisions that are in 
agreement with clinical sense. The dose levels investigated correspond to the provisional dose 
levels specified in Section 6.2.2. 
14.3.4  Operating characteristics for MCS110 + PDR001 combination arm  
A simulation study is used to illustrate the long run performance of the Bayesian dose escalation 
model. Several example scenarios were investigated ( Section 14.3.4.1 ), and i n each case 1000 
trials were simulated, with results summarized in Section 14.3.4.3. 
Novartis  Confidential  Page 147  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 14.3.4.1  Scenarios  
In order to show how the design performs, 3 hypothetical scenarios were investigated: 
1. For scenario 1, the odds of DLT are aligned with the prior information, i.e. the DLT rates 
for dose combinations are set to the median values derived from the prior. 
2. For scenario 2, the odds of DLT are assumed to be 100% increase from scenario 1 
3. For scenario 3, the odds of DLT are assumed to be 4 -folds increase from scenario 1  
To note, under scenario 1, there’s not any dose level have DLT rate falls into target or over-toxic DLT interval. Therefore, we didn’t explore any scenarios which assume smaller odds of DLT than scenario 1. Under scenario 2, there’s only one combination dose level fall into target toxicity interval and no over-toxic DLT rate. Under scenario 3, there are three combination dose levels fall into target toxicity interval and one over- toxic DLT rate.  
The true probabilities used in the simulation are presented in Table 14 -16 for each scenario 
above. 
Table 14 -16 True underlying cumulative probabilities of DLT for different 
scenarios  
MCS110 (mg/kg)  PDR001 (mg)  
100 300 
Scenario 1    
0.3 0.013  0.026  
1 0.018  0.033  
3 0.030  0.052  
5 0.044  0.074  
10 0.082  0.131  
Scenario 2    
0.3 0.026  0.051  
1 0.035  0.064  
3 0.058  0.099  
5 0.084  0.138  
10 0.152  0.232  
Scenario 3    
0.3 0.050  0.096  
1 0.068  0.120  
3 0.110  0.180  
5 0.155  0.242  
10 0.263  0.376  
- Grey shaded cells indicate True probability fall within target interval (0.16, 0.33]  
14.3.4.2  Simulation details  
1000 trials were used to simulate each scenario. The starting dose combination was chosen as 
3 mg/kg for MCS110 and 100 mg for PDR001, and the maximal dose to jump to was orthogonal, and follows the protocol specif ications ( Section 10.4.2 of the protocol). The number 
of patients to enroll in each cohort and stopping rules used to declare MTD were defined as: 
• Maximum number of patients treated: 60 
Novartis  Confidential  Page 148  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 • Minimum cohort size: 3  
• Minimum number of patients treated at a given dose combination in order to declare 
MTD: 6  
• Posterior probability of targeted toxicity at this combination dose > 50% and is the highest among potential doses, or 
• Minimum number of patients treated in the trial: 15  
Metrics  
Operating characteristics were reviewed for the simulations to compare the relative performance under each true scenario. The metrics reviewed were:  
1. Average proportion of patients receiving a target dose combination on study (I) 
2. Average proportion of patients receiving a dose combination with true P(DLT) ≥ 33% on study (II)  
3. Average proportion of patients receiving a dose combination with true P(DLT) < 16% on study (III)  
4. Proportion of trials that were recommended a target dose combination as the MTD (IV) 
5. Proportion of trials that were recommended a dose combinations with true P(DLT) ≥ 33% as the MTD (patient risk) (V)  
6. Proportion of trials that were recommended a dose combination with true P(DLT) < 16% as the MTD (VI)  
14.3.4.3  Simulation results  
Table 14 -17 below summarizes the simulated operating characteristics of the model for the 3 
different scenarios studied, additionally showing the percentage of trials stopped before declaring MTD when all dose combinations were considered too toxic. 
Table 14 -17 Results  
Scenario  Metric  
 I II III IV V VI Stopped  
1 0.000  0.000  1.000  0.000  0.000  0.998  0.002  
2 0.128  0.000  0.872  0.098  0.000  0.897  0.005  
3 0.455  0.065  0.480  0.603  0.040  0.333  0.024  
The simulated operating characteristics presented show that the combination model performs reasonably and well under the hypothetical scenarios investigated. 
Scenario 1:  
Since there’s no dose combination which has median DLT rate in the target or over toxicity 
intervals, no patient receive a target dose or over -toxic dose combination (metric I and II) on 
study, and no trial was recommended with a target dose or over- toxic dose as MTD (metric IV 
and V). Under this scenario, since both study drugs demonstrate good safety profile with low DLT rate (<16%), it may be expected to identify a RP2D before identifying the MTD. 
Novartis  Confidential  Page 149  
Amended Protocol Version 05 (Clean )  Protocol No. CMCS110Z2102 
 
 Scenario 2:  
The proportion of patients receiving target dose is low (12.8%) as is the proportion of trial with 
target dose as recommended dose (9.8%). This is because only the highest combination dose (MCS110=10 mg/kg and PDR001=300 mg) falls into the target toxicity interval [16%, 33%) . 
Further investigation reveals that there are additionally 54.4% of trials with MTD dose identified at just one dose level below the target dose (MCS110=5 mg/kg, PDR001=300 mg or MCS110=10 mg/kg, PDR001=100 mg). Of note, the probability of DLT for these dose combinations lies just below the lower limit of the target interval.  
Scenario 3:  
The proportion of patients receiving target dose is 45.5% and proportion of trial with target dose as recommended dose 60.3%. Further investigation reveals that there are additionally 22.8% of trials with MTD dose identified at just one dose level below the target dose (MCS110=5 mg/kg, PDR001=100 mg or MCS110=1 mg/kg, PDR001=300 mg). The proportion of patients receiving a dose combination with true P(DLT) ≥ 33% or trials that were recommended a dose combinations with true P(DLT) ≥ 33% as the MTD (patient risk) is very low (metric II: 6.5% and metric V: 4%)  
In all scenarios, the percentages of trials that were stopped when all dose combinations were considered too toxic are low (< 3%) in all scenarios. 
In conclusion, the simulations performed illustrate that the model has good operating 
characteristics.  
14.3.5  References (available upon request)  
Akaike, H.: A new look at the Statistical Model Identification. IRRR. Transactions on Automatic Control, AC-19 716-723, 1974 
Dempster P; Laird N. M; Rubin D.B. Maximum likelihood from incomplete data via the EM 
algorithm. Journal of the Royal Statistical Society. Series B (Methodological), Vol. 39, No. 1. (1977), pp.1-38. 
Neuenschwander B, Capkun-Niggli G, Branson M, and Spiegelhalter DJ. Summarizing 
Historical Information on Controls in Clinical Trials. Clinical Trials 2010; 7:5 -18. 
Neuenschwander B, Matano A, Tang Z, Roychoudhury S, Wandel S and Bailey S. A 
Bayesian Industr y Approach to Phase I Combination Trials in Oncology. In Statistical 
Methods in Drug Combination Studies. Zhao W and Yang H (eds), Chapman & Hall/CRC, 2014. 
Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health -
Care Evalu ation. John Wiley & Sons, New York, 2004. 